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ABSTRACT 
The thesis entitled "Studies on the Development of New Analytical 
Methods for the Determination of Drugs in Commercial Dosages 
Forms" is comprised of five chapters. The first chapter describes a general 
introduction of the subject matter. The very relevant matters include: 
• an account of different stages of the drug developmental process from the 
discovery and selection of the potential drug candidate to its registration 
and approval, 
• note on impurity profiling highlighting the various class of impurity, their 
origin, the governmental guidelines, the identification and monitoring of 
impurities found in drug products, 
• a concise description of various types of well-established analytical 
techniques required to secure the safety of the drug products qualitatively 
and quantitatively, 
• a detailed discussion of the validation of analytical procedure. 
Drug discovery and development has a long history and dates back to the early 
days of human civilization. The development of a pharmaceutical product 
requires a complex pathway from discovery of the new chemical entity to its 
analysis through characterization of quality, efficacy and safety so that it is 
made available to general public. These developmental stages have been 
discussed so that the drugs brought to the market are safe when used 
appropriately, and effective when used against the targeted disease or medical 
disorder. All pharmaceutical substances unavoidably contain impurities 
resulting from many sources. To ensure high degree of purity of drug 
substances and drug products, a variety of analytical techniques based on 
sophisticated instrumentation have been employed to quantitate drug 
substance and its impurities. These are discussed together with their 
applications in pharmaceutical and biological fluids. Before an analytical 
method can be used for routine analysis it must be demonstrated first that the 
method fulfils certain performance criteria, when this has been documented, 
the method is said to be validated. The various parameters which must be 
considered for evaluation of method reliability and overall performances are 
presented. 
A short classification of drugs is included and finally a brief literature and 
chemical structures of the concerned drugs, i.e., Clomipramine Hydrochloride, 
Isoxsuprine Hydrochloride, Piracetam and Haloperidol are presented. A well-
composed list of references is given at the end of this chapter. 
The second chapter describes a simple validated spectrofluorimetric method 
for the determination of the clomipramine hydrochloride in its dosage forms. 
The method is based on the fluorescent ion-pair complex formation between 
clomipramine and alizarin red S at pH 1.99. The ion-pair complex showed 
maximum fluorescence intensity at 561 nm with excitation at 490 nm. 
Different variables affecting the reaction conditions such as the concentration 
of alizarin red S, pH, reaction time and the extracting solvents were carefully 
studied. The possible reaction sequence is also given. Under the optimised 
conditions, the fluorescence intensity was found to be linearly related with 
clomipramine hydrochloride concentration in the range of 1.0 - 20 |igmr'. 
The detection and quantitation limits were 0.32 and 0.97 ligml'', respectively. 
No interference was observed from the excipients commonly present in dosage 
forms. The proposed method was successfully applied to the determination of 
clomipramine in its pharmaceutical tablets. The recovery values were found to 
be in the range of 99.75-100.05%. 
The third chapter deals with a kinetic spectrophotometric method for the 
quantitative analysis of isoxsuprine hydrochloride in commercial tablets. The 
method is based on the reaction of isoxsuprine hydrochloride with 
hydroxylamine hydrochloride and ammonium cerium (IV) nitrate in sulphuric 
acid medium at room temperature which resulted in the formation of yellow 
coloured product peaking at 380 nm. The reaction is followed 
spectrophotometrically by measuring the absorbance as a function of time. 
Fixed time method (AA=A4-A2, where A2 and A4 refer to absorbance 
measurements taken at 2 and 4 minutes, respectively) was adopted for 
constructing the calibration curve which was found to be linear over the 
concentration range of 30 - 80 |JgmL'' with molar absorptivity of 5.95x10 L 
mol"' cm"'. The method has been applied successfully to the determination of 
isoxsuprine hydrochloride in tablets. Statistical comparison of the results 
showed that there is no significant difference between the proposed kinetic 
method and reference method. The performance of the proposed method was 
compared with other existing spectrophotometric methods which revealed that 
the proposed method is sensitive requiring less time and cheaper reagents. 
A kinetic spectrophotometric method for the determination of piracetam in 
commercial dosage forms is presented in the fourth chapter. The method is 
based on the oxidation of drug with alkaline potassium permanganate at 
100±rc to form a green coloured product. The reaction is followed 
spectrophotometrically by measuring the increase in absorbance wjth time at 
603 run. The initial rate method is adopted for constructing the calibration 
graph, which is linear in the concentration range of 10 - 140 lagml' . The 
limits of detection and quantitation were found to be 3.1 lagmf' and 9.4 iigml" 
', respectively. The results of the proposed method are compared with those 
obtained by reference method using of point and interval hypothesis tests 
which confirmed excellent agreement, showing no significant difference 
between the two methods. The proposed method is successfully applied to the 
determination of piracetam in tablet formulations. The experimental true bias 
of all samples is less than ± 2%. 
The last chapter describes a simple, validated and sensitive spectrofluorimetric 
method for quantification of haloperidol in pharmaceutical formulations. The 
method is based on the reaction of haloperidol with eosin Y at pH 4.27 
yielding a light pink coloured ion-pair complex extractable in 
dichloromethane. The ion-pair complex in dichloromethane exhibited 
maximum fluorescence intensity at 561 rmi with excitation at 345 nm. Under 
the optimized conditions, linear relationship with good correlation coefficient 
(0.9999) was found between the fluorescence intensity and the concentration 
of haloperidol in the range of 0.2 - 3.2 \ig ml"'. A tentative reaction 
mechanism has been given. The regression analysis of calibration data yielded 
the regression equation, F = 0.443 + 170.288 C. The limit of detecfion is 0.05 
p,g ml"'. The results obtained by the proposed method were comparable with 
those obtained by the reported method. The application of the proposed 
method to the analysis of commercial dosage forms is presented. 
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CHAPTER 1 
General Introduction 
Drug discovery and development has a long history and dates back to the early 
days of human civilization. The early drugs were mainly derived from plant 
products, and supplemented by animal materials and minerals. These drugs 
were most probably discovered through trial and error experimentation and 
observation of human and animal reactions as a result of ingesting such 
products. A disease association was normally obtained through the clinical 
testing of candidate molecules in patients. These were then optimized by 
medicinal chemists to produce candidates, which were passed to development 
and eventually into the market. Scientific techniques were utilized in late 
1800s. From then on, more and more drugs were discovered, tested and 
synthesized in large-scale manufacturing plants. 
Now the drug industry has matured and as the regulatory controls have 
become more stringent, the process of discovering promising new molecular 
entities has become more difficult, more time consuming and significantly 
more expensive. The philosophy by which valuable drugs have been 
discovered during the last 50 years has evolved from one that was mostly 
based around chemistry through a more biological approach to one that is 
concentrating more on disease. Probably, nearly all pharmaceutical companies 
today follow common technology process for discovering drugs. The advent 
of molecular biology, coupled with advances in screening and synthetic 
chemistry technologies, has allowed a combination of both knowledge around 
the receptor and random screening to be used for drug discovery. 
During the last ten years, technology changes have enabled 
the process of drug discovery to evolve into a system where new lead 
molecules can be rapidly found against novel, and sometimes difficult targets. 
The development of new drugs takes a very, very long time—2 to 12 years 
from discovery to market, on average—and the cost is extremely high. This 
developmental process ensures that drugs brought to the market are safe when 
used appropriately, and effective when used against the targeted disease or 
medical disorder. These two objectives involve a series of developmental 
stages, from the laboratory bench to the marketplace. In general, the process of 
generating new therapeutics consists of two stages: 
• drug discovery and 
• drug development 
The discovery stage includes target selection, lead identification and 
preclinical studies, while the development stage includes clinical trials, 
manufacturing and product lifecycle management (Fig.1.1) 
DRUG DISCOVERY 
The identification of therapeutic targets requires knowledge of a disease 
etiology and the biological systems associated with it. Thousands of molecules 
are discovered every year with the help of the combinatory chemistry and the 
high throughput screening. Only few of these will reach the market. The 
process of drug development begins with the discovery of potential drug 
candidates. After screening through thousands of compounds that may have an 
effect on a location in the body (target), a few are selected and optimized to 
enhance the impact of the potential drug against the target. 
Target Validation 
A potential target must undergo a validation process— its role in disease must 
be clearly deiined before drugs are sought that act on it, or before it is used to 
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screen large numbers of compounds for drug activity. Typically this involves 
inhibiting the potential target in vivo and determining the outcome. 
Assay Development and Screening 
Once a target has been validated, it is used to find compounds that interact 
with it in the way that would improve the disease outcome. This is typically 
done by developing an assay that tests compounds for the desired activity on 
the target. These assays fall into different categories and all of these are 
needed for successfiil drug development: 
• In vitro and cell-based assays usually depend on a surrogate marker of the 
effect of the drug, e.g. from cell growth or cytotoxicity to reporter gene 
assays, 
• In vivo/animal model can determine pharmacological properties as well as 
efficacy, 
• High-throughput screening aims at rapidly testing the efficacy of a large 
number of compounds. 
Hits to Leads 
The screening of target assays with large libraries of existing compounds 
usually identifies a few "hits", i.e. compounds that have the desired effect on 
the target. These hits serve as the basis for the development of lead 
compounds that have the necessary degree of activity towards the target. This 
development occurs through many different paths, e.g. flirther screening of 
other similar compounds and other methods that help determine structure-
activity relationships. 
Lead Optimisation 
The purpose of lead optimization is to develop compounds with the desired 
activity of the lead compounds that also have better drug-like characteristics in 
terms of the way they interact with the body. This process involves medicinal 
chemistry which blends synthetic chemistry, molecular modeling, 
computational biology assisted drug design if the NMR or crystal structure of 
the target is known, structural genomics, and pharmacology to discover and 
design new drugs, and investigate their interaction at the molecular, cellular, 
and whole-animal level. Another important step in lead optimization involves 
animal pharmacokinetics (PK), pharmacodynamics (PD), and absorption, 
distribution, metabolism, and excretion (ADME) analyses to assess the general 
pharmacology and mechanisms of action of drugs. 
Pre-CIinical Testing 
This step is the first drug development milestone which represents the 
discovery, the synthesis and demonstration of the safety and the efficacy of 
new molecular entity (NME) (and its back-ups) in the animal .According to 
the Food and Drug Administration, USA, only 1 in 1,000 drugs pass the 
preclinical stage and are proposed for testing in humans [1]. However, almost 
half the R&D expenditures occur in the preclinical stage of development [2]. 
The key steps in the preclinical development of a potential drug involve: 
• The development of an adequate supply of the agent to permit preclinical 
and clinical development. 
• Formulation studies to develop a suitable vehicle lO solubilize the drug for 
administration to patients, generally by intravenous injection or infusion in 
the case of cancer. 
• Pharmacological evaluation to determine the best route and schedule of 
administration to achieve optimal activity of the drug in animal models, 
the half-lives and bio-availability of the drug in blood and plasma, the 
rates of clearance and the routes of excretion, and the identity and rates of 
formation of possible metabolites. 
• IND-directed [directed toward application to the appropriate regulatory 
agency (FDA) for Investigational New Drug status] toxicological studies 
to determine the type and degree of major toxicities in rodent and dog 
models. These studies help to establish the safe starting doses for 
administration to human patients in clinical trials. 
Once an agent has been granted IND status, it then advances to the clinical 
development stage which has three basic phases, i.e. Phase 1, Phase 2 and 
Phase 3. 
CLINICAL DEVELOPMENT 
Once the preclinical development and evaluation is completed or sufficiently 
advanced, the NME is studied in clinical trials (i.e. involving healthy 
volunteers or patients). From the synthesis of the active pharmaceutical 
ingredient (API) to the NDA approval, the clinical development phase (from 
the first testing in humans to NDA submission) represents close to 60% of the 
total drug development duration [3]. 
Phase 1 
This type of clinical trial, essentially devoted to safety, tolerability and 
pharmacokinetics, includes a broad range of studies: First in human (single 
dose and multiple dose escalation), food effect, drug interaction, special 
populations (hepatic/renal impaired, slow metabolizers), age and gender 
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effect, bioavailability of different formulations, etc. The initial dose used in 
First in Human studies should be devoid of any toxicity. The maximum 
recommended starting dose is usually based on administered doses and 
observed toxicities in pre-clinical development. The studies are designed to 
assess the drug's safety, its pharmacokinetics (what the body does to the drug), 
and its pharmacodynamics (what the drug does to the body). According to the 
FDA, "These studies are designed to determine the metabolic and 
pharmacological actions of the drug in humans, the side effects associated 
with increasing doses, and, if possible, to gain early evidence on 
effectiveness" [4]. This process takes about one year and if successful, will 
lead to phase II clinical trials. 
Phase II 
Classically, this represents the first opportunity to evaluate the efficacy of the 
drug on patients and is also an extension of safety evaluation done previously 
on healthy volunteer population. The phase Ila is generally a pilot trial 
involving small number of patients (20-40) that are otherwise healthy and 
aims at establishing the proof of concept and gathering efficacy data. In phase 
lib, a larger number of patients (150-500) are included (sometimes using 
multiple sites) and treated with the study drug in order to get more robust 
information about efficacy, dose response and safety. Drug-drug interactions 
are also studied carefully during Phase II as well as pharmacokinetics and 
pharmacodynamics in diseased patients, which can sometimes differ markedly 
from what was obser\'ed in healthy volunteers. If the Phase II trials have been 
well-designed, the company can then confidently make the critical decision of 
whether to proceed with the more expensive Phase III trials. With this profile 
from Phase I and Phase II, the product is submitted for the consideration of the 
regulatory authorities in order to design the third phase. 
Phase III 
Phase III studies allow us to build a good profile of how the drug behaves 
when it is used in large populations that meet the requirements of regulatory 
authorities to demonstrate that the drug is safe and effective and has an overall 
positive benefit-risk relationship. If the phase III trials prove efficacy and 
safety, the company can then submit an application to the regulatory 
authorities to market the drug. This application must contain all the clinical 
data compiled during testing of the drug. The regulatory authorities take about 
1 year to review a typical application of a "standard" product. When the drug 
is approved by the regulatory authorities, then is finally introduced into the 
market and Phase IV begins. 
Phase IV 
Phase IV studies evaluate marketed drugs to learn more about side effects, 
especially long term effects, and to learn more about the effectiveness of the 
drug, possibly in other conditions or diseases, or using different drug 
formulations, h is becoming increasingly clear that there is marked variability 
in the way individuals respond to drugs, in terms of both efficacy and toxicity 
[5]. Usually pharmaceuticals are very sensitive to the style of storage and class 
of packaging that ultimately causes degradation of the actual products. Any 
abnormality in the recommended dosage amount of a pharmaceutical 
compound or the presence of impurity may show adverse toxicological effects. 
A wide range of testing is used to evaluate and verify the identity, potency and 
availability of the APIs in the product. Stability testing is done at all phases of 
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the development, production and marketing process for quality control and 
monitoring purposes. The different pharmacopoeias, such as the British 
Pharmacopoeia (BP) and the United States Pharmacopoeia (USP), are slowly 
in-corporating limits to allowable levels of impurities present in the APIs or 
formulations. Finally, analytical procedures are used throughout the drug 
development and the manufacturing of drug substances and drug products. 
Important decisions such as the establishment of the shelf life from stability 
studies, the need for additional toxicological trials if new impurities appear or 
if known impurities exceed the qualified levels, the reworking of batches or 
batch release or rejection are based on analytical results. In order to meet the 
challenges to ensure high degree of purity of drug substances and drug 
products, a scheme (Fig. 1.2) is proposed for profiling drug impurity. 
IMPURITY 
Impurities are extraneous compounds that are not the drug substance (also 
known as the active ingredient or the active pharmaceutical ingredient) but 
arise during the synthesis, extraction, purification, or storage of the drug. 
Understanding the origin, control and measurement of impurities is critical to 
the production of high quality drug substances. Impurities fall into three main 
categories: 
Process impurities 
These arise during the manufacture of the drug substance. These include 
organic impurities, inorganic impurities, and residual solvents. 
Organic impurity can arise duilng the manufacturing and storage process. 
These can be identified or unidentified, volatile or non-volafile, and include 
starting materials, by-products, intermediates, degradation products, reagents. 
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Fig, 1.2. General Scheme of Drug Profile 
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ligands, and catalysts. In some cases enzymes are used during a chemical 
synthesis and can be present as impurity. Batches of drug substance made by 
different synthetic routes will contain different impurity. 
Inorganic impurities are normally detected and quantified using 
pharmacopoeial and other appropriate procedures. Sources of inorganic 
impurities include those that are deliberately added to the process (e.g., 
catalysts, ligands, salts from buffers), those that are carried through a process 
that is conducted according to good manufacturing practices (e.g., undetected 
contaminants from starting materials or reagents, residual metals), those 
coming from the process (e.g., leaching from pipes and other equipment), and 
those that occur naturally (e.g., from naturally derived plant or mineral 
sources). Inorganic impurities are usually known and identified. 
Residual solvents and other volatile impurities must be detected and assayed. 
Since residual solvents arise in the excipients and occasionally in the 
manufacture of drug products. According to ICH guideline [6], the residual 
solvents can be grouped into three categories: 
Category I includes solvents such as benzene (2 ppm limit) and carbon 
tetrachloride (4 ppm limit). The solvents belonging to category II are methylene 
chloride (600 ppm limit), methanol (3000 ppm limit), pyridine (200 ppm limit), 
toluene (890 ppm limit), N,N-dimethyl formamide (880 ppm limit) and 
acetonitrile (410 ppm limit). The solvents oicategory //are most commonly used 
during the manufacturing process. Acetic acid, acetone, isopropyl alcohol, 
butanol,ethanol and ethyl acetate are solvents o^ category III. These solvents have 
higher tolerance limits. 
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Degradation impurities 
Degradants are chemical breakdown compounds of the drug substances 
formed during storage. In rare cases, degradants are formed when the drug 
substance chemically interacts with other compounds or contaminants. In 
addition, degradants may also be formed by physical degradation, for 
example, aggregates of proteinaceous materials, dimers, trimers and so forth 
of synthetic compounds, polymorphs of synthetic compovmds. The levels of 
degradants will increase during storage while level of process impurities will 
remain constant. The rate of increase of degradants resulting from storage is 
dependent on the chemical nature of the drug substance. An understanding of 
the potential degradation pathways of the drug substance will lead to 
optimization of the storage conditions and will result in less impurity. ICH 
guidelines [7,8] for the identification and qualification threshold of impurities 
and degradation products are provided in Table 1.1 and Table 1.2. 
Contamination impurities 
Contaminant impurities are not drug related but are inadvertently introduced 
during processing or storage, and are not part of the synthesis, extraction, or 
fermentation process. Contaminant impurities are unexpected adulterant 
compounds found in the drug substance. Current manufacturing technology 
has reduced many of the contaminant impurities observed in drugs prepared 
decades ago. For example, heavy metals like lead that leached from pipes or 
manufacturing, storage tanks gave rise to the limit test for heavy metals in the 
drug substance. 
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Other impurities 
Different polymorphic forms may be categorized as impurities in the drug 
substances. Different polymorphs may be generated by changes in the 
manufacturing process or by seeding effects if a new polymorph arises. 
TABLE 1.1: Threshold for reporting impurities. 
Maximum daily Reporting Identification Qualification 
dose Threshold Threshold Threshold 
<2g/day 0.05% 0.10%or l.Omg/day 0.15% or l.Omg/day 
(whichever is lower) (whichever is lower) 
>2g/day 0.03% 0.05% 0.05% 
TABLE 1.2: Threshold for reporting degradation products in a new drug 
product. 
Threshold Maximum daily 
dose 
o!l% Fa 
0.05% >lg 
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ANALYTICAL TECHNIQUES 
The presence of impurities and the alterations in the recommended therapeutic 
amount of the drug may show adverse toxicological effects which can be Ufe 
threatening. The top goal of this section is to secure the safety of the drug 
products by qualitatively identifying the impurities associated with it and also 
by quantifying the active drug substances as per the requirement. To achieve 
this objective, a variety of analytical techniques have been employed. 
Following sections illustrate the applicability of analytical techniques in 
pharmaceutical analysis. 
Titrimetry 
Titrimetric methods are of particular advantage to the pharmaceutical industry, 
as these methods permit the rapid assay of a great variety of compounds, both 
in bulk and pharmaceutical preparations. Proper selection of solvents, 
indicators and titrants frequently enables one to titrate the desired 
pharmaceutically active component in presence of other compounds or 
excipients. Titrimetric methods for the assay of a number of pharmaceuticals 
have been adopted by official compendia, such as United States 
Pharmacopoeia [9], British Pharmacopoeia [10], European Pharmacopoeia 
[11] and Indian Pharmacopoeia [12]. Recently, nordiazepam was determined 
in bulk and dosage forms by complexometric and iodometric titrations [13]. 
lodometric titration has also been utilized for determination of salbutamol 
sulphate in pharmaceutical preparations [14]. For the assay of ascorbic acid in 
pharriaceutical preparations, aqueous solution was titrated with ferricinium 
salt [15]. Titration in non-aqueous medium has been employed to determine 
the content of olanzapine in commercial dosage forms [16]. 
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Thin layer chromatography 
TLC is still the most widely used chromatographic analytical method in the 
pharmaceutical industry. It is used from the first test in the synthetic research 
laboratory to follow the synthesis of a new entity, to the quality control of 
commercial finished products. It is generally agreed that TLC is most effective 
for the low-cost analysis of samples requiring minimal sample clean-up, or 
TLC allows a reduction in the number of sample preparation steps. United 
States pharmacopoeia [17] contains a general TLC identification test involving 
silica gel layer. TLC has been used for the analysis of several categories of 
drugs such as vitamin C [18], fluoroquinolones [19] and lamotrigine in 
presence of impurity [20]. A procedure for stereoselective separation and 
determination of enantiomeric purity of ropivacaine using different 
cyclodextrins as chiral selector has been described [21]. 
High performance thin layer chromatography (HPTLC) 
In recent years, HPTLC is gaining popularity as an analytical technique due to 
its advantages of low-operating cost, high sample throughput and need for 
minimum sample clean up. The commercialization of HPTLC plates and the 
availability of different types of layers have increased the possibilities of 
choice of the operating conditions and make it possible to elute the plates in 
such a way that high efficiency and reproducibility can be guaranteed. HPTLC 
procedures have been used for the simultaneous quantitation of famotidine and 
domperidone [22], amtolmetin, guacil [23] and rabeprazole and itopride 
hydrochloride [24] in bulk and dosage forms. 
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High performance liquid chromatography (HPLC) 
HPLC is widely used both in drug research and development and also 
pharmaceutical research. Applications in research and development include 
purity control of new drug syntheses, separation of products during stability 
testing of drugs and formulations and pharmacokinetics i.e. the determination 
of drugs and metabolites in biological fluids during metabolism and clinical 
investigations. In pharmaceutical manufacture, HPLC is widely used in quality 
control of both raw materials and finished dosage forms. An example of the 
HPLC application is found in the work by Tamaro etal. [25]. These authors 
have developed stability indicating HPLC method for the determination of 
alizapride and its main degradation products alizapride carboxylic acid and 
alizapride N-oxide in drug substance and product. From an analytical point of 
view, detectors in HPLC play an important role in the analytical method. 
Spectrophotometric detectors, i.e. UV-Vis detectors, diode array detectors 
(DADs) and luminescence detectors are most frequently employed in HPLC 
analysis. The main advantage of UV-Vis detectors is its low cost and 
simplicity of operation. Due to this, a large number of works using HPLC with 
UV-Vis detection for analysis of drugs is found in the literature. Examples of 
the application of these methods include the determination of betamethasone 
[26], and non-steroidal anti-inflammatory drugs [27], as well as the 
simultaneous determination of perindopril and indapamide [28], DADs are 
more sophisticated and expensive than UV-Vis detectors. Jain and coworkers 
[29] have successfully used DAD for the development of stability indicating 
HPLC method for determination of penethamate, an ester prodrug of 
benzylpenicillin. As for luminescence detectors, fluorescence detectors are 
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most often employed in HPLC procedures for direct analyte detection or 
detection of derivative of analyte. Examples of fluorometry in HPLC 
procedures include the determination of dihydroergocristine [30], vigabatrin 
and gabapentin [31]. 
Electrochemical detectors are also widely used in HPLC for 
pharmaceutical and biomedical applications. Electrochemical detection 
fundamentally differs from spectrophotometric detection because it alters the 
sample via oxidation or reduction of the analyte. This fact is responsible for an 
important drawback of electrochemical detectors in HPLC. This limitation is 
more pronounced for the determination of pharmaceutical compounds whose 
redox reactions often involve a large number of intermediates that can strongly 
adsorb onto the electrode surface. A detailed discussion about the use of 
electrochemical detectors in HPLC for pharmaceutical and biological analyses 
is available in the recent review by Ozkan [32]. HPLC method was developed 
to determine artesunate and mefloquine in human plasma using 
electrochemical detector [33]. 
The quantification of drugs in more complex matrices by HPLC using 
direct UV-Vis and electrochemical detectors becomes unreliable due to 
selectivity limitations. Therefore, sample pretreatments are often necessary in 
order to avoid damages to the HPLC system. For this purpose, liquid-liquid 
and solid-phase extraction are often employed to avoid interferences and/or to 
prevent damages to HPLC systems. Solid-phase extraction is generally 
preferred. An interesting discussion about the use of solid-phase 
miocroextraction in pharmaceutical and biomedical analysis is presented by 
Katoaka [34]. The simultaneous determination of propranolol and 4-hydroxy 
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propranolol in human plasma by solid-phase micro extraction and liquid 
chromatography-electrospray tandem mass spectrometry was reported [35]. 
Fernandez and coworkers [36] have developed procedure for simultaneous 
determination of six benzodiazepines in human plasma. The drugs were 
isolated by solid phase extraction and the subsequent analysis was carried out 
by HPLC coupled with a diode-array detector. 
Gas chromatography 
Gas chromatography is undoubtedly the most widely used technique for the 
separation and analysis of volatile compounds. In pharmaceutical analysis GC 
is typically applied to three types of problems: 
• assay of the raw material drug substance or of a synthetic precursor as the 
primary component, 
• quantitation of the drug in formulation and 
• assay of impurities or solvents in the raw material drug substance. 
Studies concerned with quantifying residual solvents [37-40], and volatile 
breakdovm products in formulated products [41] are presented in the literature. 
GC procedure has been developed for evaluating the enantiomeric purity of 
the methyl esters of ibuprofen, fenoprofen, and ketoprofen [42] and 
determining impurities in tablet preparations of benzodiazepines [43]. It is 
capable of low detection limit when appropriate detector is used. Flame 
ionization detector is the most widely used detector for GC due to its low 
detection limits, wide linear dynamic range and general reliability and utility 
especially for trace organic compounds [44]. Inverse GC approach has been 
used to measure solubility parameters of excipients [45]. Gas chromatography 
is often coupled with mass spectrometry and can be found to be useful for 
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analysis of residual solvents, drug substances and impurities. Dimethyl 
sulphate (DMS) is an alkylating reagent commonly used in organic syntheses 
and pharmaceutical manufacturing processes. Due to its potential 
carcinogenicity, the level of DMS in the active pharmaceutical ingredient 
process needs to be controlled. GC-MS method has been used for 
determination of DMS in an API intermediate [46]. Eight sympathomimetic 
amines in urine were determined by GC/MS [47]. GC/MS procedure has also 
been developed for simultaneous determination of paracetamol and three of its 
related substances [48]. 
Capillary electrophoresis (CE) 
The use of CE methods for pharmaceutical analysis has become increasingly 
popular in recent years. The wide range of applications for which its use has 
proved successful includes [49] assay of drugs, determination of drug-related 
impurities, physiochemical measurements of drug molecules, chiral 
separation, and the analysis of vitamins and pharmaceutical excipients. The 
advantages of CE for pharmaceutical analysis are: 
• speed and cost of analysis, 
• reduction in solvent consumption and 
• disposal and possibility of rapid method development. 
CE instruments can be coupled with a variety of detector types including mass 
spectrometer for special applications. There are several electrophoretic modes 
which can be used to analyse pharmaceuticals. Free-solution CE is very 
popular and involves the use of simple buffered aqueous electrol>les and 
separation of ionic drugs is achieved through pH control. Solangi and 
coworkers [50] have developed capillary zone electrophoretic (CZE) method 
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for separation and simultaneous determination of seven structurally different 
drugs-pipemidic acid, oflaxacin, pseudoephedrine, piroxicam, thiamine, 
pyridoxine and cobalamine with a borate buffer of pH 10. Non-aqueous CZE 
was investigated [51] for the separation of cinchona alkaloids using mass 
spectrometric detection. 
Perhaps one area in which CE has excelled beyond all other technologies is in 
the separation of chiral compounds. Many compounds of pharmacological 
interest have one or more centers of asymmetry and usually one of the 
enatiomers is more active than another, which might even be inactive or toxic. 
In direct enatioseparation by CE, a chiral selector - often one of the 
cyclodextrins or crown ethers - is included in the ruiming buffer where it 
interacts with the isomeric compounds to form a labile inclusion complex, 
changing the electrophoretic mobilities of the isomers. Using sulfated P-
cyclodextrin as a chiral selector, it was possible to separate basic chiral 
pharmaceuticals such as pheniramine, brompheniramine, metoxypheniramine, 
cyciopentolate, doxylamine and ketamine [52]. A capillary zone 
electrophoresis investigation on the enatiomeric separation of lomefloxacin, 
gatifloxacin, pazufloxacin and ofloxacin has been reported [53]. Resolution 
was achieved using hydroxypropyl-P-cyclodextrin as the chiral selector. 
Review articles have appeared in the literature [54-57] which offer a detailed 
discussion of detection modes coupled to CE provide examples of use of CE 
in pharmaceutical analysis. The range of CE applications in pharmaceuticals 
analysis is at least as extensive as that of HPLC. The highly complementary 
nature of the two technologies means that CE and HPLC should be viewed as 
two kindered techniques rather than opponents. 
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UV-visible spectrophotometry 
The majority of compounds of pharmaceutical interest shows distinct ultra-
violet or visible absorption spectra and therefore can be monitored by UV-
visible spectrophotometry. Many pharmaceutical compounds are colourless 
and therefore, do not absorb radiation in the visible region of the spectrum. To 
measure the absorbance of the colourless compounds, a reaction must be 
found which will produce a colour that can be measured. 
Many approaches are available and the most used are: 
• Reaction of analyte with a reagent to produce a new compound which has one or 
more chromophores, 
• chelation of the analyte to form a complex with a different colour than either the 
analyte or the original chelant, 
• using a coloured compound which is bleached by the analyte, 
• formation of an intermediate compound that can be oxidized or reduced 
afterwards to produce a coloured compound. 
Developing a test includes finding the optimum pH for reaction and colour 
development, masking of possible interferences and determining optimum 
time for measurement. 
UV-visible spectrophotometry is still considered to be a convenient 
and low cost method for determination of pharmaceuticals. Recent survey 
revealed that about 9.5% and 8.5% of the total analytical methods based on 
UV-visible spectrophotometry for the assay of bulk drug materials are 
included in Ph. Eur. 4 [58] and USP XXVII [59], respectively. Tubino and 
coworkers [60] have presented a review for the determination of vancomycin 
in biological fluids and pharmaceuticals. Several approaches using 
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spectrophotometry for the determination of active pharmaceutical ingredients 
in bulk drug and formulations have been reported and summarized in Table 1. 
3. 
Derivative spectrophotometry 
UV- visible derivative spectrophotometry is a useful analytical tool for: 
• The enhancement of the resolution of overlapping peaks, and 
• The elimination or reduction of background or matrix absorption. 
In the context of derivative spectrophotometry, the normal absorption 
spectrum is considered as zero order spectrum. In this technique, the 
absorbance of a sample is differentiated with respect to wavelength X. to 
generate first, second or higher order derivative: 
(A) = f (A.) zero order 
[dA/d>.] = f(>L) first order 
[d^ A/d>o^ ] = f (X.) second order 
The enhanced resolution and bandwidth discrimination increases with 
increasing derivative order. However, it is also found that the concomitant 
increase in electronic noise inherent in the generation of higher order spectra 
and subsequent reduction of the signal to noise ratio, place serious practical 
limitations on the higher order spectra. 
The conceptual simplicity, relatively quick and easy realization, 
increased selectivity and sensitivity in the analysis of minor components are 
the main reasons why the interest in derivative spectrophotometry is 
constantly growing for practical applications, as well as for the development 
of spectrophotometers with integrated computers and accompanying software 
for producing derivative spectra of different orders. Due to this, a number of 
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TABLE 1.3: Quantitative analysis of drugs in pharmaceutical formulations by 
UV- visible spectrophotometric procedures. 
Name of drug Reagents used m^ax (nm) Ref. 
Acetaminophen 
Acetylcysteine & 
Carbocysteine 
Amiodarone HCl 
Amiodipine besylate 
m-Cresol 
4-ChIoro-7-nitrobenzo-2-oxa 1, 
3-diazole 
p-Chloranilic acid 
2,3-Dichloro 5,6- dicyano 1,4-
benzoquinone 
p-Chloraniiicacid 
Ninhydrin in DMF medium 
2,3-Dichloro 5,6- dicyano 1,4-
640 
424 
535 
575 
540 
595 
580 
[61] 
[62] 
[63] 
[63] 
[64] 
[65] 
[66] 
benzoquinone 
Amoxycillin & 
ampicillin 
Ampiciliin, 
amoxycillin & 
carbeniciiiin 
Ascorbic acid 
Diltiazem HCl 
Ascorbic acid 
KIO3 
Folin ciocalteau phenol 
-Chloro-2,4-dinitrobenzene 
Sodium metavanadate 
Bromothymol blue 
530 
520 
[66] 
[67] 
750,770 • 
&750 
380 
750 
415 
[68] 
[69] 
[70] 
[71] 
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Enalapril maleate 
Famotidine 
Irbesartan 
Isoxsuprine 
hydrochloride 
Bromophenol blue 
Bromocresol green 
KIO4 & KI 
p-Chloranilic acid 
2,3-Dichloro 5,6-dicyano 1,4-
benzoquinone 
Iodine 
KMn04 in alkaline medium 
Ninhydrin 
Potassium iodate and iodide in 
415 
415 
352 
510 
565 
610 
590 
352 
[71] 
[71] 
[72] 
[72] 
[72] 
[73] 
[74] 
[75] 
aqueous medium 
4-Chloro-7-nitrobenzo-2-oxa-l, 3- 395 
diazole (NBD-Cl) 
[76] 
Lisinopril 
Labetalol HCl 
7,7,8,8-Tetracyanoquinodimethane 
p-Chloranilic acid 
Ninhydrin 
Ascorbic acid 
N-Bromosuccinimide 
Chloranil 
Sodium nitroprusside 
hydroxylamine 
hydrochloride 
& 
743 
525 
595 
530 
353 
520 
695 
[77] 
[77] 
[78] 
[79] 
[79] 
[79] 
[80] 
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4-Amino benzenesulfonic 
acid, sodium nitrite and 
sodium bicarbonate 
Losartan potassium KMn04 in alkaline medium 
395 [81] 
Levodopa 
Methyldopa 
L-dopa 
Menadione 
NaOH 
Metoprolol tartrate KMn04 in alkaline medium 
Ninhydrin 
Nalidixic acid 
Nicorandil 
3-Methyl-2-benzothiazoline 
hydrazone HCl-metol 
Nifedipine KMn04 in neutral medium 
603 
Ce(IV) nitrate in H2SO4 medium 510 
Ce(IV) nitrate in H2SO4 medium 550 
300 
NaOH in the presence of amine 450 
610 
595 
Persulphate in alkaline medium 320,390 
Brucine-sulphanilic acid in H2SO4 410 
medium 
560 
N-(l-naphthyl) Ethylenediamine 525 
Dihydrochloride 
530 
4-Methyl amino phenol and 525 
KjCrjO, 
Bromocresol green 415 
[82] 
[83] 
[83] 
[84] 
[85] 
[86] 
[87] 
[89] 
[89] 
[89] 
[90] 
[91] 
[92] 
[93] 
Bromophenol blue 415 [93] 
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Norfloxacin 
Olanzapine 
Bromothymoi blue 
Eriochrome Black T 
KOH in dimethylsulphoxide 
Ammonium molybdate 
KMn04 in alkaline medium 
N-Bromosuccinimide 
N-Bromosuccinimide & 
Celestine blue 
Cerium (IV) sulphate & 
Celestine blue 
415 
520 
430 
830 
603 
532 
538 
538 
[93] 
[93] 
[94] 
[94] 
[95] 
[96] 
[96] 
[96] 
Pantoprazole sodium Potassium ferricyanide and 725 
ammonium ferric sulphate 
Perindopril erbumine l-Chloro-2,4-dinitrobenzene in 420 
dimethyl sulphoxide 
Ramiprii Potassium iodate and potassium 352 
iodide in aqueous medium 
[97] 
[98] 
[99] 
Loxatidine acetate 
iydrochloride 
ilymarin 
1 -Chioro- 2,4 dmitrobenzene 
2,3-Dichloro 5,6-dicyano 1,4-
benzoquinone 
p-Chloranilic acid 
KMn04 in neutral medium 
420 
530 
530 
530 
[100] 
[101] 
[101] 
[102] 
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Thioctic acid 
Trimethoprim 
Thyroxine 
Verapamil HCi 
3-Methyl-2-benzothiazoline 
hydrazone & potassium 
persulphate 
Palladium (11) 
Persulphate in alkaline medium 
Nitrous acid 
Chloramine T 
N-Bromosuccinimide 
Potassium metaperiodate 
Tropaeolin 000 No. 1 
430 [103] 
318 
355 
420 
425 
415 
425 
400 
[104] 
[105] 
fl06] 
[107] 
[108] 
[109] 
[109] 
29 
papers dealing with the theoretical aspects and practical applications have 
appeared. 
The analytical applications of UV-visible derivative spectrophotometry have 
been reviewed [110-112]. It has been applied successfully to the determination 
of drugs in presence of their degradation products. The analytical 
characteristics of derivative techniques for assay of drugs are described in 
Table 1.4. 
Fluorimetry 
Fluorescence spectrometry has proven very useful for the analysis of 
pharmaceuticals and medicinal agents because of its great sensitivity and high 
specificity. Since many drugs are administered at very low doses, the 
analytical procedure must be highly sensitive, enough to detect the low levels 
excreted from the body. The spectrofluorimetry involves measurement of an 
enhanced or quenched fluorescent signal. Regarding fluorimetric 
methodologies, some methods involve chemical reactions, while others are 
based on the native fluorescence of the analytes. The spectrofluorimetric 
technique is maintaining its popularity as the number of papers, reviews and 
monographs published on this topic are continuously increasing every year. 
spectrofluorimetric methods for the assay of specific compounds are presented 
in Table 1.5. 
Flow injection analysis 
Flow injection analysis (FIA) is a simple, rapid, and versatile technique that is 
now firmly established, with widespread application in quantitative chemical 
analysis. The designation of FIA was proposed in 1975 by Ruzicka and 
Hansen [128]. They described it as a method based on injection of a liquid 
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TABLE 1.4: Analytical characteristics of derivative procedures for determination 
of pharmaceutical compounds. 
Compound Deriv. X^m 
Order nm 
Linear range/ Application remark Ref. 
lag mL"' 
Gemifloxacin 1st 
2nd 
Drotaverine HCl 1 st 
Paracetamol 1 st 
2nd 
Ezetimibe 
Galantamine 
480 1 -10 
500 1-15 
303.5 5 - 50 
243.5 5 - 60 
ImipramineHCl 1st 219 1-20 
Chlorodiazepoxide 1st 231.5 2-24 
Benazepril HCl 1st 213 1.2-12 
219 1.2-12 
3rd 223 1.2-12 
1st 261 1 - 16 
Hydroquinone 1st 225.8 10-26 
1st 284.8 20-100 
Tablets 
Tablets 
Tablets 
Tablets 
Raw material and 
tablets 
Cream 
Tablet 
[113] 
Simultaneous [114] 
determination of both 
drugs in commercial 
tablets 
[115] 
[116] 
[117] 
[118] 
[119] 
Hydrobromide 
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TABLE 1.5: Spectrofluorimetric methods for the determination of 
pharmaceuticals. 
Drug Reagent Xex (nm) X«m (nm) Linear dynamic Ref. 
Range (ng/ml) 
Fluvoxamine 4-Chloro-7-nitro 470 535 0.065 - 0.8 [120] 
benzo-2-oxa-l,3-
daizole 
Labetalol Eosin Y & zinc 317 452 0.5-4.0 [121] 
hydrochloride sulphate 
Doxepine Eosin Y 464 567 0.1-0.8 [122] 
hydrochloride 
Haloperidol Alizarin red S 466 564 0.8-2.0 [123] 
Famotidine TbCJ?, EDTA 290 580 0.01-0.1 [124] 
Oxamniquine 1-Dimethylamino- 335 445 0.02-0.2 [125] 
napthalene-5-
sulphonyl chloride 
Nifedipine Zinc/HCl 393 450 0.2-4.0 [126] 
Levodopa Ce (IV) 255 355 0.0-1.20 [127] 
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sample into a moving unsegmented continuous stream of a suitable liquid. The 
injected sample forms a zone, which is then transported toward a detector that 
continuously records the absorbance, electrode potential, or any other physical 
parameter, as it continuously changes as a result of the passage of sample 
material through the flow cell. FIA offers several advantages in term of 
considerable decrease in sample (10 to 50 }j,L) and reagent consumption, high 
sample throughput, reduced residence times, shorter reaction times (3 to 60 s), 
easy switching from one analysis to another, reproducibility (usually less than 
2% RSD), reliability, low carry over, high degree of flexibility, and ease of 
automation. The above mentioned advantages of FIA have led to a 
continuously increasing interest in pharmaceutical analysis and quality control 
applications [129]. M. Tubino and coworkers have developed flow injection 
methods for analysis of ketoconazole [130] and vancomycin [131] in 
pharmaceutical preparations. 
Near-Infrared spectroscopy 
Near-infrared spectroscopy (NIR) is one of the most rapidly growing 
analytical techniques in pharmaceutical analyses because it offers rapid, non-
destructive analyses of pharmaceutical dosage forms. It has been used to 
measure such properties as sample composition and identification, moisture 
content, content uniformity, homogeneity of mixing, degradation products, 
and particle size measurements. Applications of NIR have spanned the entire 
drug manufacturing process from incoming raw materials to finished drug 
products [132-134] and recently have been extended to the area of process 
analytical technology as an online monitoring tool [135]. Major 
pharmacopoeias have generally adopted NIR techniques. The European [ 136] 
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and United States pharmacopoeia [137] both contain a general chapter on NIR 
spectrometry and spectrophotometry, respectively. The use of NIR for raw 
material identification eliminates the need for sample preparation and reduces 
analysis time to a few seconds. One of the most important applications of NIR 
spectroscopy is the study of polymorphic behaviour of many different classes 
of pharmaceutically active compounds. Methods have been developed for 
studying the polymorphic behaviour of the feamates [138] and local 
anesthetics |139]. In addition to characterizing polymorphic purity, NIR has 
been used to identify the drug formulations [140]. NIR has been found to be 
especially useful in terms of evaluating crystalline conversions during drug 
manufacturing [141]. It has been employed for characterization of various 
physical properties of the manufactured products, and the assessment of 
ingredient homogeneity in pharmaceutical mixing [141-142]. NIR has been 
used to perform quantitative analysis of paracetamol [143], dexketoprofen 
[144], and benproperine phosphate [145] in pharmaceutical preparations. 
Nuclear magnetic resonance spectroscopy 
NMR spectroscopy is mostly used by pharmaceutical companies in the areas 
of drug discovery or development to monitor stereoisomeric resolutions or to 
measure the stereoisomeric purity of intermediates [146]. NMR is a powerful 
tool that can provide valuable information to every step of drug development. 
It is used for characterizing the structure and molecular dynamics of target or 
ligand molecules. It is well known that the intensity, I, of NMR signal is 
directly proportional to the number of nuclei N evoking the signal. The linear 
relationship between intensity of NMR signal and number of nuclei (in case of 
single pulse excitation) is expressed as: 
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I = Cs X N 
Where Cs is the proportionality constant arising from the parameters of the 
spectrometer and the sample. As can be seen from the above equation that the 
intensities of NMR signals can be used for quantitative analysis. 
Quantitative NMR (qNMR) spectroscopy has a strong potential in the area of 
pharmaceutical research. In all disciplines, i.e. drug identification, impurity 
profiling and assay, qNMR can be utilized. It can also be used to determine 
physical parameters [146-148] and molecular interactions (drug-drug 
interaction) [149]. Many studies have been reported on the use of NMR for 
quantitative analyses [150, 151], showing that NMR is very linear and robust 
technique with high accuracy and precision [151, 152]. Solid-state NMR 
spectroscopy (SSNMR) has been used for characterization of pharmaceutical 
compounds in the solid state [153]. This technique is fully non-destructive and 
requires no preliminary sample preparations. SSNMR has been used for 
quantification of active principles in pharmaceufical formulations [154-156]. 
Electrochemical methods 
Electrochemical techniques are suitable for both inorganic and organic 
species. Electrochemical methods have proved to be very sensitive for the 
determination of organic molecules that undergo oxidation or reduction 
reactions, including drugs and related molecules in pharmaceutical dosage 
form and biological fluids. 
Electrochemical techniques such as voltammetry, amperometry, 
potentiometry, and chromatographic analysis coupled with electrochemical 
detection are widely used for the determination of pharmaceutically significant 
substances. Voltammetric techniques are most commonly employed 
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electrochemical techniques and several reviews have appeared on the 
application of these techniques for drug analysis in dosage forms and 
biological tluids [157-161]. The most commonly used voltammetric 
techniques are linear sweep voltammetry (LSV), differential pulse 
voltammetry (DPV) and square wave voltammetry (SWV). In addition to 
voltammetric techniques, potentiometric technique has also been used in drug 
analysis. Ion-selective electrode-based potentiometric methods are simple, 
inexpensive and selective, features that make these electrodes very attractive 
for the determination of pharmaceutical compounds. Conductometry has also 
been used for the determination of drugs. However, this technique is less 
frequently used than potentiometry. The applications of various 
electrochemical modes in drug analysis are summarized in Table 1.6. 
Kinetic methods 
Kinetic methods of analysis, wherein one measures the rate of an ongoing 
chemical reaction to determine the quantity or concentration of the analyte of 
interest, are a good choice for the drug analysis. Kinetic methods have 
advantages over equilibrium techniques, especially when mixtures of closely 
related compounds, compounds that react slowly, or catalytically acting 
compounds are to be analyzed. These methods have the advantages of high 
sensitivity, extremely low detection limit, good selectivity, rapid analysis rate, 
and inexpensive instruments. Kinetic methods have been classified according 
to a number of criteria. One classification distinguishes between catalytic and 
noncatalytic methods. The catalytic methods are further divided according to 
the type of reactions involved while the noncatalytic methods are categorized 
according to whether they are used to determine a single species or several 
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TABLE 1.6: Electroanalytical methods for analysis of drugs. 
Drug Electrode Technique Sample Ref. 
Acitaminophen & Multi-walled DPV 
Mefenamic acid carbon nanotube 
Dosage forms, [162] 
Human urine 
& serum 
Acetaminophen SPE-PEDOT CV, DPV Dosage forms [163] 
FIA-amperometry 
FIA-potentiometry Dosage forms [ 164] Oxybutynin OX- PTA 
hydrochloride 
Amadiaquine, 
Chloroquine & 
Primaquine 
Metronidazole DME 
Conductometry Dosage forms [165] 
Polarography Dosage forms [ 166] 
Buzepide 
methiodide 
Verapamil 
hydrochloride 
Losartan 
GC 
GC 
HMDE 
CV, LSV, DPV dosage forms [ 167] 
DPV,OSWV dosage form [168] 
CSV dosage forms [169] 
DPV= Differential pulse voltammetry 
OX-PTA= Oxybutynin-phosphotungstic acid 
GC= Glassy carbon 
OSWV= Osteryoung Square Wave Voltammetry 
CSV= Cathodic Stripping Voltammetry 
HMDE= Hanging mercury drop electrode 
DME= Dropping mercury electrode 
SPE-PEDOT= Screen printed electrode with poly(3,4-ethylenedioxythiophene) 
film. 
LSV= Linear sweap Voltammetry 
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components in the mixture. There are various approaches that can be used for 
the determination of single components in absence of any kinetic interference 
(Table 1.7). However, fixed-time and initial rate methods have been used 
more frequently for the determination of drugs in pharmaceutical formulations 
[170-173]. Tubino and coworkers [174] have described a kinetic method for 
the determination of a-methyldopa in pharmaceutical preparations, wherein 
the calibration curve was constructed by plotting the angular coefficient (Kobs) 
against the square root of the quantity of a-methyldopa. The present degree of 
development in kinetic methods, particularly for multicomponent 
determinations relies heavily on recent breakthroughs in instrumental design, 
especially, the incorporation of microcomputers into analytical chemical 
configurations as well as the application of chemometric techniques. 
Simultaneous kinetic analysis of mixtures is based on the different rates at 
which two or more species interact with a common reagent, allowing for the 
simultaneous analysis of species without prior separation. Recently, Tavallali 
and Sheikhaei [175] have developed a kinetic method for simultaneous 
determination of paracetamol and caffeine using H-point standard addition 
technique. Safavi and Tohidi [176] have reported on the simultaneous kinetic 
determination of levodopa and carbidopa by H-point standard addition 
method. 
Chemometric methods based on factor analysis and artificial intelligence have 
found increasing applications for multicomponent kinetic determinafion [177]. 
Damiani and cov/orkers [178] have developed a chemometric assisted 
spectrophotometric method for simultaneous determination of levodopa and 
carbidopa in pharmaceutical preparations. The multivariate absorbance signals 
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TABLE 1.7: Several kinetic approaches for determination of single 
component. 
A. Direct-computation methods B. Curve-fitting methods 
1. Integral methods 
a. Fixed-time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-Point 
2. Rate methods 
a. Initial-rate 
b. Intermediate-rate 
3. Integrated-signal methods 
1. Integral methods 
a. Linear responses 
b. Non-linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2. Rate methods 
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were recorded at a fixed optimum time (4 min) after reaction of analytes with 
potassium periodate. Multivariate calibration and artificial neural network 
models [179] have been used for simultaneous kinetic spectrophotometric 
determination of carbidopa, levodopa and methyldopa. 
METHOD VALIDATION 
Method validation is the process of defining an analytical requirements, and 
confirms that the method under consideration has performance capabilities 
consistent with what the application requires. Results from method validation 
can be used to judge the quality, reliability and consistency of analytical 
results. Validation studies are most frequently conducted under the following 
circumstances: 
• when a new method is being developed for a particular problem, 
• when an established method is revised to incorporate improvements or 
extended to a new problem, 
• when the results of quality control protocol suggest that the validation 
parameters vary in time, 
• when an established method is going to be used in a different laboratory, 
or with different analysts or different instrumentation, 
• when a new analytical method is being compared with the known standard 
procedure. 
The performance of an analytical procedure is established by various kinds of 
validation characteristics. The validity of a proposed analytical procedure can 
be shown by demonstrating experimentally that the validation characteristics 
of the analytical procedure satisfy the standards set up according to the 
acceptable limits of testing. 
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Validation of analytical methods received considerable attention in the 
literature [180-183]. Guidelines from the United States Pharmacopeia, the 
International Conference on Harmonization (ICH), and the US Food and Drug 
Administration (FDA) provide a framework for performing validations. 
The parameters for method validation as defined by the ICH [184,185] and 
USP [186] are summarized in Table 1.8. 
TABLE 1.8: List of the analytical procedure parameters that should be 
validated according to the recommendations of ICH [184, 185] and USP 
[186]. 
Parameter ICH USP 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Precision 
- repeatability 
- intermediate precision 
- reproducibility 
Accuracy 
Limit of detection 
Limit of quantification 
Specificity/selectivity 
Linearity 
Measuring range 
Robustness 
Ruggedness 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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The validity of a specific method should be demonstrated in laboratory 
experiments using samples or standards that are similar to the unknown 
samples analyzed in the routine. Possible steps for a complete method 
validation are given below. 
Develop a validation protocol or operating procedure for the validation. 
Define the application, purpose and scope of the method, 
Define the performance parameters and acceptance criteria. 
Define validation experiments, 
Verify relevant performance characteristics of equipment. 
Qualify materials, e.g. standards and reagents, 
Perform pre-validation experiments. 
Adjust method parameters or/and acceptance criteria if necessary. 
Perform fiill internal (and external) validation experiments. 
Develop standard operating procedures for executing the method in the 
routine. 
Define criteria for revalidation. 
Define type and frequency of system suitability tests and/or analytical 
quality control checks for the routine, 
• Document validation experiments and results in the validation report. 
The overall validation strategy consists of four components, which are 
prevalidafion [186, 187], proper validation [184,185], study proper and 
statistical analysis. The validafion steps of an analytical procedure can be 
conducted in any order. However, after considering the sequence in which 
specific parameters are determined it seems most logical that the order should 
follow a flow chart presented in Fig. 1.3 [188j. 
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Selectivity determination 
(analysis of standard samples) 
I 
Determination of linearity, 
LOD, LOQ and measuring range 
I 
Determination of repeatability 
~\ 
Determination of intermediate 
precision 
Selectivity determination 
(analysis of real samples) 
Accuracy determination 
(analysis of reference materials) 
I 
Determination of robustness 
(e.g. interlaboratory comparisons) 
VALIDATION REPORT 
Fig. 1.3: The sequence in which validation parameters are determined. 
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Confirmation of identity 
In general analytical methods consist of a measurement stage, which may be 
preceded by an isolation stage. It is necessary to establish before proceeding 
with the characterization of an analyte based on the measured signal that this 
signal is only due to analyte's presence in the sample and not due to something 
chemically or physically similar or arising as a coincidence. This is the 
confirmation of the identity. 
Selectivity/Specificity 
The first validation parameter that should be determined is selectivity. The 
terms selectivity and specificity have been the subject of intensive critical 
comments essentially focusing on the ways in which they are often is regarded 
as something that can be graded. Analytical methods have been described as 
having good selectivity, or even high, excellent or extreme selectivity. Further 
lUPAC stated that "Specificity is the ultimate of selectivity". In view of this, a 
method is perfectly selective for an analyte or group of analytes is regarded as 
specific. The validation procedure should confirm the ability of the method to 
unequivocally assess the analyte in the presence of other components that may 
be present (for example, impurities, degradation products and matrix 
components). The necessary validation studies depend on the method's use. 
The selectivity of the measuring process mainly depends on the composition 
of the analyzed sample [190]. 
The increased selectivity can be achieved by: 
• applying analytical methods that are selective, 
• eliminating the influence of interfering components by exclusion or concealment, 
• extracting an analyte from the matrix. 
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Linearity 
Linearity is defined as the range of analytical method in which the analytical 
signal is proportional to the measured analyte concentration. The most 
common way of determining the linearity is based on the use of calibration 
plot obtained for a given measuring instrument. To this end, samples of 
standard solutions at the minimum of five concentration levels are measured 
(usually, three replicates are used for each level). The choice of analyte 
concentrations in standard solutions should reflect the expected analyte 
contents in the processed samples; usually the concentration range 
encompasses values from 80 to 120% of the expected measurements. Next, the 
linear regression method is used to estimate regression parameters. A linear 
regression equation applied to the results should have an intercept not 
significantly different from zero. If a significant nonzero intercept is obtained, 
it should be demonstrated that this has no effect on the accuracy of the 
method. 
Linearity is often tested by correlation coefficient, 'r', which can be calculated 
for a calibration curve to ascertain the degree of correlation between the 
measured instrumental veiriable and the sample concentration. 
nljc.y.-Ijc.'Ly. 
'^ M^,^)-{^,fin{ly,^}-{W' 
where, 
X = mean of all the values of X; 
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y = mean of all the values ofyi 
n = number of data points. 
When the correlation coefficient values reach at least 0.999 the linearity can 
be assumed in the concentration range for which standard solutions had been 
prepared during the calibration procedure. The value of correlation coefficient 
can be used for assuming the linearity of an analytical procedure only when 
standard solutions used for the calibration fulfill the following requirements 
[190, 193, 194]: 
• their concentration range encompasses the expected analyte concentrations 
in the measured sample(s), 
• they evenly cover the whole concentration range. 
However, it is very important to plot the data and to do visual check of the 
plot. 
Limit of detection (LOD) 
The limit of detection (LOD) is commonly defined as the lowest amount of 
analyte in a sample that can be reliably detected but not necessarily quantitated 
by a particular analytical method. The detection limit may be calculated using 
the standard deviation of responses of blank or samples containing an analyte 
close to the detection limit and the slope of the calibration curve close to the 
detecfion limit. According to ICH [185], following equation is used to 
determine the detection limit using the standard deviation of responses of 
blank samples and the slope of the calibration curve. 
So 
LOD = 3.3 X — b 
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Where So is the standard deviation of blank samples and b is the slope of the 
calibration curve. It should be ensured that the detection limit of the analytical 
procedure is lower than the specified limit for testing. 
Limit of quantitation (LOQ) 
The limit of quantification (LOQ) is defined as the lowest concentration or 
amount of analyte that can be determined with an acceptable level of precision 
and accuracy. The ICH [185] recommends determining the LOQ by the 
following formula: 
So 
LOQ= 10 X — 
Where So is the standard deviation of blank samples and b is the slope of the 
calibration curve. 
The ICH guidelines suggest three different methods for determining the 
detection and quantification limits. These are: visual determination, signal-to-
noise determination, and standard deviation and slope method. Each method 
will give different results. The signal-to noise method is the most logical, 
because it is based on comparing low levels of the analyse to a blank or 
background sample. Determination of the signal-to-noise ratio is performed by 
comparing measured signals from samples with known low concentrations of 
analyte with those of blank samples, and subsequently establishing the 
minimum concentration at which the analyte can be reliably detected. 
Accuracy 
The accuracy of an analytical method is the extent to which test results 
generated by the method and the true value agree. Accuracy can also be 
described as the closeness of agreement between the values that is adopted. 
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either as a conventional, true or accepted reference value, and the value found. 
Accuracy is usually presented as a percent of nominal, although absolute bias 
is also acceptable. Accuracy in the absence of precision has little meaning. 
Accuracy claims should be made vs^ ith acceptable precision. The accuracy 
represents a combination of the random and systematic error. Several 
approaches regarding the accuracy have been discussed in ICH guidelines are 
given in Table 1.9. 
The accuracy of analytical procedures should be determined using 
homogeneous samples with exactly known concentrations of the compounds 
to be determined. The ICH document on validation methodology recommends 
accuracy to be assessed using a minimum of nine determinations over a 
minimum of three concentration levels covering the specified range (e.g., three 
concentrations/three replicates each). Accuracy should be reported as percent 
recovery by the assay of known added amount of analyte in the sample or as 
the difference between the mean and the accepted true value, together with the 
confidence intervals. 
Range 
Linearity and LOQ determinations allow to define the measuring range. The 
range of an analytical procedure is the interval between the lower and upper 
limits (including these levels) that have been demonstrated to be determined 
with accuracy, precision and linearity using the method as written. In practice, 
it ranges from the LOQ value to the highest analyte concentration for which 
the instrument displays an increase of analytical signal. It should also be 
underlined that the higher limit of a measuring range can be assumed to be the 
maximum concentration of analyte in the standard solution for which the 
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TABLE 1.9: Quantitative approaches to demonstrate accuracy according 
to ICH [185]. 
Drug Substance Application of the analytical procedure to a reference material 
Comparison of the results with those of a second, well 
characterised procedure 
Drug Product Application of the analytical procedure to synthetic mixtures 
of drug product components 
Spiking of analyte to drug product 
Comparison of the results with those of a second, well 
characterised procedure 
Impurities Spiking of the impurity to drug substance or product 
(quantitative) Comparison of the results with those of a second, well 
characterised procedure 
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calibration curve had been plotted. Fig. 1.4 shows the graphic representation 
of definitions of linearity, measuring range, LOD and LOQ [195]. 
Precision 
Precision describes the degree of agreement among the independent 
measurements obtained during analysis of a given sample by means of a given 
analytical procedure. It relates to the random error and measures the dispersion 
or spread around the mean value. It is usually expressed as standard deviation. 
The precision should be considered at three levels with different repetition 
conditions; repeatability, intermediate precision and reproducibility. 
Repeatability/Intra-assay precision 
The repeatability expresses the precision of observed values obtained from 
multiple samplings of a homogeneous sample over a short time interval within 
a laboratory, by the same analyst, using the same apparatus and instruments, 
lots of reagents and so forth. Repeatability should be assessed using: 
• a minimum of 9 determinations covering the specified range for the assay 
(e.g., three replicates of three different concentrations) or 
• a minimum of 6 determinations at 100 % of the test concentration. 
Repeatability aims to ensure that contributing factors to the variability of 
results, such as the operator, equipment, calibration and environmental 
considerations, remain constant and have little or no contribution to the final 
results. 
Intermediate-precision 
The intermediate precision expresses the precision of observed values 
obtained from multiple samplings of a homogeneous seimple by changing a 
part of or all of the operating conditions including analysts, experimental 
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Fig. 1.4: Graphic representation of the definitions of linearity, measuring 
range, LOD and LOQ [1951. 
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apparatus and instruments and lots of reagents within a laboratory. 
Intermediate precision may reflect discrepancies in results obtained 
• from different operators, 
• from inconsistent working practice of the same operator, 
• from different instruments, 
• with standards and reagents from different suppliers, 
• a combination of these. 
The objective of intermediate precision validation is to verify that in the same 
laboratory the method will provide the same results. 
It should be noted that, according to USP-26 [196], it is in most cases 
sufficient to determine only the repeatability for proper validation of an 
analytical procedure, while the intermediate precision and reproducibility 
characteristics should be determined for procedures included in the 
pharmacopoeial articles. 
Reproducibility 
This is a measure of a method's ability to perform a routine analysis and 
deliver the same results using a particular method irrespective of laboratory, 
equipment and operator changes. The objective is to verify that the method 
will provide the same results in different laboratories. The reproducibility of 
the method is determined by analyzing aliquots from homogeneous lots in 
different laboratories with different analysts, and by using operational and 
environmental conditions that may differ from, but are still within, the 
specified parameters of the method (interlaboratory tests). Reproducibility is 
expressed in terms of relative standard deviation. Validation of the 
reproducibility is particularly important if the method is to be used for analysis 
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in other laboratories. Table 1.10 summarizes parameters which affect the 
methods reproducibility. 
Ruggedness and Robustness 
Ruggedness is a parameter that defines the suitability of a given analytical 
procedure under varying conditions [197-199]. It is a measure of 
reproducibility of test results under normal, expected operational conditions 
from laboratory to laboratory and from analyst to analyst [200]. Ruggedness is 
normally evaluated during method development. An established technique for 
ruggedness testing is described by the AOAC [201]. Ruggedness tests are 
normally applied to investigate the effect on either precision or accuracy. 
Robustness evaluates the constancy of the results when internal factors (no 
external factors as in ruggedness) such as flow rate, column temperature, 
injection volume, mobile phase composition or any other variable inherent to 
the method of analysis are varied deliberately. Its value has bearing on the 
measuring technique regime for a given analytical procedure [202]. As the 
influence of small changes in parameters on the final analytical result 
increases, it becomes mandatory to maintain these parameters at the constant 
level. Although robustness and ruggedness aim at testing the reproducibility of 
the test results regardless of internal or external influences respectively, the 
literature on method validation bears evidence that both terms are used 
interchangeably. The robustness and ruggedness of analytical procedure are 
determined via interlaboratory comparisons. The values of both parameters for 
a given analytical procedure can be calculated based on the analysis of the 
differences among standard deviations fi-om a series of measurements obtained 
while slightly changing the procedure's parameters. 
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Table 1.10: Typical parameters affecting methods reproducibility 
differences in room temperature and humidity 
operators with different experience and thoroughness 
equipment with different characteristics 
variations in material and instrument conditions 
variation in experimental details not specified by the method. 
equipment and consumables of different ages 
columns from different suppliers or different batches 
solvents ,reagents and other material with varying quality 
differences in room, temperature and humidity 
operators with different experience and thoroughness 
equipment with different characteristics 
variations in material and instrument conditions 
variation in experimental details not specified by the method. 
equipment and consumables of different ages 
columns from different suppliers or different batches 
solvents ,reagents and other material with varying quality 
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CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic 
and inorganic compounds. They can be prepared synthetically (from 
chemicals) or can be directly obtained or reconstituted from the natural 
sources/products. All the drugs having medicinal imf)ortance can be broadly 
divided into two classes. 
Chemical classification 
Here the drugs are classified according to their chemical structure and 
properties without taking the pharmacological actions under consideration. In 
this class most of the drugs are having at least an organic substrate, the further 
classification is done in the relevant manner. This classification provides no 
information at all about either the biochemical action of the drug or the 
physiological effect of drug. 
Pharmacological classification 
In this class the drugs are divided according to their action on the 
organism/organ (viz. heart, brain, lymphatic system, respiratory system, 
endocrine system, central nervous system etc.). Hence these drugs are named 
like antianginal, narcotics, soporifics, analgesics, diuretics and anaesthetics 
etc. Further classification of each group is done according to the 
therapeutic/pharmacological specificity with the relevant organ. A detailed 
classification of drugs based on pharmacological action on human organs has 
been given in Scheme 1.1. 
The present thesis deals with development of new analytical methods for the 
determination of drugs like clomipramine hydrochloride, isoxsuprine 
hydrochloride, piracetam and haloperidol in pharmaceutical formulations. 
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CLOMIPRAMINE HYDROCHLORIDE 
Clomipramine is a potent serotonin reuptake inhibitor [203] that belongs to the 
class dibenzazepine of tricyclic antidepressants. It is chemically described as 
3-chloro-5-[3-(dimethylamino) propyl]-10, ll-dihydro-5H-dibenz [b, f] 
azepine monohydrochloride. It has both antidepressant and antiobsessional 
properties. It is extensively desmethylated by first-pass metabolism in the liver 
to its primary active metabolite, desmethyl clomipramine (Fig. 1.5) [204, 
205]. 
H^C 
Clomipramine 
N CH3 
desmethylclomipramine 
Fig. 1.5. Clomipramine and its metabolite (desmethylclomipramine). 
The metabolite desmethylclomipramine has been shown to be a stronger 
inhibitor of norepineplarine and a weaker inhibitor of 5-HT uptake than the 
parent dmg. Clomipramine hydrochloride is a white to off-white crystalline 
powder with the molecular weight of 351.3 and molecular formula 
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C19H23CIN2.HCI. It is freely soluble in water, methanol, and methylene 
chloride, and insoluble in ethyl ether and hexane. 
Clomipramine hydrochloride is indicated for the treatment of obsessions and 
compulsions in patients with obsessive compulsive disorder (OCD), in 
cataplexy associated with narcolepsy, and in depression when sedation is 
required [206-208]. clomipramine inhibits norepinephrine and serotonin 
uptake into central nerve terminals, possibly by blocking the membrane-pump 
of neurons and thereby increases the concentration of transmitter monoamines 
at receptor sites. Clomipramine is presumed to influence depression and 
obsessive and compulsive behaviour through its effects on serotonergic 
neurotransmission. The actual neurochemical mechanism is unknown, but 
clomipramine's capacity to inhibit serotonin reuptake is thought to be 
important. It is rapidly and completely absorbed after oral administration with 
plasma levels peaking after 2-6 hrs after dosage. The plasma half-life after a 
single oral dose is approximately 21 hours. The metabolic pathways of both 
clomipramine and desmethylclomipramine include hydroxylation, 
demethylation and N-Oxidation. It is excreted in the urine (two-third) and 
faeces (one-third), mainly in the form of its metabolites, either free or 
conjugated form [209-211]. 
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ISOXSUPRINE HYDROCHLORIDE 
Isoxsuprine hydrochloride, chemically known as 4-hydroxy-a-[l-[(l-methyl-
2-phenoxy-ethyl) amino] ethyl] benzene methanol (CAS No. 579-56-6, M.W. 
337.85) is an orally and parenterally active peripheral and cerebral vasodilator. 
Its empirical formula is C18H23NO3.HCI and structural formula of isoxsuprine 
hydrochloride is shown below: 
,HCI 
Fig. 1.6. Isoxsuprine hydrochloride. 
It is a white to almost white crystalline powder, slightly soluble in water and 
ethanol and practically insoluble in chloroform and ether. Drug should be 
stored in a well-closed container and protected from light. Isoxsuprine 
hydrochloride tablets contain inactive ingradients such as acacia, dibasic 
calcium phosphate, lactose, magnesium stearate, starch and talc. 
Isoxsuprine hydrochloride is widely used in clinical practice for the 
treatment of cerebral vascular insufficiency, dysmerrtiea, premature labour 
[212] and p'^ripheral vascular disease caused by arteriosclerosis obliterans, 
thromboangiitis obliterans and Raynaud's disease. It caused isotropic and 
chromotropic effect on heart. The generally accepted mechanism of action of 
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isoxsuprine hydrochloride is beta-adrenergic stimulation that causes direct 
relaxation of uterine and vascular smooth muscle. Isoxsuprine hydrochloride is 
well absorbed from the gastrointestinal tract, partially conjugated in the blood 
and primarily excreated from urine. Its peak concentration in plasma occurs 
about 1 hours and the elimination half-life at steady state is reported to be 1.25 
hours.- It is supplied as 10 mg to 20 mg tablets for oral administration 3 or 4 
times daily in adults. Administration of successive large doses might lead to 
some serious adverse effects such as inhibition of platelet aggregation, 
decreases blood viscosity, tachycardia, hypotension, chest pain, and 
dermatitis. 
PIRACETAM 
Piracetam, 2-oxo-l-pyrrolidine acetamide [CeHioNjOa, 7491-74-9] is a 
member of the class of drugs known as nootropics. It is a derivative of the 
neurotransmitter y-aminobutyric acid. Its clinical application is wide such as 
the treatment of cognitive disorders, dementia, vertigo, cortical myoclonus, 
dyslexia, sickle cell anemia, post-stroke aphasia and epilepsy. It also seems to 
inhibit brain damage caused by a variety of factors including hypoxia and 
excessive alcohol consumption [213,214]. Piracetam is a white crystalline 
powder with a molecular weight of 142.16. Its structural formula is shown in 
Fig. 1.7. 
Piracetam is absorbed very well after parental and oral administration, 
with a bioavailability of almost 100% and reaches peak plasma levels 30-40 
min after a 2 g dose [215]. It is commercially available as 400 mg and 800 mg 
tablets or capsules. The recommended dosage varies based on the indication, 
usually ranging from 1.6 - 9.6 g daily. While high doses are sometimes 
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necessary, piracetam is well tolerated. Piracetam is excreted practically 
unchanged in the urine and completely eliminated after 30 h. Its elimination 
half-life is 4-5 hrs. The mechanism of action of piracetam is not fully 
understood, but it influences neuronal and vascular fiinctions and influences 
cognitive function v^ithout acting as a sedative or a stimulant [216]. At a 
neuronal level, piracetam modulates neurotransmission in a range of 
transmitter systems (including cholinergic and glutamatergic), has 
neuroprotective and anticonvulsant properties, and improves neuroplasticity. 
At a vascular level, it appears to reduce erythrocyte adhesion to vascular 
endothelium, hinder vasospasm, and facilitate microcirculation. 
0 
'NH2 
N. 
Fig. 1,7. Piracetam. 
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HALOPERIDOL 
Haloperidol, 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1 -yl]-1 -(4-
fluorophenyl) butan-1-one [(C21H23CIFNO2, 52-86-8, M.W. 375.87] is a 
butyrophenone-derivative antipsychotic drug. It occurs as a white or almost 
white powder, practically insoluble in water (1.4mg/100ml); slightly soluble in 
alcohol, methanol, chloroform, acetone, benzene and dilute acids. Haloperidol 
has a pKa value of 8.3. It should be stored in tight and light resistant 
containers. 
Haloperidol is one of the most widely used neuroleptic drugs [217]. It is 
effective in the treatment of acute schizophrenia and other psychotic disorders 
such as agitation, mania and hyperactivity. It is also used to treat Huntington's 
chorea and Tourette's syndrome [218]. Other clinical applications of 
haloperidol are the treatment of delirium, distruptive behaviour disorder, 
revention and control of severe nausea and vomiting, and the treatment of 
alcohol dependence. Pharmacological activity of haloperidol is related to its 
affinity for the dopamine receptors. It is a dopamine antagonist which mimics 
the dopamine in binding to the dopamine receptor. It is rapidly absorbed from 
the gastrointestinal tract following oral administration, and undergoes a first 
pass metabolism in the liver peaking the plasma levels within 2 to 6 h after 
oral dosing [219] and about 20 min after intramuscular administration. 
Haloperidol is metabolized in liver producing three main metabolites (Scheme 
1.2) [220]. The metabolism of the haloperidol involves the initial cleavage of 
the molecule at the CN bond of the central chain to form an inactive piperidine 
and 4-fluorobenzoylpropionic acid metabolites [221]. It is also metabolized 
through reduction at the benzylic ketone group to form an alcohol metabolite, 
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known as reduced haloperidol (RH) [222]. Long-term use of haloperidol might 
lead to some side effects such as Parkinson's disease and tardive diskinesia, an 
irreversible motor disorder. It is very important to determine the quantity of 
haloperidol in its dosage forms because photolytic degradation can be an 
important limiting factor, resulting in drug loss and potency reduction [223]. 
\ / 
Reduced haloperidol 
OH 
I 
C — C H , — C H , — C H p — N 
? / 
C — C H , — C H , — C H , — N 
\ 
Haloperidol 
? 
C CH2—CH2—CO2H 
4-Fluorobenzoylpropionic acid Piperidine metabolite 
Scheme 1.2. Metabolism of haloperidol. 
63 
REFERENCES 
[I] FDA, The FDA and the Drug Development Process: How the FDA insures 
that drugs are safe and effective, FDA Fact sheet (2002). 
[2] R. Levy, The Pharmaceutical Industry. A Discussion of competitive and 
antitrust issues in an environment of change, Bureau of Economics Staff 
Report, Federal Trade Commission (1999). 
[3] J. A. Di Masi, Clin. Pharmacol. Therap 69 (2001) 297. 
[4] FDA, New Drug Approval Reports (2003), 
http://www.fda.gov/cder/rdmt/default.htm. 
[5] W. Evans and J. A. Johnson, Annual Review of Genomics and Human 
Genetics, 2 (2001) 9. 
[6] International Conference on Harmonization of Technical Requirements for 
the Registration of Pharmaceuticals for Human use (ICH), Q3C, Guidelines 
for residual solvents 62 (1997) 673. 
[7] International Conference on Harmonization of Technical Requirements for 
the Registration of Pharmaceuticals for Human use (ICH), Q3A (R), 
Impurities in New Drug Substances (2002). 
[8] International Conference on Harmonization of Technical Requirements for 
the Registration of Pharmaceuticals for Human use (ICH), Q3B (R), 
Impurities in New Drug Substances (2002). 
[9] United States Pharmacopoeia XXIII, National Formulary XVIII, The USP 
Convention Inc., Rockville, MD, USA (1995) 65 and 1360. 
[10] British Pharmacopoeia, H. M. S. O, Pharmaceutical Press, London (1993) 
449. 
[II] The European Pharmacopoeia, Council of Europe, Strasbourg (1997). 
64 
[12] The Indian Pharmacopoeia, The Controller of Publications, Government of 
India, Delhi (1996) 256. 
[13] M. M. Mostafa and E. H. Al Gphani, J. Saudi. Chem. Soc. 14 (2010) 9. 
[14] K. Basavaiah, B. C. Somashekar and V. Ramakrishna, Acta Pharm. 57 (2007) 
87. 
[15] M. M. Aly, M. K. Hassan and R. M. Souliman, J. Chem. Technol. Biotechnol. 
30 (2007) 435. 
[16] K. Basavaiah, N. Rajendraprasad and K. B. Vinay, Chem. Ind. Chem. Eng. 
Quart. 15(2009)77. 
[17] The United States Pharmacopoeia, The USP Convention., Rockvilla, MD 
(2000). 
[18] G. S. Chakraborthy, J. Young Pharmacists 1 (2009) 82. 
[19] M. Y. Salem, N. M. El-Guindi, H. K. Mikael and L. E. Abd-El-Fattah, Chem. 
Pharm. Bull. 54 (2006) 1625. 
[20] N. Y. Youssef and E. A. Taha, Chem. Pharm. Bull. 55 (2007) 541. 
[21] E. A. Taha, Curr. Pharm. Anal. 3 (2007) 273. 
[22] S. M. Pawar, B. S. Patil and R. Y. Patil, Int. J. Adv. Pharm. Sci. 1 (2010) 52. 
[23] V. K. Bhusari, M. V. Mahadik and S. R. Dhaneshwar, Acta 
Chromatographicall (2009)299. 
[24] A. Suganthi, S. John and T. K. Ravi, Indian J. Pharm. Sci. 70 (2008) 366. 
[25] I. Tamaro, S. Aprile, G. B. Giovenzana and G. Grosa, J. Pharm. Biomed. 
Anal. 51 (2010) 1024. 
[26] Q. Fu, M. Shou, D. Chien, R. Markovich and A. M. Rustum, J. Pharm. 
Biomed Anal. 51 (2010) 617. 
65 
K. Aguilar-Arteaga, J. A. Rodriguez, J. M. Miranda, J. Medina and Barrado, 
Ta/anto 80 (2010) 1152. 
H. Jogia, U. Khandelwal, T. Gandhi, S. Singh and D. Modi, J. AOAC. Int. 93 
(2010) 108. 
R. Jain, Z. Wu and I. G. Tucker, J. Pharm. Biomed. Anal. 50 (2009) 841. 
M. Dousa and M. Dubovska, J. AOAC. Int. 93 (2010) 97. 
A. A. Al-Majed, J. Liq. Chromatogr. Rel. Technol. 28 (2005) 3119. 
S. A. Ozkan, Chromatograhia 66 (2007) 53. 
C. Lai, N. K. Nair, S. M. Mansor, P. L. olliaro and V. Navaratnam, J. 
Chromatogr. B 858 (2007) 308. 
H. Kataoka, Curr. Pharm. Anal. 1 (2005) 65. 
P. Partani, Y. M odhave, S. Gurule, A. Khuroo and T. Monif, J. Pharm. 
Biomed. Anal. 50 (2009) 966. 
P. Fernandez, C, Vazquez, R. A. Lorenzo, A. M. Carro and A. M. Bermejo, 
Anal. Lett. 43 (2010) 1075. 
S. B. Puranik, P. N. S. Pai and G. K. Rao, Indian J. Pharm. Sci. 69 (2007) 
352. 
S. B. Puranik, V. R. Pawar, N. Lalitha, P. N. S. Pai and G. K. Rao, Pak. J. 
Pharm. Sci. 22 {2009) MO. 
C. B'. Hymer, J. Chromatogr. Sci. 46 (2008) 369. 
C. B'. Hymer, Pharm. Res. 20 (2003) 337. 
E. J. Bishop and S. Mitra,./ Pharm. Biomed Anal. 37 (2005) 81. 
M. Petrovic, Z. Debeljak and N. Blazevic, J. Pharm. Biomed. Anal. 39 (2005) 
531. 
66 
[43] N. L. Bochkareva, I. N. Glazkov and I. A. Revelsky, J. Anal. Chem. 61 
(2006) 1082. 
[44] D. G. Westmorland and G.R. Rhodes, Pure Appl. Chem. 61 (1989) 1148. 
[45] K. Adamska and A. Voelkel, Int. J. Pharm. 304 (2005) 11. 
[46] J. Zheng, W. A. Pritts, S. Zhang and S. Wittenberger, J. Pharm. Biomed. 
Anal. 50 (2009) 1054. 
[47] M. Moawad, C. S. Khoo, S. Lee and J. R. Hennell, J. O. A. C. Int. 93 (2010) 
116. 
[48] T. Belal, T. Awad and C. R. Clark,./. O. A. C. Int. 92 (2009) 1622. 
[49] K. D. Altria, (ed.) Vieweg ,Weisbeden (1998) 1. 
[50] A. R. Solangi, M. I. Bhanger, S. Q. Memon, M. Y. Khuhawar and A. Mallah, 
J.O.A.C.Int. 92(2009)1382. 
[51] W. Buchberger, D. Gstottenmayr and M. Himmelsbach, Electrophoresis 31 
(2010) 1208. 
[52] A. Kwaterczak, K. Duszczyk and A. Bielejewska, Anal. Chim. Acta 645 
(2009) 98. 
[53] S. Zhou, J. Guyang, W. R. G. Baeyens, H. Zao and Y. Yang, J. Chromatogr. 
A 1130(2006)296. 
[54] L. A. Holland, N. P. Chetwyn, M. D. Perkins and S. M. Lunte, Pharm. Res. 
14(1997)372. 
[55] C. M. Boone, J. C. M. Waterval, H. Lingeman, K. Ensing and W. J. M. 
Underberg, J. Pharm. Biomed Anal. 20 (1999) 831. 
[56] J. Kraly, M. A. Fazal, R. M. Scoenherr, R. Bonn, M. M. Harw'ood, E. Turner, 
M. Jones and N. J. Dovichi, Anal. Chem. 78 (2006) 4097. 
67 
[57] J. Zhang, J. Konechy, Z. Glatz, J. Hoogmartens and A. V. Schepdael, Current 
Anal. Chem. 3(2007) 197. 
[58] The European Pharmacopoeia, 4th edn.. Council of Europe, Strasbourg 
(2002). 
[59] United States Pharmacopoeia, 27th edn., The USP Convention Inc., 
Rockville, MD (2004). 
[60] M. M. D. C. Vila, R. Machado de Oliviera, M. M. Gonclaves and M. Tubino, 
Quimica Nova 30 (2007) 1. 
[61] S. Z. Qureshi, A. Saeed and N. Rahman, Chem. Anal. (Warsaw) 37 (1992) 
227. 
[62] E. A. Tahaa, N. Y. Hassan, F. A. Aala and L. E. A. Fattah, Science Asia 34 
(2008) 107. 
[63] N. Rahman, N. A. Khan and S. N. H. Azmi, Anal. Sci. 20 (2004) 1231. 
[64] N. Rahman and S. N. H. Azmi, Anal. Sci. 16 (2000) 1353. 
[65] N. Rahman and S. N. H. Azmi, IL Farmaco 56 (2001) 731 
[66] N. Rahman and M. N. Hoda, J. Pharm. Biomed. Anal. 31 (2003) 381. 
[67] M. 1. H. Helaleh, N. Rahman and R. M. A. Q. Jamhour, Chem. Anal. 
(Warsaw) A2{\991)26\. 
[68] A. S. Ahmad, N. Rahman and F. Islam, J. Anal. Chem. 59 (2004) 119. 
[69] S. Z. Qureshi, A. Saeed, S. Haq and N. Rahman, Anal. Lett. 23 (1990) 995. 
[70] N. Rahman, S. N. H. Azmi, Microchem. J. 65 (2000) 39. 
[71] N. Rahman, S.N.H. Azmi../. Pharm. Biomed Anal. 24 (2000) 33. 
[72] N. Rahman and S. M. Haque, Analytical Chemistry Insights 3 (2008) 31, 
[73] N. Rahman and M. Kashif, Anal. Sci. 19 (2003) 907. 
[74] N. Rahman and M. Kashif, IL Farmaco 58 (2003) 1045. 
68 
[75] N. Rahman, M. R. Siddiqui and S. N. H. Azmi, Chem. Pharm. Bull. 54 (2006) 
626. 
[76] N. El-Enany, F. Belal and M. Rizk, Sci. Pharm. 74 (2006) 99. 
[77] N. Rahman, N. Anwar and M. Kashif, IL Farmaco 60 (2005) 605. 
[78] N. Rahman, M. Singh and M. N. Hoda, J. Braz. Chem. Soc. 16 (2005) 1001. 
[79] N. Rahman, M. R. Siddqui and S. N. H. Azmi, Chem. Anal. (Warsaw) 52 
(2007)465. 
[80] N. Rahman, M. Singh and M. N. Hoda, Chinese J. Chem. 23 (2005)1. 
[81] N. Rahman, H. Rahman and S. N. H. Azmi, J. Chin. Chem. Soc. 54 (2007) 
185. 
[82] N. Rahman, M. R. Siddiqui and S. N. H. Azmi, J. Chin. Chem. Soc. 53 (2006) 
735. 
[83] M. I. H. Heialeh, N. Rahman and E. S. M. Abu Nameh, Anal. Sci. 13 (1997) 
1007. 
[84] M. I. H. Heialeh, N. Rahman, R. M. A. Q. Jamhour and E. S. M. A. Nameh, 
J. Pharm. Biomed. Anal 16 (1997) 269. 
[85] M. I. H. Heialeh, N. Rahman and R. M. A. Q. Jamhour, Ann. Chim. (Rome) 
86(1996)509. 
[86] N. Rahman, H. Rahman and S. N. H Azmi, Chem. Pharm. Bull. 53 (2005) 
942. 
[87] N. Rahman, Y. Ahmad, S. N. H. Azmi, Chem. Anal. (Warsaw) 50 (2005) 116. 
[88] M. I. H. Heialeh, S. Z. Qureshi, N. Rahman, R. M. A. Q. Jamhour, Acta 
Poloniae Pharmaceutica-Drug Research 54 (1997) 111. 
[89] N. Raliman, N. A. Khan and S. N. H. Azmi, JL Farmaco 59 (2004) 519. 
0 3 
[90] N. Rahman, M. R. Siddiqui and S. N. H. Azmi, Yakugaku Zasshi 127 (2007) 
367. 
[91] N. Rahman and S. N. H. Azmi, Acta Pharm. 49 (1999) 113. 
[92] N. Rahman and M. N. Hoda, IL Farmaco SI (2002) 435. 
[93] N. Rahman, N.A. Khan and S. N. H. Azmi, IL Farmaco 59 (2004) 47. 
[94] N. Rahman and S. N. H. Azmi, Acta Biochimica Polonica 52 (2005) 915. 
[95] N. Rahman, Y. Ahmad and S. N. H. Azmi, Eur. J. Pharm. Biopharm. 57 
(2004) 359. 
[96] A. Krebs, B. Starczewska, H. Puzanowska-Tarasiewicz and J. Scledz, Anal. 
Sci. 22 (2006) 829. 
[97] N. Rahman, Z. Bano and S. N. H. Azmi, Anal. Sci. 22 (2006) 983. 
[98] N. Rahman, N. Anwar and M. Kashif, Chem. Pharm. Bull. 54 (2006) 33. 
[99] N. Rahman, Y. Ahmad and S. N. H. Azmi, AAPS Pharm. Sci. Tech. 68 (2005) 
E543. 
[100] N. Rahman, H. Rahman and S. N. H. Azmi, Inter. J. Biomed. Sci. 2 (2007) 
52. 
[101] N. Rahman and M. Kashif,./ Anal. Chem. 60 (2005) 636. 
[102] 'N . Rahman, N.A. Khan and S. N. H. Azmi, Pharmazie 59 (2004) 112. 
[103] N. Rahman, Y. Ahmad and S. N. H. Azmi, Canadian J. Anal. Sci. Sped. 50 
(2005)116. 
[104] N. El-Enany, F. Belal and M. Rizk, J. Chin. Chem. Soc. 54 (2007) 941. 
[105] S. Z. Qureshi, M. I. H. Helaleh, N. Rahman and R. M. A. Q. Jamhour, 
FreseniusJ. Anal. Chem. 357 (1997) 1005. 
[106] S. Z. Qureshi, M. 1. H. Helaleh, N. Rahman and R. M. A. Q. Jamhour, Chem. 
Anal. (Warsaw) 42 (1997) 65. 
70 
107] N. Rahman and M. N. Hoda, Anal. Bioanal. Chem. 374 (2002) 484. 
[108] N. Rahman and S. N. H. Azmi, IL Farmaco 59 (2004) 529. 
[109] N. Rahman,N. A. Khan, S.N. H. Azmi,Sci. Asia^X (2005) 341. 
[110] C. B. Ojeda, F. S. Rojas, and J. M. C. Pavon, Talanta 42 (1995) 1195. 
[I l l] G. V. Popovic, L. B. Pfendt and V. M. Stefanovic, J. Serb. Chem. Soc. 65 
(2000)457. 
[112] A. Y. El-Sayed and N. A. El-Salem, Anal. Sci. 21 (2005) 595. 
[113] D. Madhuri, K. B. Chandrashekhar, N. Devanna and G. Somasekhar, 
RasayanJ. Chem. 3 (2010) 159. 
14] S. Mahaparale, R. S. Raut, S. S. Damle and P. V. Kasture, Indian J. Pharm. 
Sci. 72(2010)133. 
115] S. Patel, N. J. Patel and S. A. Patel, Indian J. Pharm. Sci. 71 (2009) 468. 
[116] B. Stanisz, S. Paszun and M. Lesniak, Acta Pol. Pharm-Drug Res. 66 (2009) 
343. 
[117] S. M. El-Moghazy, M. A. E. Mohamed, M. F. Mohamed and N. F. Youssef, 
J. Chin. Chem. Soc. 56 (2009) 360. 
[118] P. L. Garcia, M. 1. R. M. Santoro, A. K. Singh and E. R. M. Kedor-
Hackmann, Brazilian J. Pharm. Sci. 43 (2007) 397. 
[119] H. N. Patel, A. V. Patel, V. J. Patel, J. B. Dave and C. N. Patel, J. Chem. 
Pharm. Res. 2(2010)44. 
[120] 1. A. Darwish, S. M. Amer, H. H. Abdine and L. I. Al-Rayes, J. Fluores. 19 
(2009)463. 
121] N. Rahman and S. M. Haque, Int../. Biomed Sci. 4 (2008) 100. 
[122] N. Rahman, S. Siddiqui and S. N. H. Azmi, AAPS Pharm. Scitech. 10 (2009) 
1381. 
71 
123] N. Rahman and S. Siddiqui, Drug Test. Analysis 2 (2010) 252. 
124] M. I. Walash, A. El-Brashy, N. El-Enany and M. E. K. Wahba, Int. J. 
BiomedSci. 5(2009)158. 
125] N. El-Enany, F. Belal and M. Rizk, J. Fluoresc. 18 (2008) 349. 
126] S. M. Al-Ghannam and A. M. Al-Olyan, Cent. Eur. J. Chem. 6 (2008) 222. 
127] A. P. Pagani, M. A. Cabezon and G. A. Ibanez, Anal. Sci. 25 (2009) 633. 
128] J. Ruzicka and E. H. Hansen, Anal. Chim. Acta 78 (1975) 145. 
129] L. Hlabangana, S. Hemandez-Cassou and J. Saurina, Curr. Pharm. Anal. 2 
(2006) 127. 
130] F. Scatolin, M. Tubino and M. M. D. C. Vila, Quim. Nova 33 (2010) 624. 
131] M. M. D. C. Vila, A. A. Salomao and M. Tubino, Eclet. Quim. 33 (2008) 67. 
132] J. Luypaert, D. L. Massart and Y. Vander Heyden, Talanta 72 (2007) 865. 
133] Y. Roggo, P. Chalus, L. Maurer, C. Lema-Martinez, A. Edmond and N. Jent, 
J. Pharm. Biomed. Anal. 44 (2007) 683. 
134] G. Riech, Advanced Drug Delivery Rev. 57 (2005) 1109. 
135] S. S. Rosa, P. A. Barata, J. M. Martins and J. C. Menezes,./. Pharm. Biomed. 
Anal. 47 (2008) 320. 
136] The European Pharmacopoeia. 4th edn.. Council of Europe, Strasbourg 
(2004). 
137] The United States Pharmacopoeia, 26th edn., NF 22 (2003). 
138] R. K. Gilpin and W. Zhou, J. Pharm. Biomed Anal. 37 (2005) 509. 
139] A. C. Schmidt, Pharm. Res. 22 (2005) 2121. 
140] A. Kazeminy. S. Hashemi, R. L. Williams, G. E. Ritchie, R. Rubinovitz and 
S. Sen, J. Near IR. Spectros. 17 (2009) 233. 
[141] M. Blanco, M. Alcala, Anal. Chim. Acta 557 (2006) 353. 
72 
[142] M. Otsuka and I. Yamane, J. Pharm. Sci. 95 (2006) 1425. 
[143] Y. Dou, Y. Sun, Y. Ren, P. Ju and Y. Ren, J. Pharm. Biomed. Anal. 37 (2005) 
543. 
[144] M. Blanco, J. Cruz and M. Baustista, Anal. Bioanal. Chem. 392 (2008) 1367. 
[145] M. Y. Liu, Y. Meng, J. F. Li, H. T. Zhang and H. Y. Wang, Chin. Chim. Lett. 
17(2006)1209. 
[146] J. Smith and W. Xu, D. Raftery, J. Phys. Chem. B 110 (2006) 7766. 
[147] K. Masuda, S. Tabata, H. Kono, Y. Sakata, T. Hayase, E. Yonemochi and K. 
Terada, Int. J. Pharm. 318 (2006) 146. 
[148] A. C. Schmidt, I. Schwarz and K. Mereiter, J. Pharm. Sci. 95 (2006) 1097. 
[149] I. M. Kenawi, B. N. Barsoum, M. A. Youssef, J. Pharm. Biomed. Anal. 37 
(2005)655. 
[150] T. Rundlof, M. M Athiasson, S. Bekiroglu, B. Hakkarainen, T. Bowden and 
T. Arvidsson,./. Pharm. Biomed. Anal. 52 (2010) 645. 
[151] V. Rizzo and V. Pinciroli, J. Pharm. Biomed Anal. 38 (2005) 851. 
[152] F. Malz and H. Jancke,./. Pharm. Biomed Anal. 38 (2005) 813. 
[153] R. T. Berendt, D. M. Sperger, P. K. Isbester and E. J. Munson, Trends Anal. 
Chem. 25 (2006) 977. 
[154] B. N. Nelson, L. J. Shieber , D. H. Barich, J. W. Lubach, T. J. Offerdahl, D. 
L. Lewis, J. P. Heinrich and E. J. Munson, Solid State Nucl. Magn. Reson. 29 
(2006)204. 
[155] F. Ziarelli, S. Viel, S. Sanchez, D. Cross and S. Caldarelli, J. Magn. Reson. 
188(2007)260. 
[156] S. Sanchez. F. Ziarelli, S. Viel, C. Delaurent and S. Caldarelli, J. Pharm. 
Bioemd Anal. 47 (2008) 683. 
73 
157] S. A. Ozkan, Cun. Pharm. Anal 5 (2009) 127. 
158] Q. Xu, A. Yuan, R. Zhang, X. Bian, D. Chen and X. Hu, Curr. Pharm. Anal. 
5 (2009)144. 
159] N. A. El-Maali, Bioelectrochemistry 64 (2004) 99. 
160] S. A. Ozkan, B. Uslu and H. Y. Aboul-Enein, Crit. Rev. Anal. Chem. 33 
(2003)155. 
161] A. L. Santos, R. M. Takeuchi and N. R. Stradiotto, Curr. Pharm. Anal. 5 
(2009) 69. 
162] A. Babaei. M. Afrasiabi and M. Babazadeh, Electroanalysis, 22 (2010) 1743. 
163] W. Su and S. Cheng, Electronalnalysis 22 (2010) 707. 
164] M. S. El-Hamshary, O. H. Salem and R. M. El Nashar, Anal. Sci. 26 (2010) 
437. 
165] A. S. Amin and Y. M. Issa, J. Pharm. Biomed. Anal. 31 (2003) 785. 
166] G. O. E. Syed, Microchem. J. 55 (1997) 110. 
167] S. S. Kalanur, J. Seetharamappa, U. Katrahalli and P. B. Kandagal, Int. J. 
Electrochem. Sci. 3 (2008) 711. 
168] S. Demircan. S. Kir and S. A. Ozkan, Anal. Lett. 40 (2007) 1177. 
169] I. H. I. Habib, S. A. Weshahy, S. Toubar and M. M. A. El-Alamin, 
Portuigaliae Electrochim. Acta 26 (2008) 315. 
170] I. A. Darwish, M. A. Sultan and H. A. Al-Arfaj, Int. J. Res. Pharm. Sci. 1 
(2010)43. 
171] B. Hemmateenejad, R. Miri and R. Kamali,./. Iran. Chem. Soc. 6 (2009) 113. 
172] E. A. Taha, N. Y. Hassan, F. A. Aal and L. E. A. Fatlah, Science Asia 34 
(2008)107. 
74 
[173] M. H. Abdel-Hay, E. M. Hassan, A. A. Gazy and f. S. Belal, J. Chin. Chem. 
Soc. 55(2008)818. 
[174] M. Tubino, D. C. D. V. Batista and J. A. R. Rodrigues, Anal. Lett. 39 (2006) 
327. 
[ 175] H. Tavallali and M. Sheikhaei, Afr. J. Pure Appl. Chem. 3 (2009) 11. 
[176] A. Safavi and M. Tohidi, J. Pharm. Biomed. Anal. 44 (2007) 313. 
[177] G. M. Scandar, P. C. Damianv, H. C. Goicoechea and A. C. Olivieri, 
Microchem. J. 82 (2006) 29. 
[178] P. C. Damiani, A. C. Moschetti, A. J. Rovetto, F. Benavente and A. C. 
Olivieri, Anal. Chim. Acta 543 (2005) 192. 
[179] M. Chamsaz, A. Safavi and J. Fadaee, Anal. Chim. Acta 603 (2007) 140. 
1180] M. Thompson, S. L. R. Ellison and R. Wood, Pure Appl. Chem. 74 (2002) 
835. 
[181] Validation of Chemical Analytical Methods, NMKL Secretariate, Finland 
(1996). 
[182] P. Konieczka, Rev. Anal. Chem. 37 (2007) 173. 
[183] 1. Travemiers, M. de Loose and E. Vaan Bockstaele, Trends Anal. Chem. 23 
(2004)535. 
[184] International Conference on Harmonization of Technical Requirements for 
the Registration of Pharmaceuticals for Human Use (ICH), Q2A, Text on 
Validation of Analytical Procedures, Geneva (1994). 
[185] International Conference on Harmonization of Technical Requirements for 
the Registration of Pharmaceuticals for Human Use (ICH), Q2B, Validation of 
Analytical Procedures: Methodology, Geneva (1996). 
[186] United States Pharmacopeial Convention, USP 23, US Rockville (1995). 
75 
[187] H. J. Pieniaszek, Shorl Course on Bioanalytical Method Developmeni: 
Validation and Transfer, W'' International Symposium on Pharmaceutical 
and Biomedical Analysis, USA, Washington D.C. (1999). 
[188] L. Ruber, Validation and Qualification in Analytical Laboratories, 
wvAV.labcompliance.com, (1998). 
[189] B. Persson and J. Vessman, Trends Anal. Chem. 17 (1998) 117. 
[190] M. Valcarcel, A. Gomez-Hens and S. Rubio, Trends Anal. Chem. 20 (2001) 
386. 
[191] B. Persson and J. Vessman, Trends Anal. Chem. 20 (2001) 526. 
[192] J. Vessman, R. 1. Stefan, J. F. van Staden, K. Danger, W. Lindner, D. T. 
Bums, A. Fajgelj and H. Muller, Pure Appl. Chem. 73 (2001) 1381. 
[193] S. L. R. Ellison, Accred Qual. Assur. 11 (2006) 146. 
[194] A. G. Gonzalez, M. A. Herrador, A. G. Asuero and A. Sayago, Accred. Qual. 
Assur. 11 (2006) 256. 
[195] Eurachem Guide: The fitness for Purpose of Anal>tical Methods (1998). 
[196] V. S. Pharmacopoeia, Validation of Compendial Methods, USP - 26 - NF 21 
(2003). 
[197] http://www.vub.ac.be/fabi/tutoriai/robust/index.html 
[198] http://www.pharmaqualitv.com/LabNotebook4.htm 
[199] http://www.locumusa.com/pdfygeneral/articleO 1 .pdf 
[200] http://www.labcompliance.com/tutorial/methods/default.aspx. 
[201] W. J. Youden, and E. H. Steiner, Statistical Manual of the AOAC, Association 
of Official Analytical Chemists (1975). 
[202] L. Cuadros-Rodriguez, R. Romero and J. M. Bosque-Sendra, Crit. Rev. Anal. 
Chem. 35 (2005) 57. 
76 
[203] D. Herrera, L. Mayel, M. C. Galindo and H. Jung, J. Clin. Pharmacol. 40 
(2000) 1488. 
[204] C. M. Glazener, J. H. Evans and R. E. Peto, Cochrane Database Syst. Rev. 3 
(2003) CD002117. 
[205] F. O. Muller, R. Schall, E. M. Mogilnicka, G. Groenewoud, H. K. Hundt, H. 
G. Luus, M. V. Middle, K. J. Swart and A. C. DeVaal, Biopharm. Drug 
Dispos. 17(1996)81. 
[206] W. C. Houghton, T. E. Scammell and M. Thorpy, Sleep Med. Rev. 8 (2004) 
355. 
[207] B. Vythilingum, C. Cartwright and E. Hollander, Int. Clin. Psychopharmacol. 
2 (2000) S7. 
[208] N. A. Fineberg and K. J. Craig, Psychiatry 6 (2007) 234. 
[209] H. G. Westenberg, J. Affect. Disord. 40 (1996) 85. 
[210] K. K. Nielsen, K. Brosen, M. G. Hansen and L. F. Gram, Clin. Pharmacol. 
Ther. 55(1994)518. 
[211] A. E. Balant-Gorgia, M. Gex-Fabry and L. P. Balant, Clin. Pharmacokinet. 
20(1991)447. 
[212] J. E. F. Reynolds, Martindale. The Extra Pharmacopoeia, 31st edn.. The 
Pharmaceutical Press, London (1996) 1577. 
[213] J. Vaglenova and V. Vesselinov Petkov, European 
neuropsychopharmacology. the Journal of the European College of 
Neuropsychopharmacology 11 (2001) 33. 
[214] B. Gabryel, M. Adamek, A. Pudelko, A. iMalecki and H. I. Trzeciak, 
Neurotoxicology 23 (2002) 19. 
[215] J. G. Gobert, Pharm. Belg. 27 (1972) 281. 
77 
[216] B. Winblad, CNS drug reviews 11 (2005) 169. 
[217] M. J. Lohse and B. MuUer-Oerlinghausen, Psychopharmakajn 
Arzneiverordnungsreport, Fischer Verlag, Germany, Stuttgart, (1996) 383. 
[218] E. Mutschler, H. Derendorf, M. Schhafer-Korting, K. Elord and K. S. Estes, 
Drug Actions, Basic Principles and Therapeutic Aspects, Medpharm Scientific 
Publishers, Stuttgart (1995) 116. 
[219] R. L. Kunka and J. M. Perel, Curr. Ther. Res. 45 (1989) 1088. 
[220] E. Korpi, J. E. Kleinman, R. Costakos etal., Psychiatry Res 11 (1984) 259. 
[221] Forsman, G. Folsch, M. Larsson and R. Ohman, Curr. Ther. Res. 21 (1977) 
606. 
[222] A. Forsman and M. Larsson, Curr. Ther. Res 24 (1978) 567. 
[223] G. Mc Evoy, AHFS Drug Information, American Society of Health-System 
/'/zarwac/s/.v, Bethesda (2006). . A-,,,. 
78 
CHAPTER 2 
Optimisation and Validation of 
Spectrofluorimetric method for the 
Detemiination of Clomipramine 
Hydrochloride via Ion-pair 
complexation with alizarin red S. 
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INTRODUCTION 
Clomipramine hydrochloride is chemically known as 3-chloro-5-[3-
(dimethylamino) propyl]-10, 1 l-dihydro-5H-dibenz [b, f] azepine 
monohydrochloride with a molecular weight of 351.31. Clomipramine belongs 
to a group of medications called tricyclic antidepressants [1]. It occurs as 
white to off-white crystalline powder. 
Clomipramine is used for the treatment and relief of obsessive and compulsive 
disorders as well as in depression and other emotional disturbances. It works 
by increasing the amount of serotonin, a natural substance in the brain that is 
needed to maintain mental balance. Clomipramine is extensively 
biotransformed to desmethylclomipramine and other metabolites and their 
glucuronide conjugates. Desmethylclomipramine is pharmacologically active 
and participates in both therapeutic and unwanted effects. Clomipramine is 
considered to be the most potent inhibitor of serotonin uptake among all the 
tricyclic antidepressants, while its main hepatic metabolite 
desmethylclomipramine has been shown to be a stronger inhibitor of 
norepinephrine and a weaker inhibitor of 5-HT uptake than the parent drug. 
The usual recommended initial dose is 25 mg daily. Despite the beneficial 
effects of clomipramine hydrochloride the pharmacological doses of the drug 
had many undesirable side-effects and its overdosage may cause adverse 
reactions. Therefore, the therapeutical and pharmacological importmice of 
clomipramine has prompted the development of several methods for its 
deteiTnination, both in body fluids and pharmaceuticals. 
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The assay procedure of the drug in dosage forms is official in British 
Pharmacopoeia [2], and United States Pharmacopoeia [3]. Clomipramine has 
been determined in its pharmaceutical dosage forms and biological fluids by 
high performance liquid chromatography [4-6], gas chromatography [7], 
capillary gas chromatography [8], liquid chromatography [9,10], capillary 
zone electrophoresis [11,12], flow injection analysis [13], spectrophotometry 
[14-19] and spectrofluorimetry [20,21]. These methods were associated with 
some major drawbacks such as inadequate sensitivity, time-consuming, 
tedious, and dedicated to sophisticated and expensive instruments. Although, 
spectrofluorimetry is a sensitive and simple technique, however, the literature 
relating to the suitable spectrofluorimetric methods for the determination of 
the clomipramine is scanty. So far only two spectrofluorimetric methods for 
determination of clomipramine had been reported which were time consuming 
[20]. For these reasons, the development of new, sensitive and simple 
spectrofluorimetric method that overcomes the drawbacks of the existing 
methodologies was very essential. 
The present chapter describes a new spectrofluorimetric method for the 
determination of clomipramine hydrochloride in pharmaceutical formulations. 
The method is based on the formation of ion-pair complex between 
clomipramine and alizarin red S at pH 1.99. The ion-pair complex was 
extracted with chloroform and the fluorescence intensity was measured at 561 
nm with excitation at 490 nm. The reaction conditions were optimized and 
validated as per International Conference on Hamionisation (ICH) guidelines 
[22]. 
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EXPERIMENTAL 
Apparatus 
All fluorescence spectra were recorded on an F-2500 Hitachi fluorescence 
spectrophotometer (Tokyo, Japan) equipped with xenon arc lamp. Slit widths 
were set at 5 nm. All measurements took place in quartz cells with path length 
1.0 X 1.0 cm. Excitation and emission wavelengths were set at 490 and 561 
nm. Eutech (Cyberscan pH 2100) pH meter was used to measure the pH. All 
measurements were performed at 25 ± 1 °C. 
Materials and reagents 
• Clomipramine hydrochloride pure sample was obtained from Sigma 
chemical company (St. Louis, MO, USA) and used as received. The 
following commercially available pharmaceutical dosage forms were 
subjected to analysis: CIonil-50 tablets (Intas Pharmaceuticals Ltd., 
Ahmedabad, India) labelled to contain 50mg each and Clofranil-50 tablets 
(Sun Pharmaceutical Industries, Mumbai, India) labelled to contain 50mg 
each. 
• 2.92 X lO'^ M Alizarin red S (Fluka Chemie AG, Switzerland, M.W.: 
342.26) solution was freshly prepared in distilled water. 
• Buffer solutions ranging from pH 1.42 - 3.49 were prepared by mixing 
appropriate volumes of IN sodium acetate and IN HCl. 
All chemicals and solvents used were of analytical grade. 
Standard drug solution 
A standard stock solution of clomipramine hydrochloride was prepared by 
dissolving 100 mg of drug in 100 ml distilled water. This solution was further 
82 
diluted with water to obtain 0.1 mg ml'' clomipramine hydrochloride working 
standard solution. 
General procedure 
Portions (0.05 - 1.0 ml) of working standard solution of clomipramine 
hydrochloride (0.1 mg ml"^ ) were transferred into a series of 25 ml separating 
funnels. To each separating funnel, 2.0 ml of 2.92 x 10"^  M alizarin red S 
solution and 1 ml of buffer solution (pH-1.99) were added. The contents of the 
separating funnel were shaken well with 5 ml of chloroform for 2.0 min and 
then allowed to separate the two layers. The fluorescence intensity of the 
formed ion-pair complex was measured at 561 nm after excitation at 490 run. 
The fluorescence intensity was plotted against the concentration to get the 
calibration graph. The amount of the drug was evaluated either from the 
calibration graph or from the corresponding regression equation. 
Analysis of commercial tablets 
Ten tablets of each brand were grounded and finely powdered. An amount 
equivalent to 100 mg of clomipramine hydrochloride was accurately weighed 
and treated with 30 ml distilled water and left for 10 min for complete 
extraction of the drug. The aqueous extract was filtered through Whatmann 
No. 42 filter paper (Whatmann International Limited, Kent, UK) in a 100 ml 
volumetric flask. The residue was washed well with distilled water and the 
volume was completed upto the mark. This solution was further diluted to 
obtain a suitable concentration and analysed by the proposed procedure. 
Determination of stoichiometry 
Job's method of continuous variations [23] was applied for ascertaining the 
stoichiometry of the ion-pair complex. This was achieved by combining 
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different volumes i.e. 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 4.9 ml 
of clomipramine hydrochloride (2.85 x lO""* M) with 4.9, 4.5, 4.0, 3.5, 3.0, 2.5, 
2.0, 1.5, 1.0, 0.5, and 0.1, of alizarin red S (2.85 x 10"* M) respectively into a 
25 ml separating funnel. The contents of the funnel were shaken vigorously 
with 5 ml chloroform and then allowed to stand for clear separation of the 
organic phase. The fluorescence intensity measured at 561 rmi was plotted 
against the mole fraction of drug. 
Procedure for reference method [20] 
One milliliter of working standard solution of clomipramine hydrochloride 
(0.001 - 0.01 mg ml"') was transferred into a 10 ml volumetric flask, followed 
by 1 ml of eerie ammonium sulphate (0.002M). The solutions were mixed well 
and heated in a thermostatically controlled water bath at 100 ± TC for 20 
minutes. The flasks were then cooled and diluted to the mark with distilled 
water. The fluorescence intensity was measured at 355 nm with excitation at 
254 nm. The amount of the drug in a given sample can be estimated either 
from the calibration graph or the corresponding linear regression equation. 
RESULTS AND DISCUSSION 
Literature survey reveals that tertiary nitrogen in clomipramine hydrochloride 
is capable of forming ion-pair complexes with various dyes and reagents such 
as azocarmine-G, naphthalene blue and naphthalene blue black [15], thymol 
blue [16], orange I, orange II, croceine orange, lithol Red, fast Red A [17], and 
picryl chloride [18]. The reaction of clomipramine and alizarin red S has not 
been investigated so far. In the present study clomipramine hydrochloride was 
found to react with alizarin red S at pH 1.99 resulting in the formation of 
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fluorescent ion-pair complex which is most suitably extracted in chloroform. 
Fig. 2.1 shows the excitation and emission spectra of ion-pair complex. The 
maximum fluorescence intensity was observed at 561 nm when excited at 490 
nm. The fluorescent ion-pair complex formation can be applied to enhance the 
sensitivity of the method for determination of clomipramine hydrochloride. 
Stoichiometry and reaction mechanism 
Clomipramine hydrochloride is a derivative of dibenzazepine group 
possessing nitrogen atom of tertiary amine group in the aliphatic chain which 
offers a basic characteristic to the drug. The drug is protonated at pH 1.99 and 
consequently a positive center is created in the drug molecule. Alizarin red S 
is a sodium salt of 3, 4-dihydroxy-9, 10-dioxo-2-anthracene sulphonic acid 
which ionizes in aqueous solution and thus develops a negative charge on it. 
The job's plot revealed that the combining molar ratio between clomipramine 
and alizarin red Sis 1:1 (Fig. 2.2). It indicated that one mole of clomipramine, 
providing one positive centre, reacts with one mole of alizarin red S, providing 
one negative centre, resulting in the formation of chloroform extractable ion-
pair complex. Therefore, based on the literature background and our 
experimental findings, the possible reaction sequence is shown in Scheme 2.1. 
The apparent formation constant and Gibb's free energy (AG°) were calculated 
and found to be 9.54x10^ and -39.82 kJ mol'', respectively. 
Study of experimental conditions 
Various experimental parameters affecting the formation of ion-pair complex 
were carefully studied and optiinized. Such factors were changed individually 
while the others were kept constant. The factors include concentration of 
alizarin red S, pH of aqueous solution, volume of buffer solution, shaking time 
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Step1 HaC 
Sodium acetate-HCI 
buffer solution of pH 1.99 
Clomipramine Protonated Clomipramine 
Step 2 
Protonated Clomipramine 
+ 
In chloroform 
at25+1°C 
O OH 
Alizarin red S 
Orange-yellow fluorescent ion-pair complex 
Scheme 2.1. Reaction pathway of the proposed method 
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and solvent for the extraction of ion-pair complex. 
Effect of concentration of alizarin red S 
The influence of the concentration of alizarin red S was studied using different 
volumes of 2.92 x lO'^ M solution of alizarin red S. It was found that the 
reaction of alizarin red S with clomipramine started upon using 0.5 ml of the 
dye in the presence of sodium acetate-HCl buffer of pH 1.99; keeping the 
amount of drug (20)ig) constant. Increasing the volume of alizarin red S, 
produces a proportional increase in the fluorescence intensity of the reaction 
product up to 1.9 ml and after that there was no effect on the fluorescence 
intensity. Therefore, 2.0 ml of 2.92 x IO'-'M of alizarin red S solution was 
chosen as the optimal volume of the dye (Fig. 2.3). 
Effect of pH 
In order to generate a positive centre in clomipramine, the reaction is carried 
out in acidic medium. Buffer systems (sodium acetate-HCl, potassium 
biphthalate-HCl) in the pH range 1.42 - 3.8 were tested. The sodium acetate-
HCl buffer system was found to be superior to the potassium biphthalate-HCl 
buffer since it gave the highest fluorescence intensity. The influence of pH on 
the reactions was studied by carrying out the reaction in sodium acetate-HCl 
solution of pH 1.42 - 3.49. The results indicated that the fluorescence intensity 
increased as the pH increased and maximum readings were obtained at pH 
1.99 after which the fluorescence intensity of the reaction product began to 
decrease gradually until pH 3.49 (Fig. 2.4).Therefore , pH of 1.99 was 
chosen as ihe optimum pH for the determination process. 
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Effect of volume ofpH 1.99 buffer solution 
The influence of volume of pH 1.99 buffer solution on the fluorescence 
intensity was studied in the range of 0.2 - 1.5 ml. 
The maximum fluorescence intensity was obtained at 0.9 ml and after that the 
intensity remained constant (Fig. 2.5). Therefore, 1.0 ml of pH 1.99 buffer 
solution was adopted as an optimum volume for fluorescence measurement. 
Effect of shaking time for extraction 
Different time intervals (0.5-2.5 min) were tested to ascertain the shaking time 
required for complete extraction of the complex. It was found that the highest 
fluorescence intensity was reached at 1.5 min and after that the intensity 
remained constant up to 2.5 min (Fig. 2.6). Therefore, shaking time of 2.0 min 
was adequate for the extraction of ion-pair complex into chloroform. 
Solvent effect 
In order to select the most appropriate solvent, the extraction of the ion-pair 
complex was performed in different solvents such as chloroform, carbon 
tetrachloride, dichloromethane, dichloroethane, and ethyl acetate. It is clear 
from the graph (Fig. 2.7) that the solvent which gave the highest fluorescence 
intensity was chloroform while carbon tetrachloride gave the lowest. 
Therefore, chloroform was chosen as the most appropriate solvent for 
extraction of the ion-pair complex. 
Analytical performance 
Calibration and sensitivity 
Under the optimum conditions, calibration curve for the determination of 
clomipramine hydrochloride was constructed by plotting the fluorescence 
intensity as a function of the corresponding clomipramine concentration (Fig. 
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2.8).The regression analysis of the calibration data gave the regression 
equation as: 
F= 1.268+13.615 C, 
where F is the fluorescence intensity, C is the concentration of clomipramine 
in \ig ml"'. The linear relationship was obtained in the concentration range of 
1.0 - 20.0 i^ g ml ' with a correlation coefficient of 0.9999. The LOD and LOQ 
were determined according to ICH guidelines for validation of analytical 
procedures [22]. The LOD and LOQ values were found to be 0.32 ^g ml"' and 
0.97 |ig ml"', respectively. 
Precision and repeatability 
The within days precision was evaluated through replicate analysis at three 
concentration levels i.e 2.0, 10.0 and 20.0 ng ml"' of clomipramine by 
performing five experiments on the same day using the same anal>le standard 
.solution. The inter-day precision on five successive days was evaluated 
through replicate analysis of the same concentrations of clomipramine used in 
intra-day precision. The results are summarized in Table 2.1. It can be seen 
from the table that the percent relative standard deviation did not exceed 0.3%, 
proving the high precision and accuracy of the proposed method. 
Accuracy and recovery 
Recovery studies were performed using standard addition method. For this, 
known quantities of pure clomipramine hydrochloride were mixed with 
definite amounts of preanalyzed commercial dosage forms and mixtures were 
analysed following the proposed method. The resuKs are reported in Table 
2.2. The percent recoveries obtained were quantitaUve (99.75-100.05%) 
indicating the good accuracy of the method (Fig. 2.9). 
96 
300 
250 
c 
(D 
0 
O 
c 
0) 
o 
w 
o 
3 
200 -
150 
100 
50 
0 
0 
-T -
5 10 15 
Concentration of drug (pg/ml) 
20 25 
Fig. 2.8. Calibration curve for the determination of clomipramine 
hydrochloride. 
97 
o 
o 
o 
en 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
<: 
o 
o 
o 
o o 
o 
o 
o 
o 
o 
(N 
o 
o 
Q 
C/) o o 
0 0 
o o 
o 
o 
a 
o 
u 
a. 
a 
o 
a 
H 
n 
H 
c 
C 
o 
c 
o U 
Q 
GO 
O 
m 
o O 
o 
+1 (N 
o 
o 
(N 
m 
o 
o 
o 
+1 
1 — 1 
o 
o 
' — 1 
m 
o 
o 
o 
+1 
o 
as 
OS 
^^  
IT) 
o 
o 
o 
+1 
o ON 
Ov 
' — 1 
00 
o 
o 
o 
+1 
o 0^ 
o 
as 
W-) 
o p 
o 
+1 ON 
as 
as 
^^  
c o 
o 
O 
o 
o 
o 
o 
o 
^ (N 
o 
o 
rN —I o 
o 
J 3 
t 3 
<L) 
O 
O H 
o 
O H 
-a 
s 
o 
t/2 
i-
•Id 
c/5 C 
_o 
*-w 
03 
C 
• | 
4> 
T3 
4 - ^ 
a 
T 3 
G 
U 
-o 
c 
' " • 
OJ 
> q^ 
,o 
t-t. 
c 
c<3 aj 
s 
!-^  
O 
1) 
, C3 
' ^ 
13 
c C3 
•xi 
u, 
a TS 
-4—» 
m 
w" 
< 
en 
> 
<u 
o j ^ 
a> T3 
o 
>n ON 
-»-» 
« 
• * — » 
1 
^^  
<u 
o G (L> 
-a « 
c 
o o 
^ 
U 
"c 
u 
V 
+-» C 
o 
es 
S3 
-O 
a 
C3^ 
o 
CJ 
98 
t ^ 
o 
c 
o 
•4-» 
cS 
;3 
cr D 
c 
o 
on to 
U 
V 4 
0 0 
(U 
V i 
;-> c3 
<U 
_C 
•"^  <+H 
o V5 
-*-» C 
_ 0 
' Q 
<u 
o U 
c 
o 
' - t — • 
'-5 T 3 
CO 
T 3 
^ 
c c3 
in o 
t^ o 
ON O 
ON " 
p. 
o 
ON 
ON 
ON 
ON 
C5 
>o ON 
ON 
ON 
d 
ON 
0 0 
oo 
0 0 
I ^ en ON 
Xi 
w 
-o 
u 
o ;. 
-O 
>% 
u 
C 
S 
cs 
u 
o 
o 
u 
W 
DO 
C 
I 
-4-» 
c 
CJ 
c 
o 
u 
T3 
C 3 
O 
a> 
•T3 
-a 
GO 
O 
> 0 
ON 
ON 
o 
o" 
r4 
od 
• * ' 
o 
o 
o 
o 
00 
o 
o" 
OO 
o p 
od 
o 
ns 
O 
o 
'o 
IS 
C/3 
c 
u 
T3 
C 
> 
>-• 
c 
a 
99 
-1—» 
w 
c 0) 
•*-» 
c 
0 
o 
c a> 
o U) 
0) 
t . 
o 13 
LL 
1 
300 -
250 -
200 -
150 -
100 -
— e -
b 
• ^ a 
1 1 
10 
nominal 
0 
concentration 
(ng/ml) 
10 
spiked 
20 
Fig. 2.9. Recovery of clomipramine from clonil-SO tablet by Standard 
addition technique: (a) 4.0 and (b) 8.0 ^g/mL. 
100 
Selectivity 
The selectivity of the method was evaluated by investigating the interference 
liabilities from the common excipients that might be added during 
pharmaceutical formulation. Tablet excipients such as lactose, starch, glucose, 
fructose and magnesium stearate did not interfere with the assay. The results 
of the recovery experiment also indicated that neither the accuracy nor the 
precision of the proposed method is affected by the coformulated substances. 
Robustness 
Robustness was examined by evaluating the influence of small variation in the 
method variables on its analytical performance. In these experiments, one 
parameter was changed whereas the others were kept unchanged, and the 
recovery percentage was calculated each time. It was found that variation in 
the volume of 2.92 x 10'^  M alizarin red S solution (optimum ± 0.3 ml), 
reaction temperature, 25 ± 2°C, volume of pH 1.99 buffer solution (optimum 
± 0.1 ml), shaking time (optimum ± O.Smin.) did not significantly affect the 
procedures. The proposed spectrofluorimetric method is reliable during 
normal usage and considered to be robust. 
Pharmaceutical applications 
It is evident from the above-mentioned results that the proposed method gave 
satisfactory results with clomipramine in its bulk. Thus its pharmaceutical 
dosage forms (Clonil-50 and Clofranil-50) were subjected to the analysis of 
their clomipramine contents by the proposed and the reference methods. The 
results are summarized in Table 2.3. The results were compared with those 
obtained from the reported method [20]. No significant differences were found 
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between the calculated and theoretical values of t- and F-tests at 95% 
confidence level proving similar accuracy and precision in the determination 
of clomipramine by both methods. In addition to this, in both the 
determinations, the values of lower and upper limits based on the recovery 
experiments were found to be within ± 2%; indicating the compliance of the 
regulatory guidelines [22]. 
The performance of the proposed method was compared with other existing 
methods (Table 2.4). It can be seen from the table that the linear range of the 
proposed method is quite appreciable and most of the determinations of 
clomipramine can be done in this range successfully. Moreover, the RSD 
value of the proposed method is smaller than that of other methods. 
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CHAPTER 3 
Development and Validation of Fixed-
time method for the Determination of 
Isoxsuprine Hydrochloride in 
Commercial Dosage Forms. 
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spectrophotometric methods have been reported for determination of ISx in 
pharmaceutical preparations [24, 25]. Moreover, some specific advantages of 
kinetic methods such as selectivity can be expected because of the 
measurement of evolution of the absorbance as a function of reaction time. 
There is still a need for a sensitive kinetic spectrophotometric method for 
determination of ISx that can be adopted for routine analysis of 
pharmaceutical samples. 
In the present chapter, a kinetic spectrophotometric method based 
on the reaction of ISx with hydroxylamine hydrochloride and ammonium 
cerium (IV) nitrate in sulphuric acid medium is described and the proposed 
method has been extended to the determination of ISx in tablets. 
EXPERIMENTAL 
Apparatus 
All absorption spectra were recorded using Elico UV-visible 
spectrophotometer (Elico Ltd., SL-164, Hyderabad, India) with matched 
quartz cells. Absorbance was measured using spectronic 20 D+ 
spectrophotometer (Milton Roy Co., New York, USA). 
Chemicals and reagents 
All chemicals and reagents used were of analytical grade 
• 1.82xlO"^M Ammonium cerium (IV) nitrate (Qualigens Fine Chemicals 
Ltd., Mumbai, India) solution was freshly prepared in distilled water. 
• 1.43X10"'M Hydroxylamine hydrochloride (Ranbaxy Fine Chemicals Ltd. 
New Delhi, India) solution was prepared in distilled water. 
• 2.55M sulphuric acid (Sd. Fine-Chemicals Ltd., Mumbai, India). 
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ISx as a reference standard was obtained from Farmenta Biotech Ltd., Thane, 
India (Batch No. ISOX 02-02) and used as received. Tablet formulations of 
ISx such as duvadilan (Solvay Pharma Ltd., Mumbai, India) and Tidilan 
(Juggat Pharma, Bangalore, India) were purchased from local drug stores. 
Each tablet labeled to contain 20 mg ISx. 
A standard solution of ISx (1 mg mL'') was prepared in distilled water. 
Procedure for the determination of ISx 
Aliquots of the standard solution of ISx (Img mL'') corresponding to 300-800 
Hg were transferred into 10 mL volumetric flasks. To each flask, 0.9 mL of 
1.43 X 10 ' 'M hydroxylamine hydrochloride was added followed by 1.5 mL of 
2.55 M sulphuric acid and left for 1 min after shaking. Then, 1.7 mL of 
1.82x10'^  M ammonium cerium (IV) nitrate was added and volume was 
completed with distilled water. The absorbance of the resulting solution was 
measured at 380 nm against the reagent blank as a function of time. The 
change in absorbance (AA) between the time ti (2 min) and X2 (4 min) was 
computed and plotted against the initial concentration of ISx. The amount of 
ISx in a given sample can be computed either from the calibration graph or 
corresponding regression equation. 
Assay of ISx tablets 
To determine the ISx in tablet formulations, the contents of five tablets were 
finely powdered and stirred with 25 mL distilled water and left stand for 10 
min, then it was filtered through Whatmann filter paper no. 42 and filtrate was 
diluted to volume in a 100 mL volumetric flask with distilled water. The 
content of drug in each sample was determined using the proposed procedure 
and B.P. method as a reference [3]. 
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Validation Protocol 
The proposed method has been validated for specificity, Hnearity, accuracy, 
precision, recovery and limits of detection and quantitation. 
Specificity 
The specificity of the proposed spectrophotometric method was ascertained by 
analyzing the pure ISx in presence of commercial dosage forms such as starch, 
lactose, magnesium stearate, talc and avisil. 
Linearity 
The linearity of the present method was assessed in the concentration range of 
30-80 [ig/mL. 
Accuracy and Precision 
The accuracy and precision of the proposed method was ascertained by 
determining the ISx content in quality control samples and pharmaceutical 
preparations at two concentration levels 35.0 and 75.0 ^g/mL. Each 
concentration level was analyzed five times within a day as well as for 5 
consecutive days. 
Recovery studies 
The recovery experiments were carried out by standard addition method .For 
this 2.0 ml of reference ISx solution (1.0 mg ml"') was transferred into a 10 
mL volumetric flask followed by 6.0 ml of sample solution (1.0 mg mr')and 
the volume was completed to the mark with distilled water. One milliliter of 
this solution was analyzed following the recommended procedure. 
Limits of detection (LOD) and quantitation (LOQ) 
LOD and LOQ values were calculated according to ICH guidelines [26]. 
I l l 
Evaluation of bias 
The point and interval hypothesis tests [27] have been used to evaluate the 
bias. In interval hypothesis test, the criterion for acceptance of the proposed 
method is that when the true mean is within ± 2.0 % of that of the reference 
method, i.e., 
0.98 < ^ 2 / ^ i < 1.02 
which can be generalized to 
0, < 2^ / m < 0,, 
where 0; and d„ are lower and upper acceptance limits, respectively. The 
limits of this confidence interval can be calculated using the following 
quadratic equation: 
where x, and Xj are mean values based on ni and n2 measurements, 
respectively. Sp is the pooled standard deviation and ttat is the tabulated one-
sided t-value, with (ni + n2 -2) degrees of freedom at 95% confidence level. 
RESULTS AND DISCUSSION 
It has been reported [28] that the ammonium cerium (IV) nitrate in the 
presence of hydroxylamine hydrochloride forms stable orange coloured 
complexes with aromatic hydroxyl compounds. The colour was completely 
developed in 30 - 60 min and these complexes absorbed maximally at 380 run. 
ISx possesses phenolic group in its moiety and hence, reacts in a similar 
fashion, with ammonium cerium (IV) nitrate in the presence of hydroxylamine 
hydrochloride at room temperature resulting in the formation of coloured 
complex which absorbs maximally at 380 nm. The intensity of the colour 
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increases with time and hence a kinetic spectrophotometric method has been 
developed for the determination of ISx in commercial dosage fonns. The 
absorption spectrum is shown in Fig. 3.1. 
Optimization of variables 
Various parameters affecting the formation of the coloured product were 
examined and optimized by carrying out a series of experiments. 
Effect of hydroxylamine hydrochloride concentration 
The effect of the concentration of hydroxylamine hydrochloride on the 
absorbance of the coloured product was investigated over the concentration 
range of 8.58 x lO'^ ^M - 1.72 x \{y^M; keeping the concentrations of sulphuric 
acid (0.38M), ISx (50 \xg mL"') and ammonium cerium (IV) nitrate (3.09 x 10" 
•'M) constant. The results are presented in Fig. 3.2. As can be seen, the 
maximum and constant absorbance was obtained in the concentration range 
1.14xlO"^M - 1.72xlO'^M. Therefore, 1.29xlO"^M hydroxylamine 
hydrochloride was used as an optimum concentration. 
Effect of sulphuric acid concentration 
The influence of the concentration of sulphuric acid on the formation of 
product was investigated in the range of 0.13-0.46M. It was observed (Fig. 
3.3) that the maximum absorbance was obtained with 0.3 IM sulphuric acid 
and remained constant upto 0.46M. The optimum value of sulphuric acid was 
chosen as 0.38M for the determination process. 
Effect of ammonium cerium (IV) nitrate concentration 
The effect of Ce (IV) concentration on colour development was studied in the 
concentration range of 9.1 x 10"*M - 3.64x l O'^ M; keeping the concentrations of 
ISx ( 50 |ig mL'') and sulphuric acid ( 0.38M ) and hydroxylamine 
113 
0.88 -1 
0.86 -
0.84 
0) o c 
ni 
•e 0.82 
o 
w 
< 
0.80 H 
0.78 
0.76 -t 
340 350 360 370 380 390 
Wavelength (nm) 
400 410 42C 
i - i Fig. 3.1. Absorption spectrum of the product (1 M'gmr IS\ + 0.9 ml of 
1.43 X 10 'M +1.5 ml of 2.55M H2SO4 +1.7 ml of 1.82 x lO'^ M 
ammonium cerium (IV) nitrate). 
114 
u.ou -
0.75 -
0.70 -
o 
c 
ro 
•e 0.65 -
o 
</) 
< 
0.60 -
0.55 -
0.50 -
-^ -^
/ 
/ 
/ 
/ 
1 1 1 1 1 
0.008 0.010 0.012 0.014 0.016 
Concentration of hydroxylamine HCI [M] 
0.018 
Fig. 3.2. Effect of concentration of hydroxylamine HCI on the 
absorbance of the product. 
115 
0.90 
0.85 -
0.80 
(D O 
C 
(D 
•9 0.75 
o 
(A 
< 
0.70 
0.65 
0.60 
0.10 0.15 0.20 0.25 0.30 0.35 0.40 
Concentration of sulphuric acid [M] 
0.45 0.50 
Fig. 3.3. Effect of concentration of sulphuric acid on the absorbance 
of the product. 
116 
hydrochloride (1.29 x 10"^ M) constant. It was found that increasing the 
concentration of Ce (IV) resulted in a subsequent increase in absorbance upto 
2.73xlO"^M and remained constant up to 3.64x10"^M (Fig. 3.4). Therefore, 
3.09xlO""^ M Ce (IV) was chosen as an optimum concentration for further 
studies. 
Selectivity 
The selectivity of the proposed spectrophotometric method was ascertained by 
analyzing the pure ISx in presence of tablet formulations such as starch, 
lactose, magnesium stearate, talc and avisil. It was found that common 
excipients present in tablet formulations did not cause any significant 
interference. 
Linearity 
Under the optimized experimental conditions, the absorbance of each solution 
was measured as a function of time at 380nm. The change in absorbance (AA) 
between the times ti (2 min) and Xj (4, 6,8,10 or 12 min) was computed and 
plotted against the initial concentration of ISx. The corresponding linear 
regression equations were also developed and reported in Table 3.1. The 
results showed that the most acceptable linearity was obtained when the 
change in absorbance (AA) between 2 min and 4 min (AA=A4 - A2) was 
plotted against the initial concentration of ISx. Therefore, this fixed time was 
selected for the assay procedure. The linear dynamic range, molar 
absorptivity, regression equation, correlation coefficient, limits of detection 
and quantitation, standard deviations of intercept (Sg) and slope (Sb) are 
summarized in Table 3.2. The small figures i.e. Sa and Sb obtained refer to the 
high precision of the method. 
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TABLE 3.1: Calibration Equations at Different Fixed-times. 
AA Calibration Equations* Coefficient of Correlations (r) 
A4-A2 AA = 4.51x10"^ C-1.0220 0.9952 
A6-A2 AA= 7.03x10'^ C-1.31x10"' 0.9615 
A8-A2 AA= 8.89x10'^ C-1.87x10"' 0.9683 
A10-A2 AA= 9.55x10'^ C-3.07xl0"' 0.9613 
A,2-A2 AA= 9.91x10"^ C-2.25xl0"' 0.9591 
*n = C concentration of ISx in |igmL 
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TABLE 3.2: Optical performance and regression characteristics of the 
proposed method. 
Parameters Proposed Method 
A,max (nm) 
Stability (h) 
Linear dynamic range (^g mL"') 
Molar absorptivity (L mol" cm") 
Linear regression equation 
Sa 
Sb 
Correlation coefficient (r) 
Detection limit (|ig mL'') 
Quantitation limit (ne mL"h 
380 nm 
Ihr 
30-80 
5.95x10^ 
AA=4.51 
1.703 xlO" 
3.12x10-^ 
0.9952 
6.76 
20.49 
With respect to A= a + bC, Where C is the concentration (^g mL"') and A is 
absorbance. 
Confidence interval of the intercept at 95% confidence level. 
'^ Confidence interval of the slope at 95% confidence level 
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Accuracy and Precision 
The accuracy and precision of the proposed method was ascertained by 
determining the ISx content in pure form at two concentration levels: 35.0 and 
75.0 |ig mL"'. Each concentration level was analyzed five times within a day 
as well as for 5 consecutive days. The results are presented in Table 3.3 and 
3.4. The percent relative error and RSD were less than ± 2.5% and 1.91%, 
respectively. 
Robustness 
The robustness of the proposed method was evaluated by slight variation of 
the experimental parameters such as: 
• room temperature ± S^C, 
• volume of 2.55MH2SO4, 1.5 ±0.3mL, 
• volume of 1.43x 1 0"'M hydroxylamine hydrochloride, 0.9±0.1mL 
• volume of 1.82x 1 Q-^ M Ce (IV), 1.7±0.3mL. 
To assess the robustness, the active drug content in Tidilan tablet was 
determined. The quality control sample solution containing 60ng mL"' ISx was 
analyzed five times. The percent recovery ± RSD (100.20±0.50) was found to 
be appreciable. This concluded that the proposed method is robust. 
Applicability of the proposed method 
The proposed method was further applied to the determination of ISx in 
commercial dosage forms. The analysis of same batch of samples was also 
carried out using UV spectrophotometric method [3]. The results of the 
proposed method were compared with those obtained by reference method in 
terms of mean recovery, RSD, 0L, 0U, t and F values (Table 3.5). 
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TABLE 3.3: Test of precision (Intraday and Interday assays) for determination of 
isoxsuprine hydrochloride in pure form. 
Proposed Method 
Intraday assay 
Interday assay 
Concentration (ug/ml) 
Taken 
35.0 
75.0 
35.0 
75.0 
Found^ ± SD 
35.399± 0.517 
74.689± 0.668 
34.13210.651 
74.432+ 0.705 
RSD 
(%) 
1.462 
0.894 
1.907 
0.947 
Error 
(%) 
1.14 
-0.415 
-2.48 
-0.757 
"Mean for five independent analyses. 
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TABLE 3.4: Standard addition method for the determination of 
Isoxsuprinehydrochloride. 
Concentration (|Jg/ml) 
Pharmaceutical _ _ « ^ — . ^ — ^ ^ » i . « . ^ ^ « « . ^ ^ _ » » _ ^ ^ ^ Recovery*±RSD (%) 
Formulations jaken Added Found^iSD 
Duvadilan 20.0 60.0 80.055±0.678 100.07±0.850 
Tidilan 20.0 60.0 80.097±0.353 100.12±0.441 
Mean for five independent analysis. 
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No significant difference was noticed between the proposed method and reference 
methods regarding accuracy and precision as revealed by t- and F-tests. The interval 
hypothesis test has also been performed to compare the results at 95% confidence 
level.lt was observed that true bias of all samples is less than ±2% indicating the 
compliance of the regulatory authorities [29]. 
The perfonnance of the proposed method was compared with other existing 
spectrophotometric methods. The data presented in Table 3.6 revealed that the linear 
dynamic range of the proposed method is suitable for the determination of ISx in 
tablets and its sensitivity is comparable with other existing methods. Moreover, the 
analysis time is less as compared to other methods and also does not require 
extraction of complex into organic solvent. The method is simple requiring only 
cheaper reagents. 
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CHAPTER 4 
Initial Rate method for the 
Determination of Piracetam in 
Pharmaceutical Formulations using 
Alkaline Potassium Permanganate as 
Oxidant. 
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INTRODUCTION 
Piracetam is a nootropic drug [1] and its chemical name is 2-oxo-l-pyrrolidine 
acetamide. It is a fine white crystalline powder with a molar mass of 142.16 g 
mol"'. Piracetam is used in many countries to treat cognitive impairment in 
aging, brain injuries, Alzheimer's disease, Down syndrome, dementia and 
dyslexia [2-5]. Piracetam is usually available in 400 mg and 800 mg tablets or 
capsules. The recommended dosage varies based on the indication, usually 
ranging from 1.6 - 9.6 g daily. For blood coagulation, clotting and vasospastic 
disorders, the most effective treatment range is daily dosage of 4.8 to 9.6 g in 
three divided doses [6]. Keeping in mind the importance of piracetam for the 
treatment of neurophysiological abnormalities, it was planned to develop new 
analytical method for its determination in commercial dosage forms. 
Several analytical methods have been developed for the 
determination of piracetam in biological fluids and pharmaceutical 
formulations based on high performance liquid chromatography [7], gas 
chromatography [8], capillary electrophoresis [9], thin layer chromatography 
[10], FTIR spectroscopy [11], NMR spectroscopy [12], electrokinetic 
chromatography [13] and potentiometry [14]. Derivative spectrophotometric 
[15] determination of piracetam has also been reported. The above mentioned 
techniques are sensitive but expensive and require laborious clean up 
procedure prior to analysis. Spectrophotometry is a great alternative to these 
expensive techniques due to its inherent simplicity and therefore frequently 
used in the laboratories of the developing countries to overcome versatile 
analytical problems. The formation of hydroxamic acid with the drug has been 
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utilized for its quantification in pharmaceutical formulations. This reaction has 
been exploited spectrophotometrically with various modifications [16-18]. As 
far as our knowledge is concerned, no kinetic spectrophotometric method is 
reported for the assay of piracetam. The following specific advantages 
associated with the kinetic method can be expected: (i) more selectivity since 
it involves the measure of evolution of absorbance as a function of reaction 
time instead of the measure of a concrete absorbance value: (ii) the coloured 
and /or turbidity background of the samples most likely does not interfere with 
the determination: (iii) other active compounds present in dosage form may 
not interfere if they resist optimized chemical reaction condition of the 
proposed kinetic method. 
This chapter describes a simple and sensitive kinetic 
spectrophotometric method for the determination of piracetam in drug 
formulations. The method involves the oxidation of drug with alkaline 
potassium permanganate at lOOiTC and subsequent measurement of 
absorbance of the green coloured product at 603 nm. The initial rate method is 
adopted for its determination in pharmaceutical formulations. 
EXPERIMENTAL 
Apparatus 
All absorbance measurements were made on Spectronic 20 D+ 
spectrophotometer (Milton Roy Co., USA) equipped with 1 cm matching glass 
cells. 
The heating temperature for colour development was monitored using a water 
bath shaker (NSW 133, New Delhi, India). 
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Materials and reagents 
All chemicals and reagents used were either of analytical or pharmaceutical 
grades. 
• Sodium hydroxide (Finar chemicals Ltd., Ahmedabad, India) solution, IM, 
was prepared in distilled water. 
• Potassium permanganate (Merck, Mumbai, India) solution, 6.33 x lO'^ M, 
was prepared in distilled water. It should be freshly prepared and its 
apparent purity was assayed by titrimetric method [19]. 
• Piracetam reference standard was procured from Sigma chemical 
company, St. Louis USA. 
The conunercial tablets of piracetam such as neurocet-400 (Zeus 
Pharmaceuticals Industries., Baroda, India) were purchased from local drug 
store. 
Test solution 
The standard solution of piracetam (7.034 x 10'^ M) was prepared in distilled 
water. 
General procedure for determination of piracetam 
Different aliquots of standard piracetam solution corresponding to 10 - 140 
Hgml* were pipetted into a series of 10 ml volumetric flasks. To each flask, 
1.5 ml of IM NaOH was added followed by 1.2 ml of 6.33x]0'^M potassium 
permanganate and then diluted with distilled water. The contents of each flask 
were mixed well and kept in a water bath maintained at lOOiTC. The 
absorbance was measured at 603 nm against a reagent blank prepared 
similarly. The increase in absorbance was recorded as a function of time. The 
initial rate of the reaction (v) at different concentrations was evaluated by 
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measuring the slope of the tangent to the absorbance-time curve. The 
calibration graph was obtained by plotting the initial rate of reaction (v) versus 
the initial concentration of piracetam. The amount of the drug was calculated 
either from the calibration graph or regression equation. 
Procedure for determination in commercial tablets 
A total of 5 tablets, each labeled to contain 400 mg of piracetam were weighed 
and finely powdered using a mortar and pestle. An accurately weighed portion 
of the resulting powder equivalent to 400 mg was dissolved in 50 ml of 
distilled water. The aqueous extract was filtered through the Whatmann no. 42 
filter paper (Whatmann International Limited, Kent, UK) directly in a 100 ml 
volumetric flask. The residue was washed well with distilled water and filled 
up to the volume with distilled water. The resulting solution was ftirther 
diluted to obtain a solution in the working concentration range and the content 
of the drug was determined by the proposed procedure. 
Procedure for reference method [18] 
Into a series of 25 ml volumetric flasks, different volumes of (0.6 - 2 ml) 
standard solution of piracetam (7.034 x 10"^M), 4 ml of NaOH (3.5 M) and 2.0 
ml of hydroxylamine hydrochloride (2.0M) were pipetted and heated on a 
water bath at 60±rc for 30 min. Then it was cooled and 2.0 ml of HCl (6.7M) 
was added followed by 2.0 ml of ferric chloride (0.75M) and diluted to 
volume with distilled water. The absorbance was measured against tlie reagent 
blank prepared similarly. 
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RESULTS AND DISCUSSION 
Potassium permanganate has the ability to oxidize the reducing substance in 
acidic as well as alkaline media. These reactions can be written as: 
In acidic medium 
Mn04" + 8H^ + 5e" ^  Mn^* + 4H2O E° = 1.5 V 
In alkaline medium 
Mn04~ + e '— Mn04^" E° = 0.56 V 
In the present study, it was found that potassium permanganate oxidizes 
piracetam in alkaline medium resulting in the formation of a green coloured 
product. The absorption spectra of aqueous solution of piracetam and alkaline 
potassium permanganate showed maximum absorption at 205 nm and 530 nm, 
respectively. The reaction product absorbs maximally at 603 nm. As can be 
seen from the redox reaction that the green colour is due to the formation of 
Mn04 in alkaline medium. In alkaline medium the reaction is very slow at 
room temperature. A reasonable rate is obtained when the reaction is carried 
out at 100±rc. The absorbance was followed spectrophotometrically at 603 
nm as a function of time and therefore, a kinetic method has been developed to 
determine the piracetam. Moreover, potassium permanganate also oxidizes 
piracetam in acid medium. This reaction was very fast and hence has not been 
used for quantitative analysis. 
Stoichiometry 
The limiting logarithmic method [20] was used to evaluate molar combining 
ratio between piracetam and potassium permanganate. Two sets of 
experiments were performed. In the first set, the concentration of piracetam 
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was varied over the range of 7.03 x 10"^  - 2.81 x 10" M keeping a constant 
concentration of KMn04 (1.41xlO"^M). The second set was performed at 
different concentrations of KMn04 (1.24 x 10"^- 3.62 x lO'^M); keeping the 
concentration of piracetam constant (1.41 x lO'^M). The logarithm of the 
absorbance was plotted against the logarithm of the respective varied 
concentration of piracetam or KMn04 (Fig. 4.1a, b). It is evident from the 
slope of the two straight lines that the combining molar ratio between 
piracetam and KMn04 is 1:1. 
Optimization of variables 
Preliminary experiments were performed with the objective to optimize the 
reaction conditions. Therefore, the dependence of the rate of reactions on the 
concentration of each of the reactant was exhaustively studied. 
Effect of potassium permanganate concentration 
To study the influence of the concentration of potassium permanganate on the 
initial rate of reaction, varying concentrations of potassiimi permanganate 
(3.16 X lO'^ M - 8.56 X IC^M) were mixed with constant concentrations of 
piracetam (7.034 x lO'^ M) and NaOH (0.15M). The results are reported in 
Table 4.1 and Fig. 4.2. As can be seen from table and figure that the 
maximum and constant initial rate of reaction was obtained in the 
concentration range of 6.96 x 10"^ M - 8.56 x lO'^ M potassium permanganate. 
Therefore, a concentration of 7.59 x lO'^ M potassium permanganate was 
chosen as optimal for the proposed method. 
Effect of sodium hydroxide concentration 
Different concentrations of sodium hydroxide ranging from 0.05 - 0.16M 
were treated with constant concentrations of piracetam (7.034 x 10"^ M) and 
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Fig. 4.1(a,b). Slope-ratio method for the determination of stoichiometry 
of the reaction, (a). Piracetam concentration varied, keeping [KMn04] 
= 1.41 X 10"'*M constant; (b).KMn04 concentration varied, keeping 
[Piracetam] = 1.41 x lO'^ M constant. 
137 
TABLE 4.1: Effect of [KMn04] and [NaOH] on the initial rate of reaction at 
[piracetam]= 7.034 x 10"'M. 
[KMn04] 
mol L 
[NaOH] 
mol L"' 
-i_-u Initial rate of reaction, v (mol L" s') 
KMn04 NaOH 
3.16 X 10-
5.06 X 10 
5.70 X 10-" 
6.33 X 10-
6.96 X 10' 
7.59 X 10-
8.23 X 10-
8.56 X 10-
-4 
0.05 
0.08 
0.10 
0.11 
0.12 
0.13 
0.14 
0.15 
0.16 
1.02 X 
2.43X 
2.68X 
3.34X 
5.53X 
5.53X 
5.53X 
5.53X 
: 10-' 
10-^  
10'^ 
10-^ 
10"^  
10"^  
10'^ 
10'^ 
1.82 X 10"' 
2.34 X 10-^  
2.8 Ix 10"^  
3.65X 10"^  
4.21 X 10"^  
4.90 X 10'^ 
5.53X 10"^  
5.53 X 10"^  
5.53 X 10"^  
138 
0.006 
V 0.005 
to 
o 
£ 0.004 
c 
i 0.003 
(0 
0 
i— 
o 
B 0.002 
"TO 
- 0.001 
0.000 
0.0002 0.0003 0.0004 0.0005 0.0006 0.0007 0.0008 0.0009 
Concentration of KMnO^ [M] 
Fig. 4.2. Effect of concentration of KMn04 on the initial rate of reaction 
([NaOH] = 0.15M, [Piracetam] = 7.034 x 10"*M). 
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potassium permanganate (7.59 x 10 M). It was found that the initial rate of 
the reaction increased with increase in the concentration of NaOH and became 
constant at 0.14M (Fig. 4.3). Thus, a concentration of 0.15M was selected as 
the optimum concentration. 
Effect of temperature 
The oxidation of piracetam with alkaline potassium permanganate is very slow 
at room temperature. The oxidation reaction increased substantially with time 
at 100 ± r c . Therefore, all measurements were done at 100±rc. 
Analytical parameters and method validation 
Fig. 4.4. Shows the absorbance-time curves. The initial rates of reaction were 
calculated for different concentrations of piracetam. The results are 
summarized in Table 4.2. The following rate equation for the reaction can be 
written as: 
n „ m 1 
rate = k . C p.^^^^j^ • K.Mn04 " NaOH (1) 
when CKMn04> 6.94 x 10"*M and CNaOH > 0.14 M 
the rate of reaction became independent of concentrations of potassium 
permanganate and sodium hydroxide. The equation (1) is modified as: 
ra te — Kv(( . C piracetam (2) 
where ky is the pseudo-order rate constant and n is the order of reaction. 
Taking logarithms of initial rate of reaction and concentration, equation (2) is 
transformed into: 
log (rate) = log k + n log Cpjracetam 
Regression of log (rate) versus log Cpjracetam gave the following regression 
equation: 
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Fig. 4.3. Effect of concentration of NaOH on the initial rate of reaction 
([KMn04] = 7.59X IQ-^ M, [Piracetam] = 7.034 x IQ-^ M). 
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Fig. 4.4. Absorbance-time curve for the initial-rate of reaction for 
piracetam. {Piracetam concentration [M]: (a) = 7.03 x 10'^  ; (b) = 
1.41 X 10-5; (c) = 2.11 X lO"'; (d) = 2.81 x 10"*; (e) = 3.52 x lO"*; (f) = 
4.22 X 10^; (g) = 4.92 x 10 "•; (h) = 5.63 x 10"^ ; (i) = 6.33 x 10^; (j) = 
7.03 X 10^; (k) = 7.74 x 10"^ ; (I) = 8.44 x 10"*; (m) = 9.14 x lO"*; (n) = 
9.85 X 10 ••}. 
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TABLE 4.2: Initial rate at different concentrations of Piracetam {[KMn04l = 
7.59 X 10^ M and (NaOH] = 0.15 M}. 
Concentration of piracetam (mol L'') Initial rate of reaction, v (mol L'' s"') 
7.03 X 10-^  4.73 X 10-^  
1.41x10-^ 9.35x10-'' 
2.11x10"' 1.40x10-^ 
2.81 X 10-^  1.90 X 10"^  
3.52x10"^ 2.31x10-^ 
4.22 X lO"' 2.78 X 10"^  
4.92 X 10"* 3.24 X 10"^  
5.63 X lO"* 3.76 X 10"^  
6.33 X lO"' 4.21 X 10"^  
7.03x10-^ 4.64x10-^ 
7.74 X 10"^  5.16 X 10"^  
8.44 X lO"* 5.53 X IQ-^  
9.14x10-^ 6.08x10'^ 
9.85x10-^ 6.38x10-^ 
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Log (rate) = 0.775 + 0.99 log Cpiracetam 
Thus, the reaction is first order with respect to piracetam concentration. 
The quantitative determination of piracetam under the optimized experimental 
conditions outlined above would result in a pseudo-first order reaction with 
respect to the piracetam concentration. Under the working experimental 
conditions, the calibration graph (Fig. 4.5) was constructed by plotting the 
initial rate of the reaction versus piracetam concentration which was found to 
be linear over the concentration range of 7.03x10"^- Q.SSxlO'^ M (10 - 140 
fjgmr'). The linear regression analysis of calibration data yielded the 
following regression equation for the calibration graph, 
rate = 2.64x10'^ +4.61x10"^C (r = 0.9998) 
Where C is the concentration of piracitam in |ag ml ' 
The limits of detection (LOD) and quantitation (LOQ) were calculated [21] 
and were found to be 3.1 i^g mf' and 9.4|ag ml"', respectively. 
Accuracy and precision 
The accuracy and the intra-day precision were studied by analyzing five 
solutions of three different concentrations (15.0, 75.0 and 135.0 Mgml') of 
piracetam, each of which was independently prepared and each of them being 
determined five times on the same day. The inter-day precision was also 
performed at the same three concentrations for 5 consecutive days. The resuils 
are summarized in Table 4.3. Precision analysis showed the intra-assay 
variation between 0.07 and 0.5% and the inter-assay variation between 0.03 
and 0.77%. Moreover, the accuracy of the analysis varied between 99.78 -
99.97%. These values are sufficient for successfiil analysis of drugs in 
pharmaceutical formulations 
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Fig. 4.5. Calibration curve for the determination of piracetam. 
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Recovery studies 
The accuracy of the proposed method was also assessed by performing recovery 
studies using standard addition method. The standard addition method was applied to 
the pharmaceutical preparation to which known amounts of the standard piracetam 
were added. The accuracy was then calculated from the test results (Table 4.4) as the 
percentage of analyte recovered. As can be seen from the table that the mean 
percentage recovery was found to vary between 99.78 and 99.97% with low value of 
percent relative standard deviation. It is also evident from the recovery data that the 
excipients present in the tablet formulations did not interfere in the analysis. 
Robustness 
The robustness of the method was evaluated by small and deliberate variations in the 
concentrations of the reagents used. The parameters investigated were: 
• volume of 6.33 x lO'^ M KMn04, 1.2 ± O.lmL 
• volumeof IMNaOH, 1.5±0.ImL 
Under these conditions, a sample solution containing 80.0 ixgmf' of piracetam was 
analyzed five times in one day. The values obtained were quite satisfactoiy. 
Applicability of the proposed method 
The proposed method was successftilly applied to the determination of piracetam in 
pharmaceutical formulations. The resuhs of the proposed method were compared with 
those of the reference method using point and interval hypothesis tests [22]. Table 4.5 
shows that the calculated t- and F- values at 95% confidence level are less than the 
theoretical ones, confirming no significant differences between the performance of the 
proposed method and the reference method. The previous investigation were also 
checked and confirmed by interval hypothesis tests. The Canadian health protection 
branch has recommended that a bias, based on recovery experiments, of ±2% is 
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acceptable. It is evident from Table 4.5 that the true bias of all samples of drug 
is smaller than ±2%. 
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CHAPTER 5 
A Validated Spectrofluorimetric 
method for the Determination of 
Haloperidol via Ion-pair 
formation with Eosin Y. 
152 
INTRODUCTION 
Haloperidol is a potent antipsychotic with pharmacological profile resembling 
that of piperazine substituted phenothiazines [1]. It is chemically known as 4-
[4-(4-chlorophenyl)-4-hydroxypiperidin-1 -yl]-1 -(4-fluorophenyl) butan-1 -one 
and its molecular weight is 375.87. It is the preferred drug for the treatment of 
acute schizophrenia, Huntington's disease and Giller de la Tourett's syndrome 
[2]. Usual dosages for adults with moderate symptoms are jfrom 0.5 - 2.0 mg 
twice daily or three times daily. For severe symptoms, the usual dosage is 3 -
5 mg twice or three times daily. Peak plasma levels of haloperidol occur 
within 2 to 6 hours of oral dosing and about 20 minutes after intramuscular 
administration. However, higher dosage may cause severe side effects such as 
fast heart beat, Parkinson's like symptoms, neck spasm/involuntary muscle 
spasms, insomnia etc. Owing to the therapeutic importance of haloperidol, it is 
essentially required to develop simple and sensitive analytical method for its 
determination in commercial dosage forms. 
Haloperidol is the subject of a monograph in the USP 
[3] whereby a potentiometric titration with perchloric acid and HPLC method 
are recommended for its determination in bulk and pharmaceutical 
formulations. A review of the literature revealed that several methods have 
been published for the determination of haloperidol in pharmaceutical 
preparations and biological fluids. These methods include: spectrophotometry 
[4-6], gas chromatography [7], HPLC [8-13], HPTLC [14], capillary 
electrophoresis [15], square wave-adsorptive stripping voltammetry [16], 
NMR spectroscopy [17] and conductometric titrimetry [4]. Haloperidol was 
also determined using electrochemical sensor based on multi-walled carbon 
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nanotubes [18]. Fluorescence spectroscopy is frequently employed to 
quantitate drugs in pharmaceutical preparations. In fluorimetric methods, high 
sensitivity and selectivity are generally expected. Uptill now there have been 
only two reports dealing with spectrofluorimetric determination of haloperidol 
[19, 20]. In the first report, the cited drug was determined by oxidizing with 
acidic potassium permanganate [19]. In the other report, the native 
fluorescence of haloperidol has been used to develop fluorimetric method for 
its determination [20]. The disadvantage of this method is that weak signals 
are obtained in most of the solvents. 
This chapter describes the spectrofluorimetric method for the determination of 
haloperidol in commercial dosage forms. The method is based on the 
formation of ion-pair complex between haloperidol and eosin Y at pH 4.27. 
The ion-pair complex was extracted into dichloromethane which exhibited 
maximum fluorescence emission at 561nm after excitation at 345nm. 
EXPERIIVIENTAL 
Apparatus 
Fluorescence was monitored with an F-2500 Hitachi fluorescence 
spectrophotometer (Tokyo, Japan) equipped with xenon arc lamp. All 
measurements took place in a standard quartz cells with path length of 1.0 x 
1.0 cm at 25 ±1 °C. 
An Elico LI 120 pH meter (Hyderabad, India) was used for pH measurement. 
Absorbance measurements were made on Shimadzu UV-Visible 
Spectrophotometer, model No. UV- mini 1240 (Shimadzu, Japan). 
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Reagents and Standards 
• Haloperidol (CAS: 52-86-8; M.W.: 375.87) was obtained from Sigma 
Chemical Company, St. Louis, USA and used as received. Two different 
commercial pharmaceutical formulations of haloperidol such as serenace-5 
(RPG Life sciences Ltd., India), and hexidol-5 (Torrent Pharmaceuticals 
Ltd., India) were purchased from local drug stores. 
• 2.89 X 10-3 M Eosin Y disodium salt (CAS: 17372-87-1, M.W.: 691.85, 
Fluka Chemie AG, Switzerland) solution was freshly prepared in distilled 
water. 
• Buffer solutions ranging from 3.72 - 5.57 were prepared by mixing 0.2 M 
acetic acid and 0.2 M sodium acetate in different volume ratios [21]. 
Haloperidol standard solutions 
Standard solution (10 |a,g ml'') of haloperidol was prepared in methanol. 
Procedure for the determination of haloperidol 
Aliquots of the standard solution (10 p,g ml"') corresponding to 0.5 - 16.0 \i.g 
were transferred into 25 mL separating fiirmels. Then 1.7 ml of eosin Y (2.89 
X 10"^ M) solution was added followed by 1.0 ml of sodium acetate-acetic acid 
buffer solution of pH-4.27 and was mixed well. The contents of separating 
funnel were shaken vigorously with 5 ml dichloromethane for 2.5 min and 
then allowed to stand for clear separation of aqueous and organic layers. The 
fluorescence intensity of the organic layer was measured at 561 nm after 
excitation at 345 nm. The calibration graph was obtained by plotting the 
fluorescence intensity against the concentration of haloperidol. 
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Procedure for the determination of haloperidol in commercial dosage forms 
Ten tablets were accurately weighed and finely powdered. An amount of the 
powder equivalent to 25 mg haloperidol was shaken with a sufficient volume 
of methanol. The residue was filtered using Whatmann No. 42 filter paper 
(Whatmann International Limited, Kent, UK) and the filtrate was diluted to 50 
mL with methanol. This solution was ftirther diluted and analyzed following 
the recommended procedure. 
RESULTS AND DISCUSSION 
Spectral studies and reaction mechanism 
Haloperidol is a derivative of butyrophenone with piperidyl group possesing 
tertiary nitrogen atom in its moiety. Its methanolic solution fluoresces at 544 
nm after excitation at 312 nm. In the literatxire a spectrophotometric method 
for its determination has been reported based on the ion-pair complex 
formation between haloperidol and sodium 1 , 2 - napthaquinone-4-sulfonate 
[22]. In the present study it was found that the methanolic solution of 
haloperidol containing tertiary amine group reacts with aqueous solution of 
eosin Y at pH 4.27 resulting in the formation of fluorescent ion-pair complex. 
The ion-pair complex formed is light pink in colour and was extracted in 
dichloromethane which exhibited emission at 561 rmi after excitation at 345 
nm (Fig. 5.1). The blank solution remained colourless as the eosin Y was not 
extractable into dichloromethane at pH 4.27. 
The Job's method of continuous variation [23] was employed for the 
estimation of stoichiometry of the reaction between haloperidol emd eosin Y at 
pH 4.27. Master equimolar (2.66 x lO'^ M) solutions of haloperidol and eosin 
Y were prepared. Now, different volumes, that is, 0, 0.4, 1.2, 1.8, 2.0, 2.2,2.6, 
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Fig. 5.1. Excitation and emission spectra of haloperidol and eosin Y ion-
pair complex extracted in dichloromethane. 
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2.65, 2.67, 3.2, 3.8, and 4.0 ml of haloperidol were mixed with 4.0, 3.6, 2.8, 
2.2, 2.0, 1.8, 1.4, 1.35, 1.33, 1.3, 0.8, 0.2 and 0 ml of eosin Y into a series of 
25 mL separating fuimels and were further manipulated as described under the 
general recommended procedure. The fluorescence intensity was measured at 
561 nm and plotted against the mole fraction of drug (Fig. 5.2). As can be seen 
from fig. 5.2 that the combining molar ratio between haloperidol and eosin Y 
is 1:1. The apparent formation constant and Gibbs free energy (AG) were 
calculated and found to be 3.214 x 10^  and - 37.14 kJ mol"', respectively. A 
schematic reaction proposal of the reaction pathway is given in Scheme 5.1. 
Optimization of the experimental parameters 
The spectrofluorimetric properties of the coloured ion-pair complex as well as 
the different experimental parameters affecting the colour development and its 
stability were carefully studied and optimized. The experimental factors 
include pH, volume of buffer solution, concentration of eosin Y, reaction time, 
shaking time for extraction of the ion-pair complex and solvent. Such factors 
were changed individually while the others were kept constant. 
Effect of reaction time 
The effect of the reaction time on the formation of ion-pair complex was 
studied. The ion pair complex got stabilized immediately at 25 ± TC and 
remained stable for at least 1 hour. 
Effect of the volume of eosin Y 
The effect of the concentration of eosin Y on the fluorescence intensity of the 
ion pair complex was studied using different volimies of 2.89 x 10"^ M solution 
of the reagent in the presence of acetate buffer of pH 4.27. Increasing the 
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Mole fraction of haloperidol 
Fig. 5.2. Job's plot to establish the stoichiometry of the reaction. 
Stepi 
159 
Haloperidol 
Sodium acetate-
Acetic acid buffer 
solution of pH 4.27 
Protonated Haloperidol 
Step 2 
Protonated Haloperidol 
+ 
Eosin Y 
In dichloromethane 
at25 + 1°C 
Light pink fluorescent ion-pair complex 
Scheme 5.1. Mechanism of the proposed method 
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volume of the reagent produced a proportional increase in the fluorescence 
intensity of the ion-pair complex upto 1.5 ml and remained constant upto 2.3 
ml. Therefore, 1.7 ml of 2.89 x IO'-'M solution of eosin Y was chosen as the 
optimum volume of the reagent (Fig. 5.3). 
Effect of pH 
The influence of pH on the fluorescence intensity of the reaction product was 
evaluated using sodium acetate-acetic acid buffer solution in the range of 3.72 
- 5.57. The maximum fluorescence intensity of the complex was obtained at 
pH 4.27 (Fig. 5.4). Therefore, all fluorescence intensity measurements were 
made at pH 4.27 in the determination process. 
Effect of volume ofpH 4.27 buffer solution 
The influence of the volume of pH 4.27 buffer solution on the fluorescence intensity 
of the complex was studied in the range of 0.5 - 1.5 ml. Increasing the volume of the 
buffer solution resulted in the increase of the fluorescent signal upto 0.9 ml, after 
which further increase did not alter the fluorescence intensity of the complex 
(Fig. 5.5).Therefore, 1.0 ml of pH 4.27 buffer solution was chosen as an 
optimum volume for measuring fluorescence intensity in the determination 
procedure. 
Effect of shaking time 
The dependence of the fluorescence intensity on the shaking time for the 
extraction of the ion pair complex was studied in the range of 1.0 - 3.5 min. 
The maximum fluorescence intensity of the complex was obtained at 2.0 min 
and above this up to 3.5 min, the fluorescence intensity remained constant 
(Fig. 5.6).Therefore, 2.5 min was used as an optimum shaking time throughout 
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the determination process. The ion-pair complex was quantitatively recovered 
in one extraction only and was stable for at least 1 h. 
Choice of organic solvent 
Different organic solvents such as chloroform, carbon tetrachloride, 
dichloromethane, dichloroethane, and ethyl acetate were tested for extraction 
of the ion pair complex in order to provide an applicable extraction procedure 
and maximum fluorescence intensity. The highest fluorescence intensity of the 
complex was found when extraction was carried with dichloromethane. It can 
be seen from the Fig, 5.7 that no extraction was possible with carbon 
tetrachloride. Therefore, dichloromethane was selected as the best solvent for 
extraction of the ion-pair complex. 
Method validation 
The validity of the proposed method was tested regarding linearity, specificity, 
accuracy, precision and robustness according to ICH Q2B recommendations 
[24]. 
Linearity, limits of detection and quantitation 
Under the optimum reaction conditions, the fluorescence intensity -
concentration plot for the proposed method was found to be rectilinear over 
the range 0.2 - 3.2 ^g ml"'. Linear regression analysis of the calibration data 
gave the following equation: 
F = 0.443 + 170.288C; r = 0.9999; n = 15 
where F is the fluorescence intensity and C is the concentration of haloperidol 
in |i,g ml ' . The high value of the correlation coefficient (r = 0.9999) and low 
value of intercept (0.443) indicate good linearity of the calibration graph. The 
limits of detection (LOD) and quantitation (LOQ) were calculated according 
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to ICH Q2B [24] and were found to be 0.05 and 0.16 i^g ml'', respectively. 
Accuracy and precision 
The accuracy and precision of the proposed method was determined at three 
concentration levels (lower, middle, & upper) of haloperidol within the same 
day (intra-day) and on five consecutive days (inter-day). The relative standard 
deviations and % relative error are summarized in Table 5.1. The relative 
standard deviation did not exceed 0.8 % which indicated the high 
reproducibility of the results and precision of the method. This level of 
precision is suitable for quality control analysis of haloperidol in commercial 
dosage forms. 
Recovery 
The recovery experiment was performed using standard addition method. 
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to ICH Q2B [24] and were found to be 0.05 and 0.16 ng ml ' , respectively. 
Accuracy and precision 
The accuracy and precision of the proposed method was determined at three 
concentration levels (lower, middle, & upper) of haloperidol within the same 
day (intra-day) and on five consecutive days (inter-day). The relative standard 
deviations and % relative error are summarized in Table 5.1. The relative 
standard deviation did not exceed 0.8 % which indicated the high 
reproducibility of the results and precision of the method. This level of 
precision is suitable for quality control analysis of haloperidol in commercial 
dosage forms. 
Recovery 
The recovery experiment was performed using standard addition method. 
Recoveries were calculated using the appropriate regression equations and the 
results are summarized in Table 5.2 and Fig. 5.8. The obtained recovery 
values ranged from 99.92 % - 100.09 % (Table 5.2). Also the regression line 
of standard addition method was good which indicates that the proposed 
method is precise as well as accurate. 
Selectivity 
The proposed method has the advantage of that all measurements are made at 
561 rmi after excitation at 345 rmi, as mostly the pharmaceutical additives and 
adjuvants are non-fluorescent that might be coextracted from haloperidol 
containing dosage forms. Potential interference by excipients in the dosage 
forms was studied. Samples were prepared by mixing known amount of 
haloperidol with various amounts of the common excipients such as starch, 
glucose, lactose, acacia and magnesium stearate. 
TABLE 5.1: Test of accuracy and precision. 
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Proposed Method 
Concentration (|ig/ml) 
Taken Found" ± SD 
RSD 
^0/ 
Error 
Intraday assay 
Interday assay 
0.30 
1.90 
3.10 
0.30 
1.90 
3.10 
0.299± 0.002 0.795 -0.333 
1.902+0.145 0.145 0.105 
3.101±0.002 0.709 0.032 
0.298 + 0.002 0.006 -0.667 
1.902 ±0.002 0.001 0.105 
3.092 ± 0.002 0.002 -0.258 
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Fig. 5.8. Recovery of haloperidol from serenace-5 tablet by standard 
addition technique: (a) 0.400 and (b) 0.799 fig ml'. 
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The results of analysis revealed that no interference was observed from any of 
these excipients. 
Robustness 
The robustness of the proposed method is demonstrated by the constancy of 
the fluorescence intensity with deliberate minor changes in experimental 
parameters such as: 
• volume of buffer solution of pH 4.27, 1.0 ± 0.2 ml, 
• volume of 2.89 x lO'^M eosin Y, 1.7 ± 0.1 ml, 
• reaction time, 25 ± 3°C, 
• effect of shaking time, 2.5 ± 0.5 min, 
During experimental operation, these minor changes may take place which did 
not influence the fluorescence intensity of the ion-pair complex. Also the 
regression line of standard addition method was good which indicates that the 
proposed method is precise as well as accurate. 
Application of the proposed method to analysis of haloperidol in tablets 
It is evident from the above mentioned results that the proposed 
methods gave satisfactory results which can be suitable for the quality control 
analysis of haloperidol. The proposed and reported methods [25] were applied 
to the determination of haloperidol in its dosage forms. The results obtained 
by the proposed method were compared statistically with those obtained by 
the reported method. The recovery of the labeled amount was 99.90 - 99.97 % 
(Table 5.3). The results of t- and F- tests revealed that no significant 
differences were found at 95% confidence level with regard to accuracy and 
precision. In addition, interval hypothesis test [26] was also performed which 
revealed that the true bias of all the samples lie in the range of 0.98 and 1.02 
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{0L to 9u). This also confirmed that no difference exists between the methods 
compared. 
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A simple and sensitive spectrofluorimetric method has been developed and validated for the 
determination of the antidepressant clomipramine hydrochloride in its dosage forms. The method was 
based on the fluorescent ion-pair complex formation between clomipramine and alizarin red S at pH 
1.99. The ion-pair complex showed maximum fluorescence intensity at 561 nm with excitation at 
490 nm. Different variables affecting the reaction conditions such as the concentration of alizarin red S, 
pH, reaction time and the extracting solvents were carefully studied. Under the optimised conditions, 
the fluorescence intensity was found to be linearly related with clomipramine hydrochloride 
concentration in the range of 1.0-20 ng ml' ' . The detection and quantitation limits were 0.32 and 
0.97 ng mi"', respectively. No interference was observed from the excipients commonly present in 
dosage forms. The proposed method was successfully applied to the determination of clomipramine in 
its pharmaceutical tablets with good accuracy and precision; the recovery values were 99.75-100.05%. 
1. Introduction 
Clomipramine hydrochloride is chemically known as 3-chloro-5-
[3-(dimethylamino)propyl]-10,ll-dihydro-5/y-diben2|*J]azepme 
monohydrochJoride with a molecular weight of 351.31. Clo-
mipramine belongs to a group of medications called tricyclic 
antidepressants.' It occurs as white to off-white crystalline 
powder. 
Clomipramine is used for the treatment and relief of obsessive 
and compulsive disorders as well as in depression and other 
emotional disturbances. It works by increasing the amount of 
serotonin, a natural substance in the brain that is needed to 
maintain mental balance. Clomipramine is extensively bio-
transformed to desmethylclomipramine and other metabolites 
and their glucuronide conjugates. Desmethylclomipramine is 
pharmacologically active and participates in both therapeutic 
and unwanted effects. Clomipramine is considered to be the most 
potent inhibitor of serotonin uptake among all the tricyclic 
antidepressants, while its main hepatic metabolite desmethyl-
clomipramine has been shown to be a stronger inhibitor of 
norepinephrine and a weaker inhibitor of 5-HT uptake than the 
parent drug. The usual recommended initial dose is 25 mg daily. 
Despite the beneficial effects of clomipramine hydrochloride the 
pharmacological doses of the drug had many undesirable side-
efTects and its overdosage may cause adverse reactions. There-
fore, the therapeutical and pharmacological importance of 
clomipramine has prompted the development of several methods 
for its determination, both in body fluids and pharmaceuticals. 
The assay procedure of the drug in dosage forms is official in 
British Pharmacopoeia,^ and United States Pharmacopoeia.' 
Clomipramine has been determined in its pharmaceutical dosage 
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forms and biological fluids by high performance liquid chro-
matography (HPLC),-^ gas chromatography (GC),' capillary 
gas chromatography," liquid chromatography (LC),'-'" capillary 
zone electrophoresis (CZE),"" flow injection analysis (FIA)," 
spectrophotometry,'-^" and spectrofluorimetry.^-'' These 
methods were associated with some major drawbacks such as 
inadequate sensitivity, time-consuming, tedious, and dedicated 
to sophisticated and expensive instruments. Although, spectro-
fluorimetry is a sensitive and simple technique, however the 
literature relating to the suitable spectrofluorimetric methods for 
the determination of the clomipramine is scarce and so far only 
two spectrofluorimetric methods for determination of clomipr-
amine had been reported which was time consuming.^" For these 
reasons, the development of a new, sensitive and simple spec-
trofluorimetric method that overcomes the drawbacks of the 
existing methodologies was very essential. 
The present paper describes a new spectrofluorimetric method 
for the determination of clomipramine hydrochloride in phar-
maceutical formulations. The method is based on the formation 
of ion-pair complex between clomipramine and alizarin red S at 
pH 1.99. The ion-pair complex was extracted with chloroform 
and the fluorescence intensity was measured at 561 nm with 
excitation at 490 nm. The reaction conditions were optimized 
and validated as per International Conference on Hannonisation 
(ICH) guidelines." 
2. Experimental 
2.1 Apparatus 
All fluorescence spectra were recorded on an F-2500 Hitachi 
fluorescence spectrophotometer (Tokyo. Japan) equipped with 
xenon arc lamp. Slit widths were set at 5 nm. All measurements 
took place in quartz cells with path length 1.0 x 1.0 cm. 
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Excitation and emission wavelengths were set at 460 and 561 nm. 
feutech (Cyberscan pH 2100) pH meter was used to measure the 
pH. All measurements were performed at 25 ± 1 °C. 
2.2 Materials and reagents 
• Clomipramine hydrochloride pure sample was obtained from 
Sigma chemical company (St. Louis, MO, USA) and used as 
received. The following commercially available pharmaceutical 
dosage forms were subjected to analysis: Clonil-50 tablets (Intas 
Pharmaceuticals Ltd., Ahmedabad, India) labelled to contain 
50 mg each and Clofranil-50 tablets (Sun Pharmaceutical 
Industries, Mumbai, India) labelled to contain 50 mg each. 
• 2.92 X 10"' Alizarin red S (Fluka Chemie AG, Switzerland, 
M.W.: 342.26) solution was freshly prepared in distilled water. 
• Buffer solutions ranging from pH 1.42-3.49 were prepared 
by mixing appropriate volumes of IN sodium acetate and IN 
HCl. 
All chemicals and solvents used were of analytical grade. 
Standard drug solution. A standard stock solution of clo-
mipramine hydrochloride was prepared by dissolving 100 mg of 
drug in 100 ml distilled water. This solution was further diluted 
with water to obtain 0.1 mg ml ' clomipramine hydrochloride 
working standard solution. 
2.3 Procedures 
General procedure. Portions (0.05 1.0 ml) of working standard 
solution of clomipramine hydrochloride (0.1 mg m\'') were 
transferred into a series of 25 ml separating funnels. To each 
separating funnel, 2.0 ml of 2.92 x 10-' M alizarin red S solution 
and 1 ml of buffer solution (pH - 1.99) were added. The contents 
of the separating funnel were shaken well with 5 ml of chloro-
form for 2.0 min and then allowed to separate the two layers. The 
fluorescence intensity of the formed ion-pair complex was 
measured at 561 nm after excitation at 490 nm. The fluorescence 
intensity was plotted against the concentration to get the cali-
bration graph. The amount of the drug was evaluated either from 
the calibration graph or from the corresponding regression 
equation. 
4.0, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, and 0.1, of alizarin red S 
(2.85 X lO""* M) respectively into a 25 ml separating funnel. The 
contents of the funnel were shaken vigorously with 5 ml chlo-
roform and then allowed to stand for clear separation of the 
organic phase. The fluorescence intensity measured at 561 nm 
was plotted against the mole fraction of drug. 
Procedure for reference method^ ". One milliliter of working 
standard solution of clomipramine hydrochloride (0.001-
0.01 mg ml ') was transferred into a 10 ml volumetric flask, 
followed by 1 ml of eerie ammonium sulfate (0.002 M). The 
solutions were mixed well and heated in a thermostatically 
controlled water bath at 100 ± I "C for 20 min. The flasks were 
then cooled and diluted to the mark with distilled water. The 
fluorescence intensity was measured at 355 nm with excitation at 
254 nm. The amount of the drug in a given sample can be esti-
mated either from the calibration graph or the corresponding 
linear regression equation. 
3. Results and discussion 
Literature survey reveals that tertiary nitrogen in clomipramine 
hydrochloride is capable of forming ion-pair complexes with 
various dyes and reagents such as azocarmine-G, naphthalene 
blue and naphthalene blue black," thymol blue,'* orange 1, 
orange II, croceine orange, lithol Red, fast Red A," and picryl 
chloride.'* The reaction of clomipramine and alizarin red S has 
not been investigated so far. In the present study clomipramine 
hydrochloride was found to react with alizarin red S at pH 1.99 
resulting in the formation of fluorescent ion-pair complex which 
is most suitably extracted in chloroform. Fig. 1 shows the exci-
tation and emission spectra of ion-pair complex. The maximum 
fluorescence intensity was observed at 561 nm when excited at 
490 nm. At pH 1.99 the clomipramine gets protonated and hence, 
cannot be extracted into chloroform. Similariy, the alizarin red S 
is existing as negatively charged species at pH 1.99 which also 
cannot be extracted into chloroform. Therefore, the organic layer 
does not contain either clomipramine or alizarine red S. The 
fluorescent ion-pair complex formation can be applied to 
enhance the sensitivity of the method for determination of 
clomipramine hydrochloride. 
Analysis of commercial tablets. Ten tablets of each brand were 
grounded and finely powdered. An amount equivalent to 100 mg 
of clomipramine hydrochloride was accurately weighed and 
treated with 30 ml distilled water and left for 10 min for complete 
extraction of the drug. The aqueous extract was filtered through 
Whatmann No. 42 filter paper (Whatmann International 
Limited, Kent, UK) in a 100 ml volumetric flask. The residue was 
washed well with distilled water and the volume was completed 
upto the mark. This solution was further diluted to obtain 
a suitable concentration and analysed by the proposed proce-
dure. 
Determination of stoichiometry. Job's method of continuous 
variations" was applied for ascertaining the stoichiometry of the 
ion-pair complex. This was achieved by combining different 
volumes i.e. 0.1,0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 4.9 ml 
of clomipramine hydrochloride (2.85 x lO"" M) with 4.9, 4.5, 
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Fig. 1 Excitation and emission spectra of fluorescent ion-pair complex. 
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Fig. 2 Job's plot for combining molar ratio between clomipramine and 
alizarin red S. 
3.1 Stoichiometry and reaction mechanism 
Clomipramine hydrochloride is a derivative of dibenzazepine 
group possessing nitrogen atom of tertiary amine group in the 
aliphatic chain which otTers a basic characteristic to the drug. 
The drug is protonated at pH 1.99 and consequently a positive 
center is created in the drug molecule. Alizarin red S is a sodium 
salt of 3,4-dihydroxy-9,10-dioxo-2-anthracene sulfonic acid 
which ionizes in aqueous solution and thus develops a negative 
charge on it. The Job's plot revealed that the combining molar 
ratio between clomipramine and alizarin red S is 1 : 1 (Fig. 2). It 
indicated that one mole of clomipramine, providing one po.sitive 
centre, reacts with one mole of alizarin red S, providing one 
negative centre, resulting in the formation of chloroform 
extractable ion-pair complex. Therefore, based on the literature 
background and our experimental findings, the possible reaction 
sequence is shown in Scheme 1. The apparent formation constant 
and Gibb's free energy (AG°) were calculated and found to be 
9.544 X 10' and -39.82 kj mol ', respectively. 
/ N ^ ^ \ ^ CI Sodium acetalc-HCl 
^^*^Y-^ Ti " ^ Z buffCTSolutionofpH J.99 
Cknnipramiiu: 
Protonated domipramine 
PrtilonHetf elom ipram me 
In chloraforn 
Orange-yellow fluorescent ion-pair complex 
Scheme 1 Reaction pathway of the proposed method 
3.2 Study of experimental conditions 
Various experimental parameters affecting the formation of ion-
pair complex were carefully studied and optimized. Such factors 
were changed individually while the others were kept constant. 
The factors include concentration of alizarin red S, pH of 
aqueous solution, volume of buffer solution, shaking time and 
solvent for the extraction of ion-pair complex. 
Effect of concentration of alizarin red S. The influence of the 
concentration of alizarin red S was studied using different 
volumes of 2.92 x 10 ' M solution of alizarin red S. It was found 
that the reaction of alizarin red S with clomipramine started 
upon using 0.5 ml of the dye in the presence of sodium acetate-
HCl buffer of pH 1.99; keeping the amount of drug (20 ng) 
constant. Increasmg the volume of alizarin red S, produces 
a proportional increase in the fluorescence intensity of the reac-
tion product up to 1.9 ml and after that there was no effect on the 
fluorescence intensity. Therefore, 2.0 ml of 2.92 x 10"^ M of 
alizarin red S solution was chosen as the optimal volume of the 
dye. 
Effect of pH. In order to generate a positive centre in clo-
mipramine, the reaction is carried out in acidic medium. Buffer 
systems (sodium acetate-HCl, potassium biphthalate-HCI) in the 
pH range 1.42-3.8 were tested. The sodium acetate-HCl bufTer 
system was found to be superior to the potassium biphthalatc-
HCl buffer since it gave the highest fluorescence intensity. The 
influence of pH on the reactions was studied by carrying out the 
reaction in sodium acetate-HCl solution of pH 1.42-3.49, The 
results indicated that the fluorescence intensity increased as the 
pH increased and maximum readings were obtained at pH 1.99 
after which the fluorescence intensity of the reaction product 
began to decrease gradually until pH 3.49 (Fig. 3).Therefore. pH 
of 1.99 was chosen as the optimum pH for the determination 
process. 
Effect of volume of pH 1.99 buffer solution. The influence of 
volume of pH 1.99 buffer solution on the fluorescence intensity 
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Fig. 3 Effect of different pH on the fluorescence intensity of the product 
(clomipramine, 20 ng ml'). 
was studied in the range of 0.2-1.5 ml. The maximum fluores-
cence intensity was obtained at 0.9 ml and after that the intensity 
remained constant. Therefore, 1.0 ml of pH 1.99 buffer solution 
was adopted as an optimum volume for fluorescence 
measurement. 
Effect of shaking time for extraction. Different time intervals 
(0.5-2.5 min) were tested to ascertain the shaking time required 
for complete extraction of the complex, it was found that the 
highest fluorescence intensity was reached at 1.5 min and after 
that the intensity remained constant up to 2.5 min. Therefore, 
shaking time of 2.0 min was adequate for the extraction of ion-
pair complex into chloroform. 
Solvent effect. In order to select the most appropriate solvent, 
the extraction of the ion-pair complex was performed in 
different solvents such as chloroform, carbon tetrachloride, 
dichloromethane, dichloroethane, and ethyl acetate. It is clear 
300 
200 
100 
.J^ 
y y j^' .<f 
*.«* <^ 
Solvent 
from the graph (Fig. 4) that the solvent which gave the highest 
fluorescence intensity was chloroform while carbon tetrachlo-
ride gave the lowest. Therefore, chloroform was chosen as the 
most appropriate solvent for extraction of the ion-pair 
complex. 
3.3 Analytical performance 
Calibration and sensitivity. Under the optimum conditions, 
cahbration curve for the determination of clomipramine hydro-
chloride was constructed by plotting the fluorescence intensity as 
a function of the corresponding clomipramine concentration. 
The regression analysis of the calibration data gave the regres-
sion equation as: 
F= 1.268-1- 13.615C 
where F is the fluorescence intensity, C is the concentration of 
clomipramine in \xg ml '. The linear relationship was obtained in 
the concentration range of 1.0-20.0 ng ml ' with a correlation 
coefficient of 0.9999. The LOD and LOQ were determined 
according to ICH guidelines for validation of analytical proce-
dures." The LOD and LOQ values were found to be 0.32 ng ml ' 
and 0.97 ng ml' ' , respectively. 
Precision and repeatability. The within days precision was 
evaluated through replicate analysis at three concentration levels 
i.e. 2.0, 10.0 and 20.0 ng ml"' of clomipramine by performing five 
experiments on the same day using the same analyte standard 
solution. The inter-day precision on five successive days was 
evaluated through replicate analysis of the same concentrations 
of clomipramine used in intra-day precision. The results arc 
summarized in Table 1. It can be seen from the table that the 
percent relative standard deviation did not exceed 0.3%, proving 
the high precision and accuracy of the proposed method. 
Accuracy and recovery. Recovery studies were perforincd 
using standard addition method. For this, known quantities of 
pure clomipramine hydrochloride were mixed with definite 
amounts of preanalyzed commercial dosage forms and mixtures 
were analysed following the proposed method. The results are 
reported in Table 2. The percent recoveries obtained were 
quantitative (99.75-100.05%) indicating the good accuracy of 
the method. 
Table 1 Test of precision of the proposed method 
Concentration (ng ml ') 
Proposed method 
Intraday assay 
Interday assay 
Taken 
2.00 
10.00 
20.00 
2.00 
10 00 
20.00 
Found" ± SD 
2.002 ± 0.003 
10.010 ±0.003 
19.990 ±0.003 
1.990 ±0.005 
9.990 ± 0.008 
19.990 ±0.005 
RSD (%) 
0.14 
0.03 
0.02 
0.24 
0,08 
0.02 
SAE* 
0.001 
0.001 
0.001 
0.002 
0.003 
0.002 
C.L' 
0.004 
0.OO3 
0.004 
0.006 
0.010 
0.(X)5 
Fig. 4 EITect of the extracting solvent on the fluorescence intensity of the 
ion-pair complex. 
" Mean for five independent determinations. * SAE, standard analytical 
error. ' C.L. confidence limit at 95% confidence level and four degrees 
of freedom (; = 2.776). 
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Table 2 Recovery of clomipramine hydrochloride by standard addition 
Concenlralion (fig ml"') 
Clonil-50 (taken) Standard added Found 
4.00 0,4.0,8.0, 12.0,16.0 3.99 
8.00 0,4.0,8.0, 12.0,16.0 8.00 
" Coefficient of correlation. ' Mean for live independent analyses. 
technique 
Coefficients of linear regression equation of 
standard addition 
Intercept slope 
33.51 8.39 
69.45 8.68 
r" 
0.9999 
0.9996 
Recovery* (%) 
99.75 
100.05 
Table 3 Point and interval hypothesis tests: Applicability of the proposed method in pharmaceutical formulations and its comparison with the 
reference method at 95% confidence level 
Pharmaceutical formulations 
Tablets 
Proposed method Reference method 
Clonil-50 
Clofranil-50 
Recovery" (%) RSD (%) Recovery" (%) RSD (%) r -&/" values* #L' 
0.989 100.14 
100.05 
0.061 
0.073 
100.04 0.05 1.010 ( = 0.270 
F= 1.276 
99.99 0.03 (^0.138 0.990 1.010 
F = 2.422 
" Mean for five independent analyses. * Theoretical ((" = 8) and /-"-values (v = 4) at 95% confidence level are 2.306 and 6.39, respectively.' A bias, based 
on recovery experiments, of ±2%i is acceptable. 
Selectivity. The selectivity of the method was evaluated by 
investigating the interference liabilities from the common 
excipients that might be added during pharmaceutical formula-
lion. Tablet excipients such as lactose, starch, glucose, fructose 
and magnesium stearate did not interfere with the assay. The 
results of the recovery experiment also indicated that neither the 
accuracy nor the precision of the proposed method is affected by 
the coformulated substances. 
Robustness. Robustness was examined by evaluating the 
influence of small variation in the method variables on its 
analytical performance. In these expeinments, one parameter was 
changed whereas the others were kept unchanged, and the 
recovery percentage was calculated each time. It was found that 
variation in the volume of 2.92 x 10"' M alizarin red S solution 
(optimum ± 0.3 ml), reaction temperature, 25 ± 2 °C, volume of 
pH 1.99 buffer solution (optimum ± 0.2 ml), shaking time 
(optimum ± 0.5 min.) did not significantly afTect the procedures. 
The proposed spectrofluorimetric method is reliable during 
normal usage and considered to be robust. 
3.4 Pharmaceutical appiications 
It is evident from the above-mentioned results that the proposed 
method gave satisfactory results with clomipramine in its bulk. 
Thus its pharmaceutical dosage forms (Clonil-50, Clofranil-50) 
were subjected to the analysis of their clomipramine contents by 
the proposed and the reference methods. The results are 
summarized in Table 3. The results were compared with those 
obtained from the reported me thod . " N o significant differences 
were found between the calculated and theoretical values of r and 
F-tests at 95% confidence level proving similar accuracy and 
precision in the determination of clomipramine by both methods. 
In addition to this, in both the determinations, the values of 
lower and upper limits based on the recovery experiments were 
found to be within ±2%; indicating the compliance of the regu-
latory guidelines." 
The performance of the proposed method was compared with 
other existing methods (Table 4). It can be seen from the table 
that the linear range of the proposed method is quite appreciable 
and most of the determinations of clomipramine can be done in 
Table 4 Comparision of the proposed spectrofluorimetric method with other existing methods for the determination of clomipramine hydrochloride 
Techniques/reagents l-inear range (Mg ml ') 
SPECTROFLUORIMETRY 
Ce(IV) and sulfuric acid 
Potassium dichromaie 
Alizarin red S 
SPECTROPHOTOM ETR Y 
Thymol blue 
/'-Phenylenediainine 
dihydrochloride in sulfuric acid 
FLOW INJECTION ANALYSIS 
9,10-Dimethoxyanthracene-2-
sulfonale (DMAS) 
0.05 I.I 
0.1 3.0 
1.0 20.0 
4.0-26.0 
0.1 4.0 
0.25 3.0 
ih is IOL;I T^? Royal Sofiety of Cherni^rr 
Limit of detection (ng mL') 
0.04 
0.32 
<0.30 
RSD (%) 
1.16-1.48 
0.24 
1.20-2.80 
1.92 
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this range successfully. Moreover, the RSD value of the 
proposed method is smaller than that of other methods. 
4. Conclusions 
A simple and sensitive spectrofluorimetric method for the 
determination of clomipramine hydrochloride has been success-
fully developed and validated. The method involved ion-pair 
complex formation between clomipramine and alizarin red S dye, 
and subsequent measuring the fluorescence intensity of the 
fluorescent reaction product at 561 nm with excitation at 490 nm. 
The proposed method is specific, accurate, reproducible, and 
highly sensitive to be applied on the analysis of pharmaceutical 
formulations. Furthermore, the analysis is relied on a simple 
apparatus, thus the proposed method is suitable for routine 
analysis of clomipramine hydrochloride in quality control and 
clinical laboratories. 
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Development and validation of fixed-time 
method for the determination of isoxsuprine 
hydrochloride in commercial dosages forms 
Nafisur Rahman* and Nasheed Afaq 
The main aim of this work was to develop a Icinetic spectrophotometric method for the quantitative analysis of isoxsuprine 
hydrochloride in commercial tablets. The method is based on the reaction of isoxsuprine hydrochloride (ISx) with hydroxylamine 
hydrochloride and ammonium cerium (IV) nitrate in sulphuric acid medium at room temperature which resulted in the formation 
of yellow-coloured product peaking at 380 nm. The reaction is followed spectrophotometrically by measuring the absorbance 
as a function of time. Fixed time method (AA=A4-A2, where A2 and A4 refer to absorbance measurements taken at 2 and 
4 min, respectively) was adopted for constructing the calibration curve which was found to be linear over the concentration 
range of 30-80 jigmL"^ with molar absorptivity of 5.95 x 10^ L mol~' cm"' . The method has been applied successfully to the 
determination of isoxsuprine hydrochloride in tablets. Statistical comparison (point and interval hypothesis tests) of the results 
showed that there is no significant difference between the proposed method and reference method. Copyright ® 2010 John 
Wiley & Sons, Ltd. 
Keywords: fixed-time method; isoxsuprine hydrocliloride; hydroxylamine hydroclnioride; ammonium cerium (IV) nitrate; pharmaceutical 
analysis. 
Introduction 
Isoxsuprine hydrochloride ((ISx), 4-Hydroxy-Q'-[1-[(l-methyl-2-
Phenoxy-ethyl) amino] ethyl] benzene methanol, is an orally and 
parenterally active peripheral and cerebral vasodilator (Scheme 1). 
It is used for the treatment of cerebral vascular insufficiency, 
dysmerrtiea and premature labour."' It caused isotropic and 
chromotropic effect on heart. 
The drug is official in Martindale: the extra pharmacopoeia^ The 
assay procedure is cited in the monograph of the British Pharma-
copoeias^^ which describes a UV-spectrophotometric method. In 
order to assure the quantity of ISx in dosage forms, several analyti-
cal methods have been reported which include high performance 
thin layer liquid chromatography (HPTLC),'"' high performance 
liquid chromatography (HPLC),'^ '^ ' gas chromatography,''^ flow 
injection analysis,'*"'"' lodometrics t i tration,"" voltammetery,"^' 
conductometry,"^' spectrophotometry and flourometry.'"" 
UV-vlsible spectrophotometry, due to Its low cost, and inherent 
simplicity, is the technique of choice in the research laboratories, 
hospitals, and pharmaceutical industries, even today. Some 
spectrophotometric methods have been developed for the 
determination of ISx in bulk and pharmaceutical preparations. The 
quantification of drug was done based on the reaction of ISx with 
Fe (III) and 1,10-phenanthroline,"^' chloranil,"*' Fe (III) and subse-
quent complexation of Fe (II) with 2,2'-bipyridine,"''sodium nitrite 
in acidic medium followed by alkalization,"*'diazotizedsulphanilic 
acid,"" 4-aminoantipyrine in the presence of alkaline oxidizing 
reagent,'^"' Fast red B salt in alkaline medium, eosin and Pb (II) 
in acetate buffer in presence of non-ionic surfactant, potassium-
ferricyanide and phthalophenone in alkaline medium,'^" eosin 
and Cu (11)'^ '^ and dyes such as fast green (FCF) or Orange 11.'^ '^ 
Few kinetic spectrophotometric methods have been reported 
for determination of ISx in pharmaceutical preparations.'^"'^^' 
Moreover, some specific advantages of kinetic methods, such 
as selectivity, can be expected because of the measurement of 
evolution of the absorbance as a function of reaction time. 
There is still a need for a sensitive kinetic spectrophotometric 
method for determination of ISx that can be adopted for routine 
analysis of pharmaceutical sanhples. In the present investigation, 
a kinetic spectrophotometric method based on the reaction of 
ISx with hydroxylamine hydrochloride and ammonium cerium (IV) 
nitrate in sulphuric acid medium is described and the proposed 
method has been extended to the determination of ISx in tablets. 
Experimental 
Instrumentation 
All absorption spectra were recorded using Elico UV-visible 
spectrophotometer (Elico Ltd, Model No. SL-164, Hyderabad, 
India) with matched quartz cells. Absorbance was measured using 
spectronic 20 D+ spectrophotometer (Milton Roy Co., New York, 
USA). 
Chemicals 
All chemicals and reagents used were of analytical grade 
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Me H H Me 
Scheme 1. Structural formula of Isoxsuprine hydrochloride. 
Evaluation of bias 
The point and interval hypothesis tests'^^' have been used to 
evaluate the bias. In interval hypothesis test, the criterion for 
acceptance of the proposed method is that w^hen the true mean is 
w/ithin ±2.0% of that of the reference method, i.e. 
.HCl 
(i) 
(ii) 
(iii) 
1.82 X 10 -^^  M Ammonium cerium (IV) nitrate (Qualigens Fine 
Chemicals Ltd., Mumbai, India) solution was freshly prepared 
in distilled water. 
1.43 X 10"' M Hydroxylamine hydrochloride (Ranbaxy Fine 
Chemicals Ltd., New Delhi, India) solution was prepared in 
distilled water. 
2.55 M sulphuric acid (Sd. Fine-Chemicals Ltd., Mumbai, India) 
ISx as a reference standard was obtained from Farmenta Biotech 
Ltd., Thane, India {Batch No. ISOX 02-02) and used as received. 
Tablet formulations of ISx such as duvadilan (Solvay Pharma Ltd, 
Mumbai, India) and Tdilan (Juggat Pharma, Bangalore, India) were 
purchased from local drug stores. Each tablet labeled to contain 
20 mg ISx. 
A standard solution of ISx (1 mg mL~') was prepared in distilled 
water. 
Procedure for the determination of ISx 
Aliquotsofthe standard solution oflSx(1 mg mL"M corresponding 
to 300-800 |ig were transferred into 10 mL volumetric flasks. To 
each flask, 0.9 mL of 1.43 x 10"' M hydroxylamine hydrochloride 
was added followed by 1.5 mL of 2.55 M sulphuric acid and left 
for 1 min after shaking. Then, 1.7 mL of 1.82 x 10~^ .M ammonium 
cerium (IV) nitrate was added and volume was completed with 
distilled water. The absorbance of the resulting solution was 
measured at 380 nm against the reagent blank as a function 
of time. The change in absorbance (AA) between the time ti 
(2 min) and t2 (4 min) was computed and plotted against the initial 
concentration of ISx. The amount of ISx in a given sample can 
be computed either from the calibration graph or corresponding 
regression equation. 
Assay of ISx tablets 
To determine the ISx in tablet formulations, the contents of five 
tablets were finely powdered and stirred with 25 mL distilled water 
and left stand for 10 min, then filtered through Whatmann filter 
paper No. 42. Filtrate was diluted to volume in a 100-mL volumetric 
flask with distilled water. The content of drug in each sample was 
determined using the proposed procedure and B.P. method as a 
reference.'^' 
Limits of detection (LOD) and quantitation (LOQ) 
The following expressions were used to calculate LOD and LOQ 
values: 
LOD = 3.3xSo/b and L O Q = 1 0 x S o / b 
Where So is standard deviation of the intercept and b is the 
slope. 
0.98 < M2/M1 < 1.02 
which can be generalized to 
(1) 
(2) 
where BL and Oy are lower and upper acceptance limits, 
respectively. The limits of this confidence interval can be calculated 
using the following quadratic equation: 
0^ ( ^ - S^ff„b^/n,) -I- fH-2xTxJ) + (4- SlUab^/ni) = 0 (3) 
where 3r7 and X2 are mean values based on ni and n2 
measurements, respectively. Sp is the pooled standard deviation 
and t,ab is the tabulated one-sided t-value, with (n, -1- n2 - 2) 
degrees of freedom at 95% confidence level. 
Results and Discussion 
It has been reported'^''' that the ammonium cerium (IV) nitrate 
in the presence of hydroxylamine hydrochloride forms stable 
orange-coloured complexes with aromatic hydroxyl compounds. 
The colour was completely developed in 30-60 min and these 
complexes absorbed maximally at 380 nm. ISx possesses phenolic 
group in its moiety and hence reacts in a similar fashion, with 
ammonium cerium (IV) nitrate in the presence of hydroxylamine 
hydrochloride at room temperature resulting in the formation 
of coloured complex which absorbs maximally at 380 nm. 
The intensity of the colour increases with time and hence a 
kinetic spectrophotometric method has been developed for the 
determination of ISx in commercial dosage forms. The absorption 
spectrum is shown in Figure 1. 
Optimization of variables 
Various parameters affecting the formation of the coloured 
product were examined and optimized by carrying out a series of 
experiments. 
0.88 
340 350 360 370 380 390 400 410 420 
Wavelength{nm) 
Figure 1. Absorption spectra of complex of isoxsuprine hydrochloride. 
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Effect of hydroxylamine hydrochloride concentration 
The effect of the concentration of hydroxylamine hydrochloride on 
the absorbance of the coloured product was investigated over the 
concentration range of 8.58 x 10"^ M-1.72 x 10"'^ M; keeping 
the concentrations of sulphuric acid (0.56 M), ISx (50ngmL~') 
and ammonium cerium (IV) nitrate (3.09 x 10"^ M) constant. It 
was observed that the maximum and constant absorbance was 
obtained in the concentration rangel . l4x lO"-^M-1.43xlO~^M. 
Therefore, 1.29 x 10^^ M hydroxylamine hydrochloride was used 
as an optimum concentration. 
Effect of sulphuric acid concentration 
The influence of the concentration of sulphuric acid on the 
formation of product was investigated in the range of 0.13-0.46 M. 
It was observed that the maximum absorbance was obtained with 
0.31 M sulphuric acid and remained constant upto 0.46 M. The 
optimum value of sulphuric acid was chosen as 0.38 M for the 
determination process. 
Effect of ammonium cerium (IV) nitrate concentration 
The effect of Ce (IV) concentration on colour development was 
studied in the concentration range of 9.1 x 10^''M-3.64x 10~^ M; 
keeping the concentrations of ISx (50|igmL~') and sulphuric 
acid (0.38 M) and hydroxylamine hydrochloride (1.29 x 10~-^M) 
constant. It was found that increasing the concentration of Ce 
(IV) resulted in a subsequent increase in absorbance up to 
2.73 X 10"^ M and remained constant up to 3.64 x 10^^ M. 
Therefore, 3.09 x 10"^ M Ce (IV) was chosen as an optimum 
concentration for further studies. 
Validation 
The proposed method has been validated for specificity, linearity, 
accuracy, precision, LOD, and LOQ. 
Selectivity 
The selectivity of the proposed spectrophotometric method was 
ascertained by analyzing the pure ISx in presence of tablet 
formulations such as starch, lactose, magnesium stearate, talc, 
and avisil. It was found that common excipients present in tablet 
formulations did not cause any significant interference. 
Linearity 
Under the optimized experimental conditions, the absorbance of 
each solution was measured as a function of time at 380 nm. The 
change in absorbance (AA) between the times t, (2 min) and 
t2 (4, 6,8,10, or 12 min) was computed and plotted against the 
initial concentration of ISx. It was found that the most acceptable 
linearity was obtained when the change in absorbance (AA) 
between 2min and 4min (AA = A4-A2) was plotted against 
the initial concentration of ISx. Therefore, this fixed time was 
selected for the assay procedure. The linear dynamic range, molar 
absorptivity, regression equation, correlation coefficient, LOD, 
LOQ, and standard deviations of intercept (Sa) and slope (Sb) are 
summarized in Table 1. The small figures (i.e. Sa and Sb) obtained 
refer to the high precision of the method. 
Table 1. Optical performance and 
proposed methods 
Parameters 
Arrax (nm) 
Stability (h) 
Linear dynamic range (ng mL~') 
Molar absorptivity (L mol ' cm" ' ) 
Linear regression equation 
Sa 
Sb 
Correlation coefficient (r) 
Detection limit ((ig mL"') 
Quantitation limit (,ug mL*') 
' With respect to A = a + bC, Where 
and A is absorbance. 
regression characteristics of the 
Proposed Methods 
380 nm 
1 hr 
30-80 
5.95 X 10^ 
AA = 4.51 X 10*^ C - 1.022 
1.703 X 10"^ 
3.12 X 10-" 
0.9952 
6.76 
20.49 
C is the concentration (ng mL~') 
'^  Confidence interval of the intercept at 95% confidence level. 
•^  Confidence interval of the slope at 95% confidence leveL 
Accuracy and precision 
The accuracy and precision of the proposed method was 
ascertained by determining the ISx content in pure form at two 
concentration levels: 35.0 and 75.0 fig mL~'. Each concentration 
level was analyzed five times within a day as well as for five 
consecutive days. The results are presented in Table 2. The 
percent relative error and RSD were less than ±2.5% and 1.91%, 
respectively. 
Robustness 
The robustness of the proposed method was evaluated by slight 
variation of the experimental parameters such as: 
• room temperature ±3 °C 
• volume of2.55MH2S04,1.5 ±0 .3 mL 
• volume of 1,43 x 10"' M hydroxylamine hydrochloride, 0.9 ± 
0.1 mL 
• volume of 1.82 X 10'^ M Ce (IV), 1.7 ± 0.3 mL 
To assess the robustness, the active drug content in Tidilan tablet 
was determined. The quality control sample solution containing 
60 \xg mL~' ISx was analyzed five times. The percent recovery ± 
RSD (100.20 ± 0.50) was found to be appreciable. This concluded 
that the proposed method is robust. 
Applicability of the proposed method 
The proposed method was further applied to the determination 
of ISx in commercial dosage forms. The analysis of same batch 
Table 2. Test of precision (intra-day and inter-day assays) for 
deterrriination of ISx in pure form 
Parameters 
Amount taken (|J.gmL~') 
Amount found ((igmL"') 
Standard deviation(ngmL"')' 
Relative standard deviation (%)* 
Relative error (%)^  
Intra-day assay 
35.000 75.000 
35.399 74.689 
0.517 0.668 
1.462 0.894 
1.14 -0.415 
' Mean for five independent analyses. 
Inter-day assay 
35.000 75.000 
34.132 74.432 
0.651 0.705 
1.907 0.947 
-2.48 -0.757 
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Table 3. Application of the proposed method to the determination of ISx in tablets 
Proposed method Reference method 
Formulations Recovery (%) RSD"(%) Recovery (%) RSD"(%) t&F-values'' Hi' Ou' 
Duvadilan tablet 
Tidilan tablet 
100.06 
100.12 
0.85 
0.44 
100.18 
100.19 
0.81 
0.70 
t = 0.164 p. 
t ^ 0.209 F = 
1.041 
2.542 
0.982 
0.989 
1.02 
1.01 
' Mean for five independent analyses. 
•^  Theoretical r(v = 8) and f-values (r = 4,4) at 95% confidence level are 2.306 and 6.39, respectively. 
' In Pharmaceutical analysis, a bias, based on recovery experiments, of ±2% is acceptable ("L = 0.98 and '^u = 1 02). 
Table 4. Comparison with other reported methods 
Reagent 
4-Amlnoantipyrine 
p- N, N-Diniethyl 
phenylenediamineSi 
Chloramine-T 
Fe (III) and 2, 
2'-Blpyrldlne 
Fast Green &Orange-ll 
4-Chloro-7-nitrob-
enzo-2-oxa-l,3-
diazole (NBD-CI) 
Sodium nitrite and 
Copper acetate 
Ammoniun cerium (IV) 
nitrate and 
hydroxylamlne HCI 
RT = Room temperature 
Linear 
dynamic range 
( j j g m r ' ) 
1-18 
10-40 
20-100 
0.4-4 and 2.0-20 
2-20 
8-96 
30-80 
Molar 
absorptivity 
(Lmol ' cm^') 
1.20 X 10" 
2.1 X 10^ 
1,01 X 10' 
3.32 X 10" and 9.04 x 10^ 
-
-
5.95 X 10' 
Analysis 
time 
-
7 min 
15 min heating at 100 C 
2 min at RT 
30 min 
25 min heating at 100 C 
4 min at RT 
Remarks 
Sensitive and rapid 
Tedious, requires 
extraction with 
isobutanol 
Tedious and time 
consuming 
Sensitive but tedious 
and requires 
extraction with 
organicsolvent 
Tedious, require 
heating at 
controlled temp, 
and costly reagent 
Tedious to perform 
Sensitive, easy to 
perform and cost-
effective reagent 
1 
Reference i 
1 
20 i 
28 
17 
" 
25 
29 
Present method 
of samples viias also carried out using UV spectrophotometr ic 
method.'^' The results of the proposed method were compared 
with those obtained by reference method in terms of mean 
recovery, RSD, Ou Ou, t and F values (Table 3). No significant 
difference was noticed between the proposed method and 
reference methods regarding accuracy and precision as revealed 
by f- and F- test. The interval hypothesis test has also been 
performed to compare the results at 95% confidence level. It was 
observed that true bias of all samples is less than ±2% indicating 
the compliance of the regulatory authorities.'^^' 
The performance of the proposed method was compared with 
other existing spectrophotometric methods. The data presented 
in Table 4 revealed that the linear dynamic range of the proposed 
method is suitable for the determination of ISx in tablets and its 
sensitivity is comparable with other existing methods. Moreover, 
the analysis time is less as compared to other methods and also 
does not require extraction of complex into organic solvent. The 
method is simple requiring only cheaper reagents. 
Conclusions 
The proposed method provides simple, accurate, and reproducible 
analysis of ISx in commercial dosage forms. The method has 
highmolarabsorptivity(5.95 X 10^ L m o r ' cm~')withacceptable 
linear dynamic range (30-80 (ig mL~') and high tolerance limit 
for excipients found in dosage forms. The interval hypothesis test 
proved that the proposed method has acceptable bias of ±2% 
indicating the method is accurate and precise. 
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